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A B S T R A C T
This thesis details the development of potent light-activated antimi-
crobial silicone polymers for use in healthcare environments. Upon
illumination, these polymers induce the lethal photosensitisation of
bacteria through the generation of a range of reactive oxygen species
at the polymer surface, initiating a non-site specific attack against
bacteria in the vicinity. Activation of the antimicrobial technology
developed was achieved using laser illumination (635 nm) and
UVA illumination for medical device applications, or white hospital
lighting conditions for hospital touch surface applications. Moreover,
for the first time, some photobactericidal materials developed also
demonstrated strong antimicrobial activity through an additional
dark-activated mechanism.
Antimicrobial polymers were developed through use of a swell-
encapsulation-shrink strategy to incorporate photosensitiser dyes
such as methylene blue and crystal violet, in addition to a range
of nanoparticles including 2 nm gold nanoparticles, zinc oxide
nanoparticles and titania nanoparticles, into medical grade silicone.
Specifically, the photobactericidal silicone polymer systems detailed
in this thesis are: (i) crystal violet-coated, methylene blue and 2 nm
gold nanoparticle-encapsulated silicone for both medical device and
hospital touch surface applications, (ii) crystal violet-coated, zinc
oxide nanoparticle-encapsulated silicone for hospital touch surface
applications and (iii) oleic acid-functionalised titania or gold-doped
titania nanoparticle-encapsulated silicone for medical device or
hospital touch surface applications (in combination with a suitable
light delivery system).
The materials were characterised using techniques including: light mi-
croscopy, fluorescence microscopy, transmission electron microscopy,
UV-Vis absorbance spectroscopy, X-ray photoelectron spectroscopy,
time-resolved electron paramagnetic resonance spectroscopy and
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time-resolved detection of near infrared singlet oxygen phosphores-
cence (∼ 1270 nm). Functional testing indicated that these materials
were suitable for targeted applications and demonstrated strong ma-
terial photostability and dye-polymer stability under aqueous con-
ditions. The polymers demonstrated strong light-activated antimi-
crobial activity when tested against key Gram-positive and Gram-
negative bacteria associated with hospital-acquired infections includ-
ing Staphylococcus aureus, Staphylococcus epidermidis and Escherichia coli,
with > 4 log reductions in viable bacterial numbers observed. Signifi-
cant antimicrobial activity was also noted under dark conditions. It is
anticipated that the potent antimicrobial technology detailed in this
thesis could ultimately be used in both medical device and hospi-
tal touch surface applications, to reduce bacterial surface colonisation
and the associated incidence of hospital-acquired infections.
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1.1 introductory remarks
This thesis is focused on the development of light-activated antimi-
crobial polymers for use in medical device and hospital touch surface
applications, as a strategy to decrease the incidence of hospital-
acquired infections (HAIs). This literature review chapter details the
origins of HAIs, the ongoing issue of the emergence of bacterial drug-
resistance and infection prevention measures adopted to decrease
the prevalence of these infections. This chapter specifically focuses
on catheter-related infections and provides an extensive review on
current strategies to decrease the incidence of these infections, includ-
ing the use of antimicrobial locks and flushes, antimicrobial wound
dressings and anti-infective catheter devices. The effectiveness of
each of these approaches is evaluated and compared and ultimately,
this chapter highlights the need for the development of new, more
effective infection-prevention strategies. Research detailed in this
thesis showcases the development of potent laser-activated photobac-
tericidal polymers for medical device applications, as a strategy to
address these issues and reduce the risk of device-related infections.
Further work explores how this novel antimicrobial technology can
also achieve the lethal photosensitisation of bacteria using white
hospital illumination to activate the antimicrobial properties of these
materials, for applications in hospital touch surfaces. It is hoped that
this surface technology can be used to decrease bacterial surface
colonisation in healthcare environments and reduce the incidence of
associated infections.
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1.2 an introduction to hospital-acquired infections
HAIs have been noted as one of the ‘major complications’ in modern
medical treatment and many of these infections are associated with
the increased use of invasive medical devices, or inappropriate use of
antimicrobial treatments [1]. As exampled in Figure 1 [2], HAIs range
from septicaemia to respiratory tract infections and these infections
are commonly linked to bacterial colonisation of surfaces of devices
commonly used in medical practice, such as indwelling catheters,
intravenous cannulas and endotracheal tubing [3–5]. In fact, key
HAIs include central line-associated bloodstream infections, catheter-
associated urinary tract infections, ventilator-associated pneumonia,
in addition to surgical site infections [1, 5]. These infections not
only present a taxing financial and resource burden on healthcare
institutions, but result in extensive hospitalisation durations, patient
discomfort and in some cases, mortality [3, 4, 6].
Educational programmes, hygiene training, antibiotic prophylaxis
and implant surface modifications and coatings are just a few
examples of strategies adopted to help decrease the risk of infection,
however, the incidence of these infections is still significant [4, 7, 8].
Consequently, there remains a need to increase the stringency to
which infection-prevention regimes are followed and to introduce
Figure 1: Probable source of hospital-acquired bacteraemia [2]
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new, more potent antimicrobial approaches. This chapter explores
and evaluates the current prevalence of hospital-infection attributed
to the use of catheters, with a particular focus on intravascular
devices including peripheral intravenous-devices (such as cannulae)
and central-lines and assesses the efficacy of infection-control strate-
gies that have been adopted in medical institutions.
1.2.1 The escalating burden of bacterial drug-resistance
The use of antimicrobial agents to combat bacterial infections was
developed ca. 65 years ago [9]. However, soon after the widespread
introduction of antibiotics as a means of managing and treating
bacterial infections, the emergence of bacterial resistance was docu-
mented and has been acknowledged as an escalating problem [9, 10],
posing a serious threat to global healthcare services and the effective
prevention and treatment of infection [11]. The Centers for Disease
Control and Prevention (CDC, 2013) reported an estimated 2 million
patients were affected by antibiotic resistant infections, resulting
in at least 23,000 deaths in the U.S. alone, [12, 13] although it has
been suggested that these figures are in fact an underestimation [12].
A high proportion of bacteria causing device-associated infection
demonstrate drug-resistance and it has been reported that infected
patients utilise greater hospital resources than patients infected with
the drug-sensitive bacteria [11].
In hospitals, the greatest incidence of bacterial drug-resistance is
encountered in intensive care units (ICU) and the increase in resis-
tance over time, particularly in ICUs, can be linked to the systemic
use of antimicrobial agents such as antibiotics, as a strategy to treat
and prevent bacterial infections [8, 9, 14–16]. Consequently, infection
management is proving increasingly challenging, since the number
of effective antibiotic treatments is diminishing and few new antimi-
crobials are entering the market [14, 17]. The correlation between
the escalation in the emergence of microbial drug-resistance and
bacterial exposure to antimicrobial agents, can be theorised through
Darwinian evolutionary concepts and rationalised as follows [3, 15].
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Upon contact with antibiotics, the few bacteria that harbour genes
encoding antibiotic resistance, will out-compete those bacteria that
are sensitive to the antimicrobial agent [3]. Consequently, due to the
elimination of drug-sensitive bacteria, conditions are favourable for
the remaining bacteria to rapidly grow and reproduce, transferring
genes encoding antibiotic resistance, ultimately generating large
populations of resistant bacteria. As a result, the prevalence of
bacterial drug-resistance increases proportionally to drug exposure
[3].
One approach to decrease the incidence of microbial drug-resistance
is to target and reduce the over-prescription and misuse of antibiotics
in medical practice [10]. Hospital antibiotic stewardship programmes
have been implemented to control and optimise the utilisation of
antibiotic therapies, as a means to minimise microbial drug resistance
[10, 14, 16–19]. With the increasing rate of bacterial drug resistance
and the difficulty and cost associated with the development of new
antibiotics, the preservation of existing antibiotics is essential and
stewardship programmes can assist with achieving this goal [10, 19].
Such programmes have been recommended for up to 20 years in the
U.S. and more recently, in Europe [10], however, the fight against
bacterial drug resistance must be strengthened and more effective
infection control strategies are key.
1.2.2 Catheter-associated infections; the origins of an acute problem
Drug-resistant bacterial pathogens and subsequent nosocomial infec-
tions have been associated with increased duration of hospitalisation,
healthcare expenditure and mortality [20]. Each year in the U.S.
there are an estimated 2 million cases of HAIs and 99,000 associated
deaths, with hospital-infection costs ranging from $10,500 to $111,000
per case and total associated costs exceeding $33 billion [1, 21]. The
British National Audit Office reported that in the U.K., HAIs cause an
estimated 5,000 deaths annually, costing the National Health Service
(NHS) at least £1 billion and in Europe, approximately 4 - 10 % of all
hospital admissions result in an HAI [21], such as a device-associated
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bloodstream infection. A Public Health England report indicated
that although there has been a decrease in the incidence of both
methicillin resistant Staphylococcus aureus (MRSA) and Clostridium dif-
ficile since the survey conducted in 2006, the prevalence of infections
attributed to Escherichia coli and Salmonella sp. is increasing [22, 23].
The utilisation of polymeric medical devices is fundamental in daily
medical practice. More than 30 million urinary catheters are inserted
annually in the U.S. and their use is associated with high infection
rates (10 - 30 %) [24, 25]. Approximately 449,334 cases of catheter-
associated urinary tract infections are reported each year in the U.S.,
costing an additional $749 - $1,007 per hospital admission, with costs
increasing up to ca. $3,744 in the event of a bloodstream infection
[26], however, the attributable mortality rates are low [25]. Moreover,
an estimated 5 million central-venous catheters are inserted each
year in the U.S. and over 200,000 are inserted in adult patients in
the U.K. alone [25, 27]. The associated incidence of central-venous
catheter-related bloodstream infections ranges from 80,000 to 400,000
cases annually in the U.S. and the mortality rate is higher than for
urinary catheterisation (up to 25 %) [28, 29]. These devices are crucial
in the treatment of critically ill patients, however, most cases of
infection in this patient category are associated with their use [25].
It has been noted that 95 % of urinary tract infections are related to
urinary catheterisation, 86 % of cases of pneumonia are attributed to
mechanical ventilation and 87 % of bloodstream infections are caused
by indwelling intravascular devices [25].
Prior to insertion, the surface of the medical device, for example,
an intravascular catheter, can be described as ‘clean’ and ‘sterile’
[30]. However, immediately after device implantation, a conditioning
film is deposited on the surface [30] and microbial colonisation
and biofilm formation occurs within 24 h [28]. The composition
of the conditioning film is highly dependent upon the catheter
insertion location and is comprised of adsorbed high molecular-
weight proteins present in the fluid in the environs of the implant,
for example, intravascular catheters are prone to encrustation by
fibronectin and fibrin [3, 30, 31]. The presence of the “mesh-like”
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conditioning film is crucial for microbial implant adherence as
it obscures the smooth, somewhat inhospitable implant surface
that most bacteria are unable to effectively interact with, providing
a rough, charged surface to which planktonic bacteria can adhere [30].
Sessile bacteria that attach to the mesh-like conditioning film on the
catheter surface rapidly grow and divide, colonising the surface and
creating a biofilm through the secretion of an exopolymeric matrix,
composed principally of polysaccharides, proteins and nucleic acids
[28, 32]. The presence of the biofilm matrix may enable further
species of planktonic bacteria to interact with and attach to the
implant surface, forming a more diverse microbial community with
many different microenvironments within [32]. It has been noted that
microbes within a biofilm are less susceptible to antimicrobial agents
than their planktonic counterparts [32]. However, bacterial overcrowd-
ing can effect challenging conditions within the biofilm community,
resulting in shortages of available nutrients required for the sessile,
biofilm-embedded bacteria to survive [3, 32]. Consequently, colonised
bacteria may become planktonic and detach from the biofilm and
it has been suggested that this microbial dissemination may effect
the onset of a bloodstream infection, especially if the quantity of
planktonic bacteria exceed a certain limit [3, 28].
Microorganisms commonly associated with intravascular catheter-
related infections include both Gram-positive and Gram-negative
bacteria such as coagulase-negative staphylococci, MRSA, methicillin-
sensitive Staphylococcus aureus, E. coli, Pseudomonas aeruginosa,
Enterobacter species, in addition to the yeast Candida albicans and
there is a correlation between the microbial species and site of
catheterisation [33]. HAIs are commonly caused by bacteria from the
patient’s skin microbiota, although there may be additional microbes
present, originating from the inanimate hospital environment, equip-
ment or staff [5]. These microorganisms usually access the catheter
through extraluminal migration down the device from the site of
insertion, colonising the catheter-tip and subsequently, effecting the
onset of a bloodstream infection [28]. Another frequent cause of
catheter-related bloodstream infections is the microbial colonisation
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of the catheter-hub [34] and this type of contamination, usually
caused by hospital-acquired microorganisms transferred through hub
manipulation by healthcare personnel, leads to bacterial migration
along the intraluminal catheter surface [35]. More rarely, blood-
stream infections can be attributed to the microbial contamination
of catheter-infusate such as parenteral nutrition (intravenous feeding
lines), during the preparation process [36].
It has been noted that in the case of short-term intravascular catheter-
isation (< 10 days), for example with intravenous-peripheral or
non-tunnelled devices (see section 1.4.2 for definition), the most
frequent source of microbial colonisation is the catheter insertion
site [28]. However, in patients catheterised for extensive periods,
for example with tunnelled, cuffed central-venous catheters, blood-
stream infections can often be attributed to hub contamination [28].
The different pathogens responsible for the onset of infection may
require the consideration of different antimicrobial therapies and
regimens [28]. Although it is often necessary to prescribe antibiotics
to treat catheter-related infections, this may escalate the emergence
of drug-resistant bacteria, especially due to the more resistant nature
of biofilm-embedded microbes colonising medical implants [30].
Reports suggest that the spread of HAIs is frequently attributed to
poor staff compliance with hygiene guidelines [37, 38] and there-
fore, staff training and education programmes are recommended [39].
1.3 the use of antimicrobial agents for infection-
prevention
The integration and implementation of evidence-based guidelines
through catheter care bundles and the reduction of unnecessary
catheterisation, has resulted in a decrease in the incidence of as-
sociated infections [6, 26, 39–42]. However, despite interventions
reducing the risk of device-associated infection, this tactic alone will
not eliminate or decrease entirely, the incidence of catheter-associated
infections. Subsequently, additional infection-prevention approaches
are required to further decrease the rate of catheter-related infections
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and associated mortality [39]. In the following section, the utilisation
of antimicrobial catheter lock solutions is described, as a strategy to
prevent bacterial intravascular catheter colonisation and decrease the
incidence of catheter-related infections.
1.3.1 Antimicrobial lock therapy
Pneumonia, urinary tract infections and bloodstream infections are
the most prevalent infections in ICUs and are largely associated with
the use of biomaterial devices such as catheters [42]. It has been
proposed that in the case of long-term catheterisation, bloodstream
infections can be attributed to intraluminal, rather than extraluminal
bacterial contamination [43]. Central-venous access devices are rou-
tinely flushed with a heparin solution to prevent blood clot formation
and prolong catheter patency, however, the efficacy of this strategy
is inconclusive [44–46]. Moreover, heparin possesses no intrinsic
antibacterial properties and as a result, does little to reduce microbial
catheter colonisation [47].
Routine antimicrobial lock solutions can be used as a strategy to
sterilise the internal catheter lumen and enhance the efficacy of the
implementation of catheter care bundles by decreasing intraluminal
catheter colonisation [42, 48–50]. The volume of antimicrobial lock
solution used, is such that it fills the complete catheter lumen in
addition to the extension tubing [43]. The antimicrobial solution
is allowed to dwell in the internal lumen for a specified duration,
before it is withdrawn and the catheter is flushed with a heparin/
saline solution [43]. Multiple investigations have demonstrated
the efficacy of antimicrobial lock therapy as an infection-control
approach against catheter-related infections, using systemic antibiotic
therapy in conjuction with antimicrobial lock solutions including:
minocycline-ethylenediaminetetraacetate (EDTA) [47], heparin in
combination with vancomycin, gentamicin, cefazolin, ethanol [49]
and fusidic acid lock solutions [51].
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Guidelines suggest that antimicrobial lock therapy may be par-
ticularly beneficial in the case of certain “high-risk” patients, or
those that present recurrent intravascular catheter-related infec-
tions [48, 52–54]. Candida species are associated with 10 - 15 % of
catheter-related bloodstream infections and Gram-positive bacteria
account for a further 75 % of such infections [47]. Consequently, the
antibiotic/anticoagulant combination of vancomycin and heparin
is frequently used as a prophylaxis therapy and has demonstrated
effective bactericidal activity against catheter-related infections [47,
55, 56]. A meta-analysis of 7 randomised trials evaluated the antimi-
crobial efficacy of a vancomycin/ heparin lock solution compared
to a control heparin lock solution and concluded that vancomycin
lock therapy was effective at lowering the risk of catheter-associated
bloodstream infections in high-risk patients [42, 57]. However, it
should be highlighted that the systemic use of antibiotics in medical
regimes may be discouraged due to concerns about the increased risk
of microbial drug resistance [3, 9, 14, 15].
It should be noted that in one prospective, randomised double-blind
trial, the routine locking of peripheral catheters with a heparin/ van-
comycin solution, decreased the incidence of associated bloodstream
infections, with no evidence of vancomycin resistance amongst
catheter colonising bacteria [43]. The reduced incidence of catheter-
related bloodstream infections upon use of the vancomycin/ heparin
lock solution, was attributed to impedance of biofilm formation -
through the inhibition of bacteria adhering to the catheter walls -
rather than a direct, rapid bactericidal activity of the presence of the
low-levels of vancomycin (∼10 µg) in the catheter lumen [43].
Overall, the use of antimicrobial lock therapy has demonstrated clini-
cal efficacy as a prophylaxis for catheter-related infections [48–50, 54–
57], predominantly caused by vancomycin-sensitive Gram-positive
bacteria [43, 55–57]. However, it can be suggested that the lock
solution efficacy against vancomycin-sensitive bacteria may improve
“living conditions” for vancomycin-resistant bacteria through the
reduction in bacterial competition within the biofilm community,
thereby generating conditions suitable for rapid microbial multiplica-
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tion [3, 48]. Moreover, it should be noted that enterococcal infections
attributed to vancomycin-resistant Enterococcus species correlate with
lengthier hospitalisation durations (18 days) and greater healthcare
costs compared to vancomycin-sensitive bacteria, in addition to
a 29 % risk of morbidity [58]. Vancomycin lock solution use as a
strategy for infection-prevention has been termed an “independent
risk-factor” for the emergence of vancomycin-resistant Enterococcus
sp. [59] and CDC guidelines advise control of its use, overshad-
owing its advantages as a prophylaxis. Although the use of lock
solutions comprising of combinations of minocycline/ EDTA have
demonstrated clinical efficacy in a small study [47], the associated
risk of antibiotic-resistant bacteria is unknown. Consequently, the
use of antibiotic lock solutions should be carefully considered and
employed only in cases where the catheterised patient is at a high
risk of developing an associated infection.
1.3.2 Ethanol lock therapy
One alternative ‘lock therapy’ approach is the use of ethanol lock
solutions [49, 60–63]. It has been suggested that contrary to antibiotic-
based prophylaxes, bacterial ethanol ‘resistance and resilience’ is
improbable, since the mode of bacterial kill is through a “non-specific”
protein deactivation mechanism, deterring catheter colonisation and
preventing consequent infection [49, 64]
Anticoagulants such as heparin are frequently used to prevent
catheter-attributed thrombosis [48]. However, it has been noted that
ethanol-lock therapy should not be used in combination with heparin
flushes as precipitate formation may occur [49, 64, 65]. The absence
of an anticoagulant in the lock solution however, may result in
thrombosis formation, increasing the risk of infection. Nevertheless,
in-vitro studies have reported the use of ethanol in combination
with alternative anticoagulants such as EDTA [66–68]. Moreover,
ethanol has inherent anticoagulation properties and therefore may
prevent catheter-associated thrombosis without the need for further
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anti-coagulants [64].
In-vitro studies indicate that the use of at least a 30 % solution of
ethanol-containing lock solutions were effective at achieving bacterial
kill on silicone Hickman catheter sections, when tested against S.
aureus [64, 68]. Moreover, the study indicated that the use of ethanol
lock solutions (> 30 % concentration) was more efficacious than lock
solutions containing either minocycline, ciprofloxacin, vancomycin,
EDTA, minocycline/ rifampin, ciprofloxacin/ rifampin, vancomycin/
rifampin or minocycline/ EDTA, against a range of microorganisms
including Staphylococcus epidermidis, P. aeruginosa and Candida species
[64, 68]. Further in-vitro studies indicated that the use of lock solu-
tions containing ethanol alone, or in combination with antibiotics or
anticoagulants, inhibited biofilm formation by both Gram-negative
and Gram-positive bacteria in addition to Candida species [64, 66, 67].
In clinical studies, the utilisation of ethanol lock therapy has been
reported both in terms of the treatment and prevention of catheter-
associated bloodstream infections and has demonstrated significant
antimicrobial activity [61, 64, 69–72]. However, it has been pointed
out that these clinical trials are associated with various limitations
including narrow trial patient populations, retrospective design,
un-standardised ethanol locking durations, the additional adminis-
tration of antibiotics intravenously and the use of only one catheter
polymer type (silicone) [64]. Moreover, adverse side-effects have been
attributed to the utilisation of ethanol-lock therapy such as nausea,
light-headedness, unusual taste sensations, dyspnea, chest pain and
fatigue [62, 64]. Other potential undesirable clinical side-effects of
ethanol-lock therapy include the risk cardiac arrhythmias, especially
when used in combination with EDTA if there is leakage into patient
blood circulation [49]; ‘central nervous system depression’; and local
phlebitis [64].
An additional point for consideration with regard to the use of
ethanol lock therapy, is the effect of the lock solution on the stability
of the polymeric catheter material [49, 64]. Mechanical testing studies
indicated that relative to a control, there was a minor decrease in the
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elasticity modulus of polyurethane and silicone catheters, as well as a
slight swelling of the polyurethane catheter walls, upon exposure to a
70 % ethanol lock solution [49, 64, 73]. However, no other discrepancy
in the results of catheter integrity investigations were observed and
overall, it was concluded that the use of an ethanol lock solution
did not cause any significant change to the mechanical properties of
the catheter that would detrimentally affect its suitability in clinical
applications [64, 73]
Further in-vitro investigations that explored the effect of ethanol
lock solutions on the integrity of selected catheter implants included
structural damage assessment, in addition to leaching effects. Scan-
ning electron microscopy indicated that the immersion of silicone
catheters in a 95 % concentration ethanol solution for 15 days at 37
oC (to simulate host conditions), caused no structural damage to the
internal catheter lumen relative to a control [64, 74]. Conversely, gas
chromatography, in addition to further analytical methods, showed
that the immersion of the silicone catheter in 95 % ethanol resulted
in the leaching of a higher concentration of cyclic polydimethylsilox-
anes, compared to catheters immersed in 0.9 % sodium chloride
or 60 % ethanol solutions [64, 74]. The greatest leaching effects
were noted within the first 4 h of immersion in the 95 % ethanol
solution, although no significant difference in the subsequent release
of polydimethylsiloxanes was noted, between immersion in 60 %
ethanol or 0.9 % sodium chloride solution [64, 74]. The adverse
effects associated with the dissemination of polydimethylsiloxanes
and other chemicals into the patient circulatory system are unknown
[64] and it is advised that this is further investigated to ensure safety
for application in clinical practice.
1.3.3 Antimicrobial flushes
Many different approaches have been tested in an attempt to decrease
the incidence of catheter-related infections, including the use of sys-
temic antibiotics [29, 75, 76]. Similar to antimicrobial lock therapy,
another method of reducing microbial catheter colonisation and asso-
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ciated infections is the use of antimicrobial flushes; the sterilisation
of the internal catheter lumen, by flushing antibacterial solutions
through the catheter. Flush solutions containing the anticoagulant
heparin [75], antibiotics such as vancomycin [76], in addition to
solutions containing antibiotics and anticoagulant combinations such
as minocycline/ EDTA or vancomycin/ ciprofloxacin/ heparin have
been investigated [77, 78].
It has been reported that the administration of a vancomycin flush
immediately post catheter insertion results in a decrease in the
prevalence of catheter-related infections, suggesting that this was
the best prophylactic strategy in terms of both benefit and cost,
in high-risk patients [76]. In a different study, a significant reduc-
tion in the rate of catheter-related bloodstream infections caused
by vancomycin-sensitive bacteria was reported, when antibiotic/
heparin flush solutions (vancomycin/ ciprofloxacin/ heparin or
vancomycin/ heparin) were used, compared to when a heparin flush
solution was used [78]. However, conflicting findings were reported
in another clinical study, where no significant difference in the rate
of central-venous catheter-related infections was documented in
paediatric patients, when vancomycin/ heparin lock solutions were
used, compared to heparin lock solutions [79]. Moreover, due to
fears concerning the potential development of vancomycin-resistant
Enterococcus sp. [59, 80], the vancomycin flush strategy is recom-
mended only in the case of high-risk patients, for example adult
and paediatric oncology patients [75, 76]. Likewise, although the
use of a minocycline/ EDTA catheter flush solution eradicated the
incidence of associated infection in a small-scale clinical trial of
adult patients who had previously collectively presented 40 cases
of intravascular catheter-related infections, CDC guidelines only
recommend the use of an antimicrobial treatment strategy in the
case of high-risk catheterised patients, for example those that present
recurrent infections [24, 48, 77].
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1.3.4 Evaluation of Antimicrobial Locks and Flushes
The clinical data reviewed in this chapter shows some effectiveness
of antimicrobial catheter flushes as a prophylaxis for catheter-related
infections [61, 64, 69–72, 76, 78], however, this approach requires
more investigation. The use of an antimicrobial catheter lock, rather
than flushing the catheter, has also demonstrated greater antimi-
crobial efficacy [39, 57] and therefore, may be presented as a more
effective prophylactic strategy against catheter-associated infections.
Nevertheless, recommendation of such therapies are only encouraged
in the case of ‘high-risk’ patients, such as those that present recurring
infections [53]. This is due to concerns regarding an increased risk of
bacterial resistance upon exposure to antibiotics, in addition to the
potential for systemic toxicity from leakage of the lock solution into
the patient bloodstream [53]. The use of ethanol as an alternative lock
treatment method was also associated with significant drawbacks
[49].
Overall, the utilisation of antimicrobial locks or flushes as a pro-
phylaxis against catheter-associated infections have demonstrated
efficacy, but each approach is encumbered with significant problems
and in general, are recommended for use in the case of high-risk
patients only. Consequently, the examination of alternative infection-
prevention strategies for example, the use of antimicrobial catheter
devices or wound-dressings is necessary to impact on the rate of
catheter-related bloodstream infections.
1.4 antimicrobial medical devices as an infection-
prevention strategy
The incorporation of antimicrobial therapies, such as catheter locks
and flushes into catheter-care regimes, have impacted on the inci-
dence of catheter-related bloodstream infections. However, the use
of these therapies to enhance standard evidence-based catheter-care
bundles has been widely recommended only in the case of high-
risk patients. An alternative tactic to reduce the risk of associated
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infections in catheterised patients, is the use of anti-infective medical
devices and wound-dressings to decrease bacterial contamination at
the insertion site or on the device itself.
1.4.1 Antiseptic wound-dressings
The enhanced risk of bloodstream infections associated with the use
of catheter devices has resulted in the implementation of educational
training regarding asepsis for clinical personnel, in addition to
extensive guidelines concerning device insertion, manipulation and
care [81]. Emphasis on clinical asepsis upon catheter insertion is
imperative, since bacterial contamination due to the migration of host
skin microbiota down the external catheter surface, has been noted
as the most prevalent cause of infection in short-term central-venous
catheterisation [81]. Subsequently, the insertion and manipulation
of central-venous catheter devices is accomplished with stringent
adherence to aseptic technique protocols, including cutaneous anti-
sepsis prior to device insertion, using a > 0.5 % chlorhexidine-based
agent unless contraindicated, as well as maximum sterile-barrier
precautions [39, 48] to decrease bacterial extraluminal colonisation
and reduce the risk of associated infection.
Post catheter implantation, CDC guidelines advise the covering of the
insertion site with a sterile wound-dressing [39, 48], to prevent subse-
quent extrinsic microbial contamination and it has been documented
that the frequency that the wound-dressing should be changed, is
dependent on the catheter type and duration of catheterisation [39].
It has been suggested, though not evidenced, that the permeability of
the site dressing is linked to the incidence of infection, for example,
non-permeable dressings that trap moisture create optimal conditions
for microbial proliferation [81]. Consequently, the two types of sterile
wound-dressings that are frequently employed in medical practice;
transparent, adhesive polyurethane dressings or ‘gauze-and-tape’
dressings, are both semi-permeable [39, 48, 81].
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Polyurethane dressings are often preferred as their application is
straightforward, patients can bathe and shower without saturating the
dressing and the material is transparent, which facilitates continuous,
unobtrusive surveillance of the insertion site [81, 83]. These dressings
also require less frequent changes than ‘gauze-and-tape dressings’
[81]. However, in one meta-analysis comparing different dressing
types for peripheral and central catheters, the use of polyurethane
wound-dressings was linked to an increased risk of catheter tip
colonisation compared to ‘gauze-and-tape’ dressings and it was
speculated that this may be due to insufficient “moisture-vapour”
permeability of the polyurethane, creating a favourable environment
for microbial growth and multiplication [83, 84]. A Cochrane review
on the subject provides a more extensive comparison between the use
of polyurethane and ‘gauze-and-tape’ dressings and concluded from
the available evidence, that the use of polyurethane dressing results
in a four-fold increase in the risk of catheter-associated bloodstream
infections [85]. However, it was reported that larger, better quality
studies are crucial, to confirm these findings [85]. Although current
guidelines specifically advise the use of standard ‘gauze-and-tape’
dressings in cases where the insertion site is bleeding or oozing,
otherwise, they recommend the use of either ‘gauze-and-tape’ or
‘semi-permeable’ dressings to cover the catheter insertion site [39, 54].
Figure 2: Diagram to show the antimicrobial action of BIOPATCH® wound
dressings, through a chlorhexidine gluconate release mechanism, adapted
from [82]
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The use of an anti-infective wound dressing, Biopatch®, as a strategy
to decrease the incidence of catheter-associated infections, has been
investigated in clinical studies [86–90]. Biopatch® is an antiseptic
chlorhexidine-gluconate impregnated sponge (2.5 cm) that can be
placed over the catheter insertion site (Figure 2) and is subsequently
covered with a transparent polyurethane wound-dressing [88, 91].
The Biopatch® dressing continuously delivers the antimicrobial agent
chlorhexidine gluconate to the insertion site, for a period of up to
7 days [88, 91, 92]. Since external bacterial catheter colonisation is
a principal mechanism of central-venous catheter-related infections
[87], the application of these dressings is relevant. However, it is
anticipated that the use of antimicrobial wound dressings such
as Biopatch® may not impact on the rates of infection caused by
bacterial hub contamination or the migration of microbes along the
intraluminal catheter surface.
Several clinical studies have investigated the efficacy of chlorhexidine-
impregnated wound-dressings as a strategy to decrease the risk of
catheter contamination and associated infection, with varying results
[91]. A small study reported that the use of the chlorhexidine-
containing dressings did not result in a statistically significant
difference in either microbial catheter-tip contamination or, skin exit-
site contamination, however, it was reported that a larger randomised
controlled trial is crucial to evaluate the efficacy of this device [88].
In another study, the use of Biopatch® did not result in a statistically
significant decrease in the incidence of bacteraemia/ septicemia in
patients with tunneled, cuffed central venous catheters, however,
there was a statistically significant reduction in the prevalence of
local exit-site infections [90]. The use of Biopatch® did not decrease
the incidence of catheter-related bloodstream infections among
hemodialysis patients with tunneled central venous catheters and it
was speculated that in this patient population, contamination of the
catheter hub, rather than the catheter exit site, plays a larger role in
the pathogenesis of associated bloodstream infections [89].
Numerous large clinical trials have demonstrated the effective antimi-
crobial activity of chlorhexidine-gluconate impregnated catheter-site
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wound-dressings [86, 87, 93]. A meta-analysis of 8 randomised trials
examining the efficacy of the use of Biopatch® as a prophylaxis for
catheter-related infections, indicated that the use of the antimicrobial
wound-dressing resulted in a substantial reduction in vascular and
epidural catheter colonisation [94]. This however was only associated
with a ‘trend’ towards a decrease in episodes of vascular and epidu-
ral catheter-related infections [94]. The authors of the meta-analysis
subsequently published a further comment concluding that upon
the incorporation of the results of 2 large European trials, conducted
post-publication of the initial meta-analysis, evidence suggested
that the use of a chlorhexidine-impregnated wound dressing was an
efficacious preventative measure against catheter-related bloodstream
infections and recommended its use with vascular catheters in adult
patients [87, 93, 95]. More recently, a meta-analysis of 9 randomised
controlled trials concluded that the use of chlorhexidine-impregnated
dressings was effective at preventing microbial catheter contami-
nation and also, effected a decrease in the incidence of associated
bloodstream infections [96]. The authors of this meta-analysis also
recommended routine use of chlorhexidine-impregnated dressings,
in patients with central venous or arterial catheters at a high-risk of
catheter-associated bloodstream infection [96].
In conclusion, evidence suggests that the incorporation of
chlorhexidine-impregnated dressings is beneficial in preventing
microbial catheter contamination and the onset of associated blood-
stream infections [95, 96]. However, although usually well-tolerated
by patients [87, 93], it has been reported that the use of chlorhexidine
as an antimicrobial agent in medical devices has caused adverse
events such as hypersensitivity reactions [97–102], including an
incident involving the use of the Biopatch® in low birth-weight
neonatal patients [99]. In addition, localised contact dermatitis has
been reported when Biopatch® has been used in low-birth weight
neonatal patients [48, 98, 103]. A further 7 cases of erosive irritant
contact dermatitis were reported - in six cases, the patients were
children aged 4 months to 2 years and in one case, the patient
was a critically ill 62-year-old man - and it was suggested that
care should be taken in using chlorhexidine-impregnated dressings
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in immunosuppressed or critically ill patients, since they may be
more sensitive to irritant effects [104]. Overall, although reports
have suggested that in some cases it may be beneficial to use
chlorhexidine-gluconate impregnated wound-dressings to prevent
microbial catheter contamination and the onset of infection, and the
use of the antiseptic-dressing is recommended in the case of high-risk
patients over 2 months in age [94, 95, 105], the associated risk of
hypersensitivity and skin reactions, diminishes the efficiency of this
strategy as a wide spectrum catheter-infection control strategy.
1.4.2 Antimicrobial catheter cuffs
Intravascular catheters can be classified into two categories; tunnelled
and non-tunnelled devices. Non-tunnelled catheters are percuta-
neously inserted into the jugular or subclavian vein under local
anaesthesia and are used for short-term catheterisation [91]. For
long-term catheterisation, catheters that are surgically tunnelled
under the skin for several inches to a cannulated vein are used and a
subcutaneous Dacron cuff secures the device in place, as it becomes
entangled with fibrous host tissue [91, 106].
One of the frequently noted complications associated with
intravascular-catheter devices is the contraction of bloodstream
infections caused by host skin microbiota contamination of the
catheter-insertion site and this highlights the importance of cuta-
neous antisepsis prior to catheter insertion [48, 106]. Nevertheless,
even after skin disinfection, repressed microbial levels can escalate,
especially after the application of a wound-dressing, resulting in
bacterial contamination of the exit site [81, 106] and subsequent
migration and colonisation along the catheter length. However, as
aforementioned, tunnelled catheters, used in long-term catheteri-
sation, have a subcutaneous cuff placed 0.25 cm to 0.75 cm below
the surface of the skin and this acts as a barrier to bacteria tracking
and colonising the catheter, hindering the onset of infection [106, 107].
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Studies have investigated the clinical efficacy of the impregna-
tion of a subcutaneous collagen catheter cuff with antimicrobial
agents, as a means to enhance its infection-prevention properties,
through presenting both a chemical and mechanical barrier to
microorganisms [39, 48, 106]. The cuff (VitaCuff®), comprises of
a biodegradable collagen matrix - in which subcutaneous tissue
can grow, anchoring the catheter - with chelated silver ions [106].
However, the enhanced anti-infection efficacy of catheters with an
antimicrobial subcutaneous cuff is controversial. In an early (1988)
multi-centre, randomised trial, consisting of 234 catheters, it was
found that the use of the silver-impregnated catheter cuff resulted
in a three-fold decrease in the risk of microbial catheter colonisation
and an even greater reduction in bacteraemia, relative to a control
group consisting of ‘non-cuffed’ catheterised patients [106]. However,
later trials reported that the anti-infective catheter cuff did not effect
a statistically significant reduction in microbial catheter colonisation
or the risk of associated infection, in either short-term or long-term
catheterised patients [107–112]. Moreover, since the catheter cuff is
biodegradable, concerns were expressed regarding the loss of the
chemical and physical antibacterial attributes of the cuff over time
in cases of long-term catheterisation [108]. Overall, there is limited
evidence demonstrating that the use of a silver-impregnated cuff is
an effective strategy in preventing bacterial catheter contamination
and associated infection.
1.4.3 Antibiotic-coated catheters
An alternative anti-infection strategy is the use of antimicrobial
catheter-devices to prevent microbial catheter contamination and
the subsequent onset of infection. Pre-clinical trials have demon-
strated that the treatment of commercial catheters with the antibiotic
ciprofloxacin, effected potent antimicrobial activity against P.
aeruginosa and hindered bacterial catheter adhesion [113]. It was
reported that the modification of commercial catheters to enable
antimicrobial activity can be achieved using a simple dip-coating
method and further pre-clinical trials evaluated the antimicrobial
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efficacy of catheters coated with antibiotics including gentamicin and
norfloxacin, indicating promising results [114–116]. Moreover, the
antibiotic nitrofurazone has been used to coat urinary catheters and
both in-vitro and in-vivo trials have established that these antibiotic
catheters demonstrate an anti-infective efficacy and show promise
in reducing the incidence of urinary tract infections in short-term
catheterised patients, within the constraints of the studies performed
[116–123]. The use of combination antibiotic-coated catheters also
demonstrated antimicrobial efficacy compared to standard catheters,
in short-term urinary catheterised patients [122]. Minocycline and
rifampin-coated catheters resulted in reduced rates of asymptomatic
bacteriuria compared to control catheters, in patients catheterised for
less than one week, however, no statistically significant reduction was
noted in patients catheterised for more than one week [122].
The use of a combination of antibiotics to coat the inner and outer
catheter lumens, has also been explored as a prophylactic strategy to
decrease the incidence of intravascular-catheter associated infection.
The two broad spectrum antibiotics, minocycline and rifampin, effec-
tive against a wide range of bacteria including MRSA, were coated
onto commercial catheters pre-treated with a tridodecylmethylam-
monium chloride surfactant [124, 125]. The synergistic combination
of the two antibiotics, minocycline and rifampin, exhibited enhanced
efficacy compared to other combinations of antibiotics including
vancomycin/ rifampin, inhibiting bacterial catheter colonisation, in
particular by slime-producing S. aureus and S. epidermidis [125, 126]
- slime is bacterial exopolymer associated with biofilms. These dual
antibiotic-coated catheters also demonstrated antimicrobial efficacy
in a multi-institutional, double-blind randomised trial in the U.S.
[125]. The study indicated that the use of minocycline/ rifampin
(MR) coated central-venous catheters (Cook Critical Care, Indiana)
effected a substantial decrease in the prevalence of microbial catheter
colonisation when compared to a control group (8 % and 26 %
of cases respectively), with no reported cases of catheter-related
infection in patients catheterised with the MR-coated device [125].
A meta-analysis of eight randomised controlled trials indicated
MR-coated catheters are effective at reducing the risk of bacterial
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catheter colonisation and associated infection [127]. It has also been
suggested that the use of these catheters may be a cost-effective
preventative strategy [124, 125, 127].
These catheters are approved by the U.S. Food and Drug Admin-
istration (FDA), commercially available in the U.S. and in addition
to standard catheter care protocol, guidelines recommend the
integration of these antibiotic catheters into medical practice in
the case of high-risk patients requiring extensive catheterisation
[39, 54, 128]. A meta-analysis of eight-randomised controlled trials
indicated that the use of these catheters decreased catheter coloni-
sation and the incidence of associated catheter-related bloodstream
infections [127]. However, it was noted that in all trials reviewed,
cutaneous antisepsis was executed using povidone-iodine, rather
than a chlorhexidine-based preparation; the antisepsis approach
strongly recommended in catheter-care guidelines [48, 105, 127].
Consequently, it is disputable whether the antimicrobial efficacy
exhibited by the MR-coated catheters would be significant compared
with the effective prophylaxis against infection demonstrated by
the use of chlorhexidine-based skin antisepsis, as both approaches
prevent infection from similar microorganisms [127]. Some trials also
indicated that the use of an MR-coated catheter impacted on the type
of microorganism colonising the catheter, with a marked increase
in the proportion of Candida species documented on MR-coated
catheters [127, 129–131].
The incorporation of this antibiotic anti-infective strategy into med-
ical regimes, especially at sub-optimal antibiotic dosage levels, has
raised concerns about the potential escalation in the development of
drug-resistant bacteria [125, 132, 133]. In particular, a chief concern
regarding the widespread use of these antibiotic central-venous
catheters, is the development of resistance against rifampin [132].
This antibiotic is used to treat tuberculosis infections caused by
Mycobacterium tuberculosis, which infects ca. 40 % of the population
in India [132]. Rifampin-resistance in MRSA has been reported in
units treating tuberculosis patients and hence, the emergence of
rifampin-resistance in M. tuberculosis is possible when the antibiotic
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is used as a treatment against MRSA [132, 134]. Moreover, some
cases of rifampin-resistance in M. tuberculosis in France have been
reported and there are fears that this may be a precursor to multi-
drug resistance [135]. It can also be speculated that the potential
issue of the development of genes encoding rifampin resistance
in M. tuberculosis may also present a problem in the U.K., since
recent findings suggest that there are nearly 8,000 reported cases
each year [136, 137]. Moreover, it has been remarked that nearly 40
% of tuberculosis infections in the U.K. are diagnosed in London,
where the prevalence of infection has risen by more than 50 % since
1999 [136, 137]. In response to these reports, it can be commented
that the more widespread use of antibiotic catheters coated with
rifampin as a prophylaxis against catheter-related infections, may
effect detrimental outcomes with regard to infection-control and
minimising the escalation in bacterial drug-resistance.
Despite these concerns, as yet, clinical studies have demonstrated
no evidence of the emergence of bacterial resistance associated with
the use of MR-coated catheters and the incidence of this occurring is
reported as ‘unlikely’ [125, 132, 138]. This is since the two antibiotics,
minocycline and rifampin, have different modes of action, the former
inhibiting bacterial protein synthesis, whereas rifampin inhibits
DNA-dependent RNA polymerase required for transcription [132].
Therefore, it can be suggested that even if bacteria develop resistance
against one type of antibiotic, they are likely to be susceptible to the
attack mechanism of the second, thus rendering the Darwinian selec-
tion of a resistant sub-population unlikely. Moreover, the antibiotics
used to coat the catheters, minocycline and rifampin, are not systemi-
cally used to treat bloodstream infections and both antibiotics exhibit
a broad-spectrum of bactericidal activity against both Gram-negative
and Gram-positive bacteria, in addition to Candida species, deeming
the subsequent development of drug-resistance unlikely [125, 139].
Overall, the utilisation of antibiotic catheters such as the MR-coated
catheters have demonstrated significant antimicrobial activity, hinder-
ing bacterial catheter colonisation and reducing the risk of associated
bloodstream infections [125, 132, 140]. Relative to an uncoated but oth-
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erwise identical device, the additional cost of an MR-coated catheter
is $14 per catheter device, compared to the estimated cost of each
episode of catheter-related bloodstream infection, which is approxi-
mately $740 [125]. Consequently, it is clear that the use of antibiotic
catheters is a valuable and cost-effective infection-prevention strategy.
However, guidelines only recommend their use in cases where the
risk of catheter-related bloodstream infection is unacceptably high,
despite the implementation of basic infection-control strategies [54].
1.4.4 Silver-coated anti-infective catheters
The efficacy of antibiotic-coated medical devices as a novel prophy-
laxis against catheter-related infections has been established through
clinical trials. However, the use of these catheters has received a
varied response as a result of drawbacks regarding its suitability,
including the associated risk of potential escalation in the emergence
of drug-resistance amongst bacteria and limitations in broader device
applications due to its greater efficacy at preventing infections caused
by Gram-positive, rather than Gram-negative bacteria [141]. An
alternative catheter-related infection prevention strategy that involves
the coating or impregnating of catheters with silver-based antiseptic
agents, has been reported in the literature and commercialised
products are available in the U.S. [128].
The intrinsic antimicrobial properties of silver has been utilised
for countless applications including the treatment of infections,
burns and wounds [142]. Modern technology has harnessed the
anti-infective properties of silver and silver ions and its incorporation
into medical implants results in materials that show efficacious
antimicrobial activity, even at low silver concentrations [97, 143], with
lower toxicity to human cells, relative to other heavy metals [97, 143].
Metallic silver is ‘inert’, however, it reacts with moisture for example,
on a patient’s skin and rapidly ionises, generating highly reactive
species [97, 142]. These silver ions can bind to DNA and RNA in mi-
crobial cells and tissue-proteins, ultimately effecting cell deformation
and death, subsequent to impeding cellular replication and causing
structural changes in bacterial cell walls and nuclear membranes
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[142–144]. Silver-based antimicrobials have been developed using
metallic silver, nanoparticulate silver, silver sulfadiazine and silver
zeolites and it has been commented that the antimicrobial activity
demonstrated is proportional to both the amount of silver and the
rate it is released from its host [142].
Although the complete mechanistic detail of its bactericidal activity
is not fully understood, silver-compounds have been employed as
an antimicrobial coating in medical devices including catheters [143,
145–148], to prevent bacterial surface colonisation and reduce the
risk of associated infection. The use of urinary catheters impregnated
with silver alloy resulted in a statistically significant reduction in bac-
teriuria, in patients catheterised for both less than and more than one
week [122]. However, no similar effect was noted when silver oxide
impregnated catheters were used [122], or in patients catheterised
with silver alloy impregnated devices for long-term bladder drainage
[149]. The use of silver alloy intravascular catheters has not been
reported in the literature. However, intravascular catheters have been
modified such that they exhibit antimicrobial properties through the
incorporation of anti-infective agents, such as the combination of
chlorhexidine and silver sulfadiazine and these catheters have been
reported as an efficacious and prospectively cost-effective approach
[124, 148, 150].
1.4.5 Chlorhexidine and silver sulfadiazine-coated catheters
‘First-generation’ antiseptic catheters were coated with chlorhexidine/
silver sulfadiazine (CSS) on the external surface only and gradually
release the antimicrobial agents into the host tissue in the environs of
the implanted catheter, demonstrating antimicrobal activity against
a range of pathogens causing nosocomial vascular catheter-related
bloodstream infections [148]. In a multi-centre randomised trial it
was observed that in comparison to a control group, the use of
these CSS anti-infective catheters achieved a sevenfold decrease
in microbial cutaneous colonisation of the catheter insertion site,
in addition to a fivefold reduction in the incidence of associated
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bloodstream infections, especially those caused by Gram-negative
bacilli, enterococci, S. aureus and Candida species [148]. More than 16
randomised clinical studies have investigated the antibacterial effi-
cacy of ‘first generation’ CSS catheters and these trials indicate that
the use of these devices decreases bacterial catheter colonisation [91].
However, only two studies showed a statistically significant reduc-
tion in the incidence of catheter-associated bloodstream infection [91].
A blind, multi-institutional comparative study inferred that central-
venous catheters coated on both surfaces with an antibiotic com-
bination of MR achieved a greater decrease in the incidence of
bloodstream infection than CSS-catheters coated with the antiseptic
agent on the external lumen only [151]. Bacterial catheter colonisation
was 1/3 as likely on MR-coated catheters as CSS-coated catheters
and the associated incidence of bloodstream infection was 1/12 as
probable on MR-coated catheters [151]. In addition, it was found
that the silver antiseptic catheters demonstrated only a short term
antimicrobial activity (3 - 7 days), whereas the MR-catheters exhibited
efficacious antimicrobial activity over a longer duration (4 weeks)
[152].
It can be speculated that the discrepancy in the duration of an-
timicrobial efficacy of the two catheters may at least in part, be
consequent to the difference in the number of surfaces coated with
the antimicrobial agents. To be exact, the MR-catheter had the
antimicrobial agent present on both the internal and external catheter
surfaces, whereas the CSS-catheter had the antiseptic agent present
on the external surface only [148]. Although both the outer and inner
catheter surfaces are key routes of central venous catheter-related
infection, extraluminal bacterial contamination caused by microbial
migration from the insertion site, is a frequent cause of infection
in patients undergoing short-term catheterisation [153]. Therefore,
an antimicrobial coating on the external catheter may help prevent
microbial colonisation and the onset of infection. Conversely, the
incidence of infection in patients catheterised for extensive time
lengths can be predominantly attributed to intraluminal bacterial
colonisation caused by catheter-hub or infusate contamination
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[153] and subsequently, the incorporation of antiseptic agents on
both the internal and external catheter surfaces may help decrease
the incidence of microbial catheter colonisation irrespective of the
catheterisation duration.
‘Second-generation’ CSS-catheters were developed and both the
internal and external surfaces of these catheters were coated with the
antiseptic agent [91]. Moreover, the concentration of the antimicrobial
agent on the external surface of the ‘second-generation’ CSS catheters
was three times higher than the concentration used to coat the same
surface in the ‘first-generation’ CSS catheters [154]. The antibacterial
efficacy of these ‘second-generation’ anti-infective catheters was
investigated in three multi-institutional, randomised clinical trials
[91, 154–156]. It was reported that although the antiseptic catheters
significantly decreased bacterial catheter contamination, there was
no statistically significant reduction in the prevalence of associated
bloodstream infection [154–156]. However, these studies were un-
derpowered to show a statistically significant decrease in the rate
of catheter-related infections [39, 91]. In a more recent study, the
use of ‘second-generation’ CSS catheters reduced the prevalence
of catheter-related bloodstream infections in patients catheterised
using internal jugular venous access [157]. Moreover, it was found
that the use of these catheters reduced immediate intravascular
catheter related costs [157] and may be a cost-effective strategy in
settings where there is a high risk of catheter-related bloodstream
infections [39, 158]. Nevertheless, several disadvantages have been
noted regarding the utilisation of these catheters, including the use of
sulfadiazine resulting in bacterial cross-resistance with the frequently
used antibiotic trimethaprim-sulfamethoxazole, chlorhexidine resis-
tance in Gram-negative bacteria, in addition to possible anaphylaxis
attributed to chlorhexidine sensitivity [91, 152, 157].
Hypersensitivity reactions caused by CSS catheters have been ob-
served in Japan and in 1997, they were withdrawn from the Japanese
market after 13 incidents of catheter-associated hypersensitivity
responses were reported [128, 159, 160]. It can be suggested that the
anaphylactic response is triggered by the presence of chlorhexidine-
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based antiseptics in the catheter coating, which have reportedly been
associated with inducing hypersensitivity reactions in other medical
applications [97, 161], in many countries including the U.S. [98], U.K.
[99, 100], Switzerland [101] and Japan [102]. In catheter applications,
the concentration of chlorhexidine employed for antisepsis is below
the documented threshold for cytotoxicity, however, hypersensitivity
reactions caused by drugs can be dose-independent and a reaction
can potentially be induced by even minimal leaching of the chlorhex-
idine into host tissue in the environs of the catheter [97, 159, 162].
In addition to prior findings indicating chlorhexidine sensitivity
in medical applications [98, 99, 128, 163], recently, there have been
an increasing number of reported cases regarding anaphylaxis
associated with the utilisation of the CSS catheters in the U.S. [164],
U.K. [165–167] and Australia [168]. Nevertheless, catheters coated
with a combination of chlorhexidine and silver sulfadiazine have
been approved for use by the FDA and are commercially available
in the U.S., where sales of these catheters have exceeded 2.5 million
units [128]. CDC guidelines (2011) ‘strongly recommend’ the use
of antiseptic catheters such as the CSS- or MR-coated catheters, in
patients with an expected catheterisation duration of > 5 days, where
adherence to standard catheter care strategies (maximal sterile barrier
precautions, healthcare personnel education and cutaneous antisepsis
using > 0.5 % chlorhexidine/ alcohol) has not effectively reduced the
rate of associated bloodstream infection [39, 128].
Overall, the CSS-coated central-venous catheters have demonstrated
antimicrobial efficacy and cost-effectiveness, reducing bacterial
catheter colonisation and decreasing the incidence of associated
infection in high-risk patients [124, 150, 169]. However, the estimated
additional cost of the CSS-coated catheter ($25) in comparison to
uncoated catheters, exceeds that of the MR-coated catheters ($14),
despite the reduced antibacterial activity demonstrated [125, 148,
151]. Moreover, although no evidence of bacterial resistance was
exhibited in clinical studies [148], the emergence of microbial resis-
tance to a chlorhexidine-based compound was demonstrated in an
in-vitro investigation [164, 170], raising concerns that the introduction
of these antiseptic catheters in routine healthcare practice, could
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effect the development of bacterial resistance to anti-infective agents.
Consequently, although these catheters are FDA approved and
recommended for use in high-risk patients, the considerable concerns
associated with their use, indicates that an alternative antimicrobial
strategy to reduce the risk of catheter-related bloodstream infections
is necessary.
1.4.6 Oligon catheters
Intravascular catheters coated with antimicrobial agents, for example
MR-coated catheters or CSS-coated catheters, have been associated
with a decreased incidence of microbial catheter colonisation and a
reduced risk of catheter-related bloodstream infections [125, 148, 152].
However, the antimicrobial activity demonstrated by these catheters
can be attributed to a coating on the catheter surface, rather than
the incorporation of the antimicrobial agents throughout the catheter
material bulk, perhaps limiting the bactericidal efficacy. A novel
catheter composed of an antibacterial material, oligon, consisting of
a polyurethane host matrix impregnated with carbon, platinum and
silver, was developed [171]. The silver antiseptic agent was impreg-
nated throughout the catheter material, resulting in a controlled and
sustainable release of antibacterial silver ions from both the intra-
and extraluminal surfaces, through an iontophoretic reaction [172],
hindering microbial catheter colonisation [171].
In-vitro investigations indicate that when placed in a “conductive
fluid medium” such as saline solution or blood, oligon effects a
continual release of silver ions down the ‘electrochemical gradient’ to
the surface of the catheter and this ion release mechanism continues
over a period of nine months [172]. Moreover, in-vitro studies demon-
strated that oligon exhibits strong antimicrobial activity against a
range of Gram-positive and Gram-negative bacteria notorious for
catheter-colonisation, including S. epidermidis, S. aureus, E. coli, P.
aeruginosa and Candida species [97, 172]. Clinical studies, including
a multi-institutional investigation, showed that the use of an oligon
catheter reduced the incidence of microbial catheter colonisation in
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intravascular-catheterised patients and may decrease the incidence
of associated infection [130, 171, 173]. Conversely, other trials have
concluded that oligon catheters are not effective in reducing bacterial
catheter colonisation or the risk of associated bloodstream infections
[172, 174].
A recent in-vitro study investigated the comparative antimicrobial ac-
tivity, in addition to the anti-adherence efficacy, of a range commer-
cial anti-infective catheters such as MR-coated, CSS-coated and silver-
impregnated (oligon) devices, against multi-drug resistant bacteria
commonly associated with catheter-related infections [175]. The rel-
ative bactericidal activity against catheter-associated Gram-negative
and Gram-positive bacteria, including vancomycin-, rifampin- and
methicillin-resistant S. aureus was evaluated and it was observed that
the most potent and enduring antimicrobial and anti-adherence prop-
erties were demonstrated by the MR-coated catheters [175]. Moreover,
it was noted that the silver impregnated (oligon) catheters exhibited
comparatively inferior bactericidal and anti-adherence activity, rela-
tive to the MR- and CSS-coated catheters [175]. These in-vitro results
were supported by the findings of a comparative clinical study, which
demonstrated that the MR-coated catheters superseded that of the
oligon catheters, in terms of the prevention of bacterial catheter coloni-
sation [130]. Overall, the results of the in-vitro studies and the incon-
sistencies in the findings of clinical studies, casts doubt on the efficacy
of the antimicrobial properties of the oligon catheters and its strength
as a strategy to decrease the risk of catheter-associated infection.
1.4.7 Silver/ hydrogel-coated catheters
An alternative method to control microbial device colonisation,
is the use of catheters with extremely hydrophilic surfaces. This
can be achieved using a hydrogel coating which helps to prevent
microorganisms from adhering to the device surface. Hydrogels
are macromolecular cross-linked polymers capable of absorbing
substantial volumes of fluid within their structures, resulting in the
formation of a thin ‘sheet’ of water on the surface which facilitates
an inherent ‘self-cleaning’ action [116, 176, 177]. Catheters modified
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with a hydrogel coating would present an extremely smooth, hy-
drophilic surface that is unfavourable for microbial attachment and
colonisation, hindering biofilm formation and potentially reducing
the likelihood of the incidence of associated infection [97, 116]. In
addition, the thin film of water at the hydrogel-coated catheter
surface, increases lubricity and this may prove beneficial in clinical
applications, by enhancing patient comfort through relieving irrita-
tion to host membranes [97, 116].
There are many commercially available hydrogel-coated (urinary)
catheters and although they may demonstrate antimicrobial adhesion
properties, these catheters have no intrinsic anti-infective capabilities.
Attempts have been made to incorporate antiseptic silver ions into the
hydrogel-coated catheters and in-vitro studies confirmed the efficacy
of silver/ hydrogel-coated catheters, at repressing both Gram-positive
and Gram-negative bacterial surface adhesion, compared to both
hydrogel-coated and uncoated control catheters [116, 178, 179]. The
suppression of microbial silver/ hydrogel-coated catheter adhesion
may prove advantageous in clinical applications, particularly in
preventing or delaying the onset of urinary tract infections in
catheterised patients [178]. Conversely, an in-vitro investigation indi-
cated that hydrogel coatings assist bacterial migration across catheter
surfaces and it was found that the additional incorporation of
antiseptic silver into the hydrogel coating, did not impede microbial
migration across the catheter surface [116, 180]. Moreover, clinical
studies, including one multi-institutional investigation, reported
conflicting findings regarding the efficacy of the bactericidal activity
of the silver/ hydrogel-coated catheters [116].
A double-blind clinical study demonstrated that the use of silver/
hydrogel-coated catheters was an adequate prophylaxis against
catheter-related urinary tract infections caused by Candida species
and Gram-positive bacteria that generally frequent the extraluminal
catheter surface [121, 181]. Furthermore, a multicentre randomised
trial indicated that the use of hydrogel catheters coated on both
the intra- and extraluminal surfaces with a monolayer of metallic
silver, effected a “trend” towards a decrease in the prevalence of
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catheter-related infections [182]. However, in most cases this trend
was deemed “statistically insignificant”, although the use of these
catheters was still categorised as a cost-effective approach in one
centre [182]. Further clinical trials reported that the utilisation of
silver/ hydrogel-coated catheters resulted in a noticeable decrease in
the incidence of urinary tract infections in catheterised patients [183,
184]. Due to the insufficient evidence that the use of silver/ hydrogel-
coated catheters reduces the risk of catheter-related infections, the
use of these catheters is not recommended [185, 186].
Overall, the efficacy of the bactericidal activity of silver/ hydrogel-
coated catheters is inconclusive and their use as a prophylaxis
for catheter-related infections is currently not acknowledged in
urinary-catheter care recommendations [116, 187]. Moreover, to date,
antiseptic hydrogel technology has not been used for applications
in intravascular catheterisation and clinical studies have focused on
the prevention of urinary tract infections in catheterised patients.
Consequently, due to the inconclusive antimicrobial efficacy of the
antiseptic hydrogel catheters, in addition to their limited applicability,
it can be suggested that this is not an effective preventative strategy
against catheter-associated infections.
1.4.8 Problems associated with the use of silver as an infection-prevention
strategy
The use of silver as an antiseptic agent in clinical applications has
raised concerns about the development of argyria, where the most
dramatic symptoms are the accumulation of silver in the host skin
tissue due to leaching of silver ions from the polymeric host, resulting
in a grey skin hue [97, 141, 188]. An additional concern is that genes
encoding silver-ion resistance, are often selected for upon bacterial
exposure to silver salts in hospital antiseptics and it has been reported
that more than 10 % of an arbitrary selection of enteric bacteria in
a hospital in Chicago, demonstrated genes for silver-ion resistance
[189, 190]. Silver-resistance has also been documented in bacteria
colonising the urinary tract, including strains of Proteus mirabilis,
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Klebsiella pneumoniae [191] and E. coli [189] and therefore, it can be
suggested that widespread silver exposure, for example, through the
integration of silver-coated catheters into daily medical care, may
impact on the prevalence of silver-resistant bacteria [97, 190].
Overall, the use of catheters incorporated with silver, for example,
in silver/ hydrogel and oligon devices, has demonstrated inconclu-
sive evidence in reducing the risk of catheter-associated infection.
Catheters coated with CSS have exhibited efficacious antimicrobial
activity, reducing microbial catheter colonisation, however, clinical
studies have indicated that these catheters are not as effective as the
antibiotic MR-coated devices [130, 150, 175].
1.4.9 Heparin-coated catheters
Heparin, a polysaccharide anticoagulant with no inherent antimicro-
bial properties, has been used by itself or in combination with other
antimicrobials, as a catheter rinse or lock [192–195]. The anticoagulant
properties of heparin stem from its ability to bind to antithrombin,
forming antithrombin-thrombin complexes, thus inactivating it and
preventing the conversion of fibrinogen to fibrin [195]. It has been
documented that catheter-related bloodstream infections can be
caused by thrombosis formation in catheterised patients [192] and
therefore heparin is systemically used to reduce the risk of blood
clots in central-vascular catheterised patients, to decrease the risk of
infection [196].
Protein constituents of a thrombus such as fibrinogen, fibrin and
fibronectin, can assist catheter surface adherence of key causative
pathogens for nosocomial infection, including S. epidermidis, S. aureus
and Candida species [192, 197–199]. Consequently, heparin-coating or
-bonding on catheters has been used as a strategy to help decrease
the risk of device-associated infection [195, 200–203] since the 1980s
[200]. Although the mechanism of infection-prevention activity has
not been entirely rationalised, it can be suggested that the presence
of heparin decreases the accrual of fibronectin, hindering bacterial
33
surface adherence and subsequent catheter colonisation [200, 203]. A
heparin-coated polyurethane catheter for haemodialysis applications
has been approved for use by the FDA and the heparin is covalently
bound to both catheter surfaces through an ‘end-point linkage
mechanism’ [195]. The advantage of this strategy for heparin attach-
ment is that it does not impinge on the site at which the molecule
binds to antithrombin (enabling complexation with and deactiva-
tion of thrombin) [195]. After complexation with antithrombin, the
antithrombin-thrombin complex ‘detaches’ from the polyurethane-
bound heparin molecule, enabling continual anticoagulant catheter
activity [195] and potentially, a prolonged efficacy at reducing the
risk of associated infection.
Results across three clinical studies demonstrated that the use of
heparin-bonded catheters resulted in a significant decrease in the
incidence of associated bloodstream infection compared to standard,
uncoated central-venous catheters [200, 202–204]. A further trial
demonstrated that the use of a heparin-bonded haemodialysis
catheter reduced the risk of catheter-related bacteremia, however,
it was noted that it did not impact on the incidence of catheter
malfunction [205]. The lack of improvement on catheter patency was
also observed in a different trial [195]. Moreover, the use of heparin
can also trigger antibody-mediated thrombocytopenia (condition
where platelet count is low) and several cases have been reported in
the early use of pulmonary-artery catheterised patients with heparin-
associated antiplatelet antibodies [206, 207]. If heparin-induced
thrombocytopenia occurs, removal of the catheter is necessary to
reverse thrombocytopenia and avoid complications [207]. However,
according to the catheter manufacturer (Cook, Indiana, U.S.A.), no
cases have been associated with the use of their catheters [200].
Various clinical studies have directly compared the antimicrobial
activity of different types of antiseptic catheters. One trial evaluated
the antimicrobial efficacy of heparin-coated central-venous catheters
inserted in the subclavian vein under operating room conditions,
relative to that demonstrated by CSS-coated central-venous catheters
inserted under identical conditions [208]. It was observed that the
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incidence of catheter-related infection was only marginally higher
in the heparin-catheter arm of the study than in the CSS-catheter
arm and the chief causative pathogens for infection were coagulase-
negative staphylococci, S. aureus, Candida species and P. aeruginosa
[208]. Interestingly, there was a similar incidence of central-venous
catheter associated thrombosis in both study arms [208]. Another
clinical study comparing the antimicrobial efficacy of the heparin-
bonded catheter and CSS-catheter confirmed these findings and
reported that the use of CSS-catheters did not reduce the incidence
of catheter-related infections, compared to heparin-coated catheters
[209]. However, the prevalence of catheter colonisation was lower in
the CSS-catheter group [209].
A recent “network meta-analysis” indicated that the use of heparin-
bonded catheters decreased the prevalence of catheter-related blood-
stream infections and demonstrated a similar infection-prevention
efficacy as MR-coated catheters [210]. Moreover, a further systematic
review commented that currently, the strongest line of defence in
reducing the incidence of catheter-related bloodstream infections
are heparin-coated or MR-coated catheters [200]. Nevertheless, no
reduction in microbial catheter colonisation was noted for heparin-
bonded devices and it was commented that this may decrease the
reliability of the infection-prevention efficacy of these catheters [210].
The network meta-analysis cautiously concluded that compared to
the other antiseptic catheters reviewed (including CSS, silver alloy,
oligon and heparin), MR-catheters can be considered as a superior
anti-infective catheter in clinical applications, as a prophylaxis
against catheter-related infection [210], although a high-quality, large,
randomised controlled trial is necessary to conclusively determine
which is more effective [200].
1.4.10 Are anti-infective devices the way forward?
The prevalence of catheter-related bloodstream infections has gener-
ated much interest amongst the scientific community and hundreds
of different prophylactic strategies have been investigated and eval-
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uated over the decades. The modification of commercial catheters
such that they incorporate antiseptic agents as a means to prevent
microbial catheter colonisation and subsequent bloodstream infec-
tion, has been thoroughly examined and several of these products
have been commercialised, including oligon catheters, CSS-catheters,
heparin-bonded catheters and MR-catheters. It has been suggested
that MR-coated catheters demonstrate the most efficacious infection-
prevention activity, nevertheless, the effectiveness of heparin-coated
catheters is also significant [200, 210]
The use of antimicrobial catheters as a cost-effective strategy has
been evaluated in the literature [124, 150, 211–213]. It has been
commented that the cost of heparin-coated or antibiotic-coated
catheters (Cook Inc., U.K.) is almost double that of standard uncoated
catheters, but CSS-catheters are less expensive [200]. However, the
financial burden associated with the incidence and treatment of
catheter-related bloodstream infections is heavy and therefore, the
use of anti-infective catheters is recommended as a cost-effective
approach in ICU patients, even when the risk of infection is relatively
low [200, 211–213]. Comparing MR-catheters and CSS-catheters,
the former device has been reported to perform better ‘financially’
and is a more economically attractive strategy for the prevention of
catheter-associated bloodstream infections [212]. However, there are
disadvantages and concerns associated with the use of antimicrobial
devices. It has been noted that in many of the clinical trials conducted
that cutaneous antisepsis was accomplished using the povidone-
iodine antiseptic, rather than the recommended chlorhexidine-based
preparation [125, 127, 129, 171, 173, 202, 209]. Consequently, it is
unclear whether the use of the antimicrobial catheter would result in
a significantly enhanced effect against catheter-related infections, if
the recommended cutaneous antisepsis protocols had been executed.
Moreover, there are fears that the use of antibiotic-based strategies
may escalate the prevalence of bacterial resistance [125, 132, 133,
135]. Consequently, although the use of antiseptic catheters such as
MR-coated or heparin-coated devices may be a cost-effective strategy
and impact on the incidence of catheter-associated infections, these
antimicrobial devices are associated with significant shortcomings
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and therefore, research into an alternative infection-prevention strat-
egy, in particular, one in which the emergence of bacterial resistance
is improbable, is key.
Antimicrobial medical devices have demonstrated efficacy in reduc-
ing the risk of catheter-related infections. However, the development
of alternative antimicrobial surface technologies for use in healthcare
applications with a reduced associated risk of the emergence of
bacterial resistance are sought after, to decrease the incidence of
HAIs without compromising current antibiotic approaches. The next
chapter introduces a novel surface disinfection strategy, that through
light-activation, generates cytotoxic species that initiate a multi-site
attack against bacteria in the vicinity, so killing them. This chapter
also provides a foundation for the research strategy detailed in this
thesis.
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2
P H O T O D I S I N F E C T I O N O F S U R FA C E S
2.1 photodynamic therapy approach
The previous chapter reviewed strategies to decrease the risk of
HAIs associated with the use of catheter devices and highlighted
that current infection-prevention approaches demonstrate varying
efficacies in terms of their antimicrobial activity and impact on
associated infection rates. The chapter also detailed further concerns
including the potential increase in bacterial resistance where an-
tibiotics are used in prophylaxis approaches and the incidence of
severe adverse reactions to infection-prevention strategies using the
antiseptic ‘chlorhexidine’. Consequently, there is a dire need for the
development of new, efficacious antimicrobial surfaces for use in
medical device and hospital touch surface applications, with the aim
of reducing the risk of hospital-acquired infections.
This chapter details the development of antimicrobial surfaces that
kill bacteria through a novel light-activated mechanism. The chap-
ter details the origins of the ‘photodynamic reaction’ exploited in
this antimicrobial strategy, the photophysical processes involved and
reviews the development of photosensitiser-based photobactericidal
polymers. This chapter provides a foundation for the research de-
tailed in this thesis, which exploits the ‘photodynamic reaction’ in
the development of light-activated antimicrobial polymers with in-
corporated photosensitiser dyes and nanoparticles, that kill bacteria
through the photo-generation of cytotoxic species.
2.1.1 Photodynamic Therapy; A Brief History
In the beginning of the 20th century, a lethal, light-activated bacte-
ricidal technique; photodynamic therapy (PDT), was pioneered [1].
Oskar Raab first observed the phototoxicity of acridine hydrochloride
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against Paramecia caudatum [1–3] and further investigation into this
phenomenon by his supervisor, Hermann von Tappeiner, confirmed
that the deactivation of bacteria was not a consequence of heat, but
rather a light-activated effect, a “photodynamic reaction” [1, 4, 5].
Since the discovery of this photodynamic reaction, much research
effort has been invested into the utilisation of PDT, particularly
in applications related to tumour detection [2, 6–10] and tumour
photodestruction [2, 11–16]. However, until recently, photodynamic
antimicrobial therapy has been less well studied [17].
The use of PDT as a powerful antimicrobial tool was abandoned
upon the discovery of antibiotics such as penicillins around 60 years
ago, as antibiotics were found to possess antibacterial therapeutic
effectiveness [1, 18–20]. However, with the accelerating rise in bac-
terial drug resistance [19], recently there has been much research
Figure 3: Chemical structures of examples of tetrapyrrole-based and non-
tetrapyrrole based photosensitiser molecules
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into the development of alternative anti-infective strategies. These
include the use of organic photosensitisers or inorganic nanoparticles
(TiO2) in PDT [21] to treat localised infection [22] and to effect the
photocatalytic destruction of bacteria for example on glass surfaces
[23, 24], polymer surfaces [25–33] and titania surfaces [34–36], to
reduce the prevalence of microbial contamination.
2.1.2 The Use of Photosensitiser Molecules in PDT
Photosensitisers used in PDT are commonly heterocyclic ring type
structures, as exampled in Figure 3, that demonstrate low toxicity in
the dark, but which generate cytotoxic species upon photo-activation
in the presence of oxygen [37, 38]. These photosensitive compounds
can be sub-categorised under (i) porphyrin-based and (ii) chlorophyll-
based structures, in addition to (iii) dye molecules [38].
The photoprocesses that occur upon excitation of photosensitiser dye
molecules, shown in Figure 4, are as follows. Upon illumination, typ-
ically with laser light of a wavelength correlating to the absorbance
peak maximum, the photosensitiser molecule is promoted to an
excited singlet state, after which it undergoes a radiationless process,
an intersystem crossing, to a lower energy, longer lifetime triplet
state [2]. This triplet state can undergo one of two photochemical
processes namely, a Type I (electron transfer) or a Type II (energy
transfer) photoprocess [2, 37]. The Type I photochemical pathway
involves the interaction of the triplet state with substrate molecules,
for example biomolecules, generating a wide range of reactive oxygen
species (ROS) such as superoxide anions and hydroxyl radicals, in
addition to other radicals [1, 2]. The triplet state can also undergo a
Type II photoprocess in which it is quenched through collision with
molecular oxygen in the environs, generating the highly reactive,
transient species, singlet oxygen, which subsequently forms adducts
with organic substrate molecules [1, 2]. The triplet state species of the
excited photosensitiser can interact with molecular oxygen, since it
has a triplet state ground state and low lying excited states and this
interaction between the two triplet states results in the production of
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Figure 4: Jablonski diagram representing processes involved in photody-
namic therapy. The ground state photosensitiser molecule absorbs a photon
of energy and is promoted to an excited singlet state. The excited singlet
state molecule can release energy radiatively (fluorescence), via internal con-
version or can undergo an intersystem crossing to the excited triplet state.
The triplet state molecule can release energy as radiation (phosphorescence)
or transfer its energy to surrounding molecules by either Type I or Type II
photoprocesses and return to the ground state. A Type I photoprocess in-
volves the interaction of the triplet state dye with substrate molecules in the
vicinity, resulting in their oxidation and a Type II photoprocess involves the
quenching of the triplet state by molecular oxygen
singlet oxygen, a low energy triplet-singlet transition in oxygen of
∼ 22 kcal mol-1 [2]. The ROS generated upon the irradiation of the
photosensitiser molecule can subsequently initiate a multi-site attack
mechanism against cellular membranes, intracellular proteins and
DNA of bacteria in the vicinity, rendering the likelihood of the inci-
dence of resistance, improbable [18, 28, 39]. Multi-site attack reduces
the likelihood of resistance as multiple mechanisms of resistance will
have to occur simultaneously in the same microorganism.
The generation of ROS such as the cytotoxic singlet oxygen species,
gives rise to the potential for the utilisation of photosensitisers in
antimicrobial PDT applications. However, an important factor for
consideration is the selectivity of the photosensitising agent towards
bacterial cells. Studies demonstrated that antimicrobial PDT regimes
67
sufficient to cause the efficacious photosensitisation of the bacteria
tested, did not result in a similar cytotoxicity towards mammalian
cells [40–43]. It was found that photosensitiser concentrations and
illumination time-periods that effectively reduced bacterial levels, did
not damage mammalian cells [40, 41, 43]. Moreover, the photo-kill
rates of human keratinocyte cells was on average 200-fold slower
than cutaneous prokaryotic bacteria and 18-fold lower than Candida
species tested previously, using the same irradiation conditions [42,
44]. However, it was noted that exposure to higher photosensitiser
concentrations did impact on the survival rate of human fibroblasts
and keratinocytes [41]. In addition, lengthier irradiation times (>
90 minutes) affected the ability of mammalian cell recovery (48 %),
implying a greater likelihood of irreversible keratinocyte cell damage
[42]. Nevertheless, these more rigorous conditions far surpass those
required for the effective photosensitisation of the bacteria tested
and thus, it can be suggested that PDT conditions that efficaciously
eradicate bacteria are not expected to cause irreversible damage to
surrounding host cells.
Although the discovery of the “photodynamic reaction” was asso-
ciated with bacterial photoinactivation [1], initial intensive research
relating to PDT used this technique for tumour detection and
photodestruction [2]. Many of the photosensitisers examined for the
treatment of tissue disease and cancers, such as the porphyrin-based
PhotofrinTM, chlorophyll-based chlorins and bacteriochlorins and so
forth, are based on a tetrapyrrole nucleus type structure [37, 38]. The
use of PDT can result in the rapid destruction of tumours, however,
damaged healthy tissue efficiently recovers over the course of 6 - 8
weeks after treatment [45]. It has also been noted that some photo-
sensitisers preferentially accumulate in tumour tissues as opposed
to normal surrounding tissues and this can be used to help deliver
a sufficient concentration of photosensitiser to target cells for PDT,
without causing unnecessary photodamage to normal tissue [16, 45].
PDT has also been considered for and utilised in many other medical
applications, including as a strategy to treat Barrett’s oesophagus
[37, 46], a treatment for age-related macular degeneration [37, 47, 48]
and also as a potential therapeutic measure for psoriasis, although
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adverse associated side effects such as burning sensations and pain
have been reported [1, 37, 49, 50].
Many of the photosensitiser molecules used in PDT cancer therapies
are porphyrin- or chlorin- based structures, however, there are many
photosensitisers with different molecular structures, for example,
photosensitiser dyes which are used in antimicrobial PDT for the
lethal photosensitisation of microorganisms [37]. Numerous studies
have examined the use of planar tri-heterocyclic photosensitiser dye
molecules, including phenothiazines such as toluidine blue O [51, 52],
halogenated xanthenes such as rose bengal [53] or acridines [20, 54],
to effect the lethal photosensitisation of bacteria [37]. Trials investigat-
ing the use of PDT to treat bacterial wound infections caused by both
Gram-positive and Gram-negative bacteria have proven successful
in animal models [1, 22, 55–61]. Moreover, although in one study
it was reported that a strain of Candida glabrata was insensitive to
PDT under the conditions used [62], overall, the results of in-vitro
investigations demonstrated that some Candida sp. are susceptible to
photosensitisation and the use of PDT may be a promising alternative
to current fungicidal strategies to treat infections [62–65]. The use
of methylene blue-mediated PDT has also shown promising results
in an in-vivo study using mice models, in the treatment of oral
candidiasis [63].
PDT has been exploited for dentistry related applications including
oral cancer therapies, in addition to the treatment of bacterial and
fungal oral infections [1, 22, 66]. Toluidine blue-mediated PDT re-
sulted in the photo-inactivation of Porphyromonas gingivalis, a bacteria
considered to be a leading cause of periodontitis in adults, in a rat
model [67]. Further in-vivo studies employing rat models [68–72]
or a beagle dog model [73] of periodontal disease, demonstrated
the therapeutic efficacy of PDT in the treatment of periodontitis,
both alone [70, 71, 73] and as an adjuvant treatment to mechanical
scaling and root planing methods [68, 69, 72]. Pre-clinical trials have
indicated potential advantages in the utilisation of PDT to treat
periodontal disease and recently there have been some small-scale
clinical trials (6 24 patients) [22, 74–77], to determine whether this
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beneficial effect is demonstrated in actual clinical applications.
Clinical trials indicated conflicting results with regard to the overall
benefit of using PDT in combination with mechanical scaling and
root planing methods to treat periodontal disease [74–77]. In two
trials it was found that as an adjunctive method, a single episode
of PDT failed to enhance the effects of scaling and root planing
strategies in patients with chronic periodontitis in terms of “probing
depth” reduction and “clinical attachment level” gain, however, it was
noted that there was a statistically substantial reduction in “bleeding
scores” [74, 75]. Conversely, a different study indicated that the use of
adjunctive PDT proved efficacious in the treatment of patients with
chronic periodontitis [76]. Although PDT was reported to be well
tolerated in patients and is a less time consuming treatment strategy
than implemented scaling and root planing methods, further clinical
trials are vital in order to determine whether the use of adjunctive
PDT is beneficial in the clinical treatment of periodontal disease [77].
Despite the inconsistencies in the small-scale clinical trials conducted,
currently there is much industry research interest into the use
of antimicrobial PDT to treat dental infections. Three companies:
Ondine Biopharma (North America), HELBO Photodynamic Systems
(Austria) and Denfotex (United Kingdom), are involved in clinical
trials and the commercialisation of PDT therapies, including those
for the treatment of periodontitis [22]. Ondine Biopharma have devel-
oped PeriowaveTM, a system to be used in conjunction with scaling
and root planing methods, for the photodestruction of remaining
oral bacteria [78]. Ondine Biopharma have instigated 5 clinical trials
to evaluate the validity and safety of this antimicrobial strategy
and the system, which utilised the photosensitiser methylene blue
in combination with a 660 nm laser device, has been used in over
75,000 treatments and is currently available in Canada, Korea, Mexico
and the U.K. [22, 78, 79]. Ondine Biopharma have also invested
research power into the development of PDT systems for chronic
sinusitis (SinuwaveTM), nasal bacterial decolonisation (MRSAidTM),
the photo-sterilisation of endotracheal tubes in mechanically ven-
tilated patients (ExelumeTM) and the decolonisation of the birth
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canal to prevent transmission of HIV and other pathogens in third
world countries (VitalwaveTM) [78]. HELBO Photodynamic Systems
and Denfotex have also developed light-activated oral disinfection
systems employing another phenothiazine dye toluidine blue O, in
combination with a 635 nm red laser light system, for the potential
treatment of periodontitis and endodontic infections [22, 80, 81].
Overall, PDT utilising photosensitiser molecules has exhibited a
promising efficacy in in-vitro and in-vivo investigations for the lethal
photosensitisation of pathogenic microorganisms. The demonstrated
antimicrobial efficacy can be further exploited through the fixation
of these molecules in polymeric materials, such that the resultant
modified materials are theoretically self-sterilising.
2.2 self-sterilising polymers
2.2.1 The Role of Surfaces in Hospital-Acquired Infection
It has been estimated that in ICUs of U.S. hospitals, the endogenous
microbiota of patients is a key source of pathogens, associated with
approximately 40 - 60 % of nosocomial infection [82, 83]. Surfaces
in healthcare environments have been acknowledged as potential
reservoirs of bacteria associated with the incidence of HAIs [84] and
it is likely that hands of healthcare workers become contaminated
from direct patient contact, or from exposure to colonised hospital
surfaces. These surfaces act as reservoirs of bacteria and constant
contact by healthcare personnel between these surfaces and patients
aid the transfer of bacteria and facilitate the spread of infection within
healthcare institutions [84, 85]. The transmission of bacteria such
as MRSA via person-person contact may not cause serious health
complications outside a clinical environment, but in a healthcare
setting in which there are immunocompromised patients, this simple
transmission of bacteria between healthcare personnel and patients,
may result in morbidity [86]. Although rigorous cleaning regimes
are enforced, it is difficult to prevent the contamination of touch
surfaces in hospitals and despite promotion of healthcare worker
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Figure 5: The role of surfaces in the transmission of hospital infection. (a)
Cycle of bacterial transfer from surfaces to patients. (b) Disruption of cycle
due to the use of an antimicrobial surface
hygiene protocols, in heavily contaminated areas, hand washing may
be ineffectual [84]. Studies have demonstrated bacterial colonisation
of a variety of hospital surfaces including: X-ray cassettes, door
handles, mops, telephones, computers and keyboards, taps, pens,
stethoscopes, sterile packaging and so forth [84, 87–94]. Evidence also
suggests that the resilient spores of C. difficile contaminate hospital
surfaces and medical equipment, with contamination persisting
for extensive durations of up to 5 months, in an unused hospital
room [85, 95, 96]. Similarly, both methicillin-susceptible S. aureus
and MRSA have demonstrated longevity despite desiccation, under
varying experimental conditions [84, 85, 97]. Bacterial contamination
of hospital touch surfaces is extremely prevalent and can cause
potentially avoidable infections. One strategy to reduce hospital
contamination is the use of self-sterilising surfaces (Figure 5). By
utilising an antimicrobial surface, the transmission of bacteria from
surfaces to patients and from surfaces to healthcare workers is
disrupted and may result in a decrease in the spread of associated
infection in healthcare environments.
To prevent the spread of HAIs through direct contact, these microbial
reservoirs need to be targeted. Consequently, the development of
antimicrobial coatings for surfaces, or the modification of materials
such that they demonstrate bactericidal properties, may play an
important role in decreasing the incidence of HAIs, through inhibit-
ing the cycle of the transference of microorganisms from patient to
healthcare worker to surface and so forth, acting to enhance routine
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cleaning regimes [84].
2.2.2 Porphyrin-Based Light-Activated Antimicrobial Polymers
One approach by which this can be achieved is through the de-
velopment of light-activated antimicrobial surfaces incorporating
photosensitisers, that continually and effectively self-clean [98–102].
The utilisation of photosensitisers is advantageous since they effect
a non site-specific, multi-site attack against microorganisms in the
vicinity, hence rendering the development of bacterial resistance
unlikely [37, 103]. Porphyrin-based compounds have demonstrated
the photosensitisation of pathogenic microorganisms upon visible
light irradiation [102] and although the photochemical activity can
effect changes in the structure of the photosensitiser, it has been
noted that the predominant photodegradation products are stable
with respect to subsequent “self-sensitised photooxygenation” and
exhibit a good Type II photochemical activity [102, 104]. Porphyrin-
based photobactericidal materials have been developed by grafting
porphyrin-based compounds onto nylon fibres [102] and alkylated
cellulose [105].
Protoporphyrin IX and zinc protoporphyrin IX were grafted on to
nylon fibres to form light-activated antimicrobial materials which
effected the photo-inactivation of S. aureus, although it should be
noted that the zinc protoporphyrin IX sample showed a more potent
antimicrobial efficacy [102]. Moreover, the zinc protoporphyrin IX
grafted nylon sample exhibited some antimicrobial activity against
E. coli, but only upon irradiation with light intensities of greater than
60,000 lux [102]. These porphyrins have also been grafted on to nylon
films, although the resultant photo-activated antimicrobial activity
was not reported [106]. In a different study, the covalent attachment of
porphyrin compounds to cellulose polymers via a “one-pot, two-step”
esterification reaction to form photo-activated bactericidal films, was
reported [105]. The photobactericidal films synthesised demonstrated
antimicrobial activity against both Gram-positive bacteria (S. aureus)
and Gram-negative bacteria (E. coli), upon illumination with a visible
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light source and it was speculated that the photochemical activity
proceeded via a Type II pathway [105]. The potential use of these
photoactive bactericidal materials in healthcare institutions, may
help decrease the prevalence of microbial surface contamination,
particularly by Gram-positive bacteria [102].
2.2.3 Phenothiazine-Based Photobactericidal Polymers to Coat Surfaces
Phenothiazine photosensitiser dyes such as methylene blue, tolu-
idine blue O and rose bengal have also been used to develop
photo-activated bactericidal materials [25, 26, 28, 29, 98–101]. New
methylene blue, which has been documented to effect cell death as
well as the photodestruction of a P. aeruginosa biofilm on silicone
tubing [107], was incorporated into polymer resins and the antimicro-
bial activity of the resultant copolymer films was tested against both
Gram-positive and Gram-negative bacteria [101]. It was found that
the antimicrobial activity was dependent upon the composition of the
copolymer films, the concentration of the photosensitiser present, in
addition to the light dose received [101]. The photo-activated antimi-
crobial activity of methylene blue-containing styrene-butadiene films
was greater than that observed for the corresponding polyacrylic
ester films and overall, higher concentrations of photosensitiser and
greater light dose energy led to greater lethal photosensitisation of
bacteria [101]. Moreover, in all cases, the demonstrated antimicrobial
activity of the photobactericidal films was more effective against
the Gram-positive bacterium S. epidermidis, than the Gram-negative
bacterium E. coli [101].
Toluidine blue O was incorporated into cellulose acetate, for use as
an antimicrobial paint on surfaces [33, 98–100]. Toluidine blue O in-
corporated cellulose acetate demonstrated promising light-activated
antimicrobial activity against MRSA and P. aeruginosa, with bacterial
kills of the order 105 cfu /cm2 over a 24 hour period of white light
illumination (60-W domestic lamp bulb); adequate to maintain low
levels of microbial contamination on surfaces in occupied hospital
rooms [98]. Subsequent studies involved the incorporation of a com-
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bination of photosensitiser dyes, rose bengal and toluidine O, into
cellulose acetate, to maximise the absorption of light over the visible
spectral range [33, 99, 100] and enhance the lethal photosensitisation
of bacteria.
When illuminated with a white light source (28-W fluorescent lamp)
for periods ranging from 2 hours to 16 hours, the cellulose acetate
coating incorporated with rose bengal and toluidine blue O achieved
the photoinactivation of a range of microorganisms including S.
aureus, MRSA, C. difficile, E. coli and C. albicans under laboratory
conditions [99]. C. albicans was found to be the least susceptible
to photosensitisation using this system, with an 88 % reduction in
viable yeast after 16 hours irradiation [99]. It was also noted that the
Gram-negative bacterium E. coli was less sensitive to photosensitisa-
tion than the Gram-positive bacteria tested, however, 100 % kills were
achieved upon exposure to the dye-incorporated surface irradiated
with white light for 16 hours [99].
When irradiated with a white light source for 6 hours, there was a
significant reduction in the viable count of S. aureus deposited on the
photosensitiser-incorporated cellulose acetate coating, although the
efficacy of bacterial photoinactivation was found to be dependent on
the fluid the bacteria was suspended in [100]. The reduction in viable
bacterial counts was greatest when the S. aureus was suspended
in PBS (99.8 % kill), with decreased activity demonstrated when
aerosols in human saliva and horse serum were used (97.6 % and
78.9 % kill respectively) [100]. Significant kills were also observed
when photosensitiser-free cellulose acetate coatings inoculated with
S. aureus were illuminated, although the photoinactivation of bacteria
on these surfaces was less potent than in the presence of the photo-
sensitiser dye [100, 108]. This interesting finding may be accounted
for by the reported presence of an endogenous photosensitiser in S.
aureus, which is activated when irradiated by light with a wavelength
of 632 nm [33].
The antimicrobial activity of toluidine blue O and rose bengal
incorporated cellulose acetate coatings under the settings of a clinical
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environment was evaluated, to determine whether they effected any
reduction in surface contamination [33]. The study was conducted
over a period of 24 hours and a compact fluorescent lamp was used
to irradiate the dye incorporated coatings [100]. Despite demon-
strating a lesser antimicrobial efficacy than in previous laboratory
investigations [33], the toluidine blue O and rose bengal incorporated
cellulose acetate coatings induced the lethal photosensitisation of
bacteria prevalent in the clinical environment [33]. Moreover, due to
the negligible leaching of the photosensitiser dyes once incorporated
in the coatings, concerns relating to photosensitiser phototoxicity
should not arise, in potential applications to reduce surface contami-
nation in clinical environments [33].
2.2.4 Incorporation of Photosensitiser Dyes into Medical Grade Polymers
A simple dipping method was used to coat medical devices such as
endotracheal tubes and catheters with the antiseptic chlorhexidine,
in combination with triarylmethane dyes for example, gentian
violet and brilliant green [109–113]. Although the light-activated
antimicrobial properties of these materials were not explored, in-vitro
investigations highlighted the inherent bactericidal properties of
the medical devices coated with the broad-spectrum antiseptic
combination [109–111]. These coated samples demonstrated non-
photoactivated anti-adherence properties against Candida species
[109–111], as well as against a range of bacteria including MRSA
[110], P. aeruginosa strains, vancomycin-resistant Enterococcus and
E. coli strains [110, 111]. The gentian violet/ chlorhexidine-coated
surfaces also helped prevent biofilm formation [111]. A further study
demonstrated that endotracheal tubes coated with either the brilliant
green/ chlorhexidine combination or the gentian violet/ chlorhexi-
dine combination prevented device biofilm formation of P. aeruginosa,
MRSA, Enterobacter cloacae, K. pneumoniae and Acinetobacter baumannii,
in addition to C. albicans, demonstrating superiority in terms of their
efficacy at inhibiting biofilm formation, in comparison to commer-
cially available silver catheters [112]. Recent research has also shown
that the use of gentian violet/ chlorhexidine antimicrobial cuffed
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endotracheal tubes effectively prevented microbial proliferation and
transmission, in an in-vitro model [114]. However, concerns regarding
potential chlorhexidine irritation need to be further investigated in
in-vivo studies [114].
Much research effort has been invested into the use of a simple
solvent-facilitated dipping technique, a “swell-encapsulation-shrink”
approach, to incorporate a range of photosensitiser dyes into medical
grade polymers [25, 26, 28–31]. This strategy exploits the finding that
biomaterials such as silicone, swell when exposed to certain solvents
[25, 26, 28–31]. Consequently, polymers immersed in solutions of
solvated photosensitisers swell enabling the diffusion of the dye
molecules throughout the polymeric matrix [25, 26, 28–31]. After re-
moval from the swelling solution, any trapped residue solvent within
the swollen polymer evaporates and it shrinks to its original size,
resulting in strongly coloured dye-encapsulated polymer sections [25,
26, 28–31].
The dye-encapsulated polymers prepared using this “swell-
encapsulation-shrink” technique induced the lethal photosensiti-
sation of both planktonic Gram-positive and Gram-negative bacteria,
when illuminated with either white light [31] or a laser light source
of an appropriate wavelength [25, 26, 28–30]. Reports suggested that
methylene blue solutions also demonstrated a dark toxicity against
some tested S. aureus and MRSA strains [27, 115, 116]. However,
dye-encapsulated polymers kept in the dark demonstrated no bac-
tericidal activity against either the Gram-positive or Gram-negative
bacteria tested [25, 26, 28–31]. This discrepancy can be attributed
to the far greater concentrations of dye that were used in solution
studies, compared to the dye concentrations that were encapsulated
into the polymeric materials investigated [27, 115, 116]. These studies
also showed that despite the fact that the gold nanoparticles used
had no intrinsic antimicrobial properties when in aqueous solution,
the presence of gold nanoparticles significantly enhanced the photo-
sensitisation of bacteria by toluidine blue O [117].
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In contrast to the results of solution studies [117], the additional
incorporation of 2 nm gold nanoparticles did not enhance the
light-activated antimicrobial activity demonstrated by the toluidine
blue O encapsulated polymers when tested against E. coli and in fact,
the presence of gold nanoparticles reduced the potency of the pho-
tosensitisation effects of the material [28]. However, some minimal
enhancement in the photo-activity of toluidine blue O was noted
when toluidine blue O and gold nanoparticle encapsulated polymers
were tested against S. aureus [28]. It was also noted that toluidine blue
O encapsulated polyurethane (with and without gold nanoparticles)
exhibited a more efficacious bactericidal activity than corresponding
silicone samples [28]. This can be attributed to a greater uptake of the
photosensitiser dye into the polyurethane, resulting in a larger yield
of cytotoxic singlet oxygen species upon photoactivation [28]. When
tested against MRSA, all viable bacterial counts decreased below the
detection limit upon irradiation of the samples with red laser light for
< 2.5 minutes, whether nanogold was present or not [28]. However,
in a similar study in which a white light source was used to activate
the dye, a 0.5 log enhancement in the bacterial kill was noted when
polyurethane samples were encapsulated with toluidine blue O in
addition to 2 nm gold nanoparticles, when the samples were tested
against S. aureus [31].
Studies showed that polymers encapsulated with another phenoth-
iazine dye, methylene blue, in addition to 2 nm gold nanoparticles,
demonstrated an enhanced light-activated antimicrobial activity
against Gram-positive and Gram-negative bacteria, compared to
those encapsulated with methylene blue only [25, 26, 31]. The
properties of gold nanoparticles are size dependent and particles
greater than 4 nm demonstrate a phenomena termed ‘surface plas-
mon resonance’, which results in strong nanoparticle colouration
[25]. Therefore, the effect of the varying the diameter of the gold
nanoparticles on the photobactericidal activity of the methylene
blue/ nanogold-encapsulated silicone sample was investigated [26].
It was found that the incorporation of 20 nm gold nanoparticles
reduced the light-activated antimicrobial activity of the methylene
blue embedded silicone polymer, when tested against both the Gram-
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positive bacterium and Gram-negative bacterium S. epidermidis and
E. coli respectively [26]. The presence of 5 nm gold nanoparticles did
not dramatically improve the light-activated antimicrobial activity of
methylene blue encapsulated silicone polymers when tested against
E. coli [26]. However, a significant enhancement was observed when
tested against S. epidermidis [26]. Conversely, the incorporation of 2
nm gold nanoparticles - below the size limit for the occurrence of
surface plasmon resonance - significantly enhanced the bactericidal
activity of methylene blue embedded silicone against MRSA, S.
epidermidis and E. coli, when irradiated with red laser light [25, 26].
Silicone encapsulated with 2 nm gold nanoparticles only, did not
demonstrate any antimicrobial activity against E. coli or MRSA [25].
This indicates that the 2 nm gold nanoparticles embedded in the
silicone polymer do not exhibit any direct toxicity against either the
Gram-positive or the Gram-negative bacteria tested [25]. It has been
speculated that the enhancement in photobactericidal activity may be
dependent upon the wavelength of light used to activate the dye, as
this may affect the interaction of the nanoparticle and photosensitiser
[28]. Alternatively, the dye-nanoparticle interaction may influence
the photochemical pathway the dye undergoes, impacting on the
distributions of ROS generated [28, 31]. In addition, fluorescence
studies have indicated that dye fluorescence is suppressed when
nanogold is present [117, 118], which correlates with time-resolved
electron paramagnetic resonance spectroscopy studies, which showed
that the presence of nanogold results in increased dye triplet state
production in methylene blue encapsulated PVC catheters [30]. This
enhancement in dye triplet state production may ultimately lead
to the generation of a greater concentration of ROS. However, as
yet, there is no definite explanation as to why the presence of 2
nm gold nanoparticles effects a synergistic enhancement in the
photosensitisation of bacteria on methylene blue- and toluidine blue
O- embedded polymers.
This chemistry has been geared towards the development of self-
sterilising polymers for medical devices such as catheters (Figure 6)
[27, 30], although the potent lethal photosensitisation demonstrated
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Figure 6: Methylene blue-encapsulated silicone catheter prepared using a
swell-encapsulation shrink approach, compared to standard untreated sili-
cone catheter, with a diagrammatic representation of the mechanism of an-
timicrobial activity upon light-activation
upon white light activation indicates that this technology is not
limited to device-related applications. Pre-clinical studies indicated
that silicone encapsulated with methylene blue and 2 nm gold
nanoparticles effectively reduced S. epidermidis biofilm formation
under specific laser irradiation regimes [27]. The experiments were
performed using a flow cell and polymer samples received a constant
energy dose of laser irradiation in situ, with varying irradiation
times and frequency [27]. Irradiation conditions were preliminarily
optimised to maximise the efficacy of the photocatalytic prevention of
S. epidermidis biofilm formation on the modified polymer sample [27].
It was found that hourly 10 minute laser irradiation of the methylene
blue and 2 nm gold nanoparticle embedded polymer resulted in
a more than 50 % decrease in surface biofilm coverage, compared
to untreated silicone elastomer control samples [27]. Live-dead
staining indicated that in both the control and treated samples,
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nearly all the bacterial cells attached to the polymeric surface were
alive, irrespective of the laser irradiation, although laser irradiation
significantly reduced biofilm coverage on the treated surface [27].
Consequently, it can be speculated that the ROS produced on the
irradiated methylene blue-nanogold embedded surface damage the
external structures such as the adhesion proteins and pili on the
bacterial cells, impacting on their ability to maintain attachment
to the polymer surface [27]. This may contribute to the reduction
of bacterial surface contamination and efficacious prevention of S.
epidermidis biofilm formation exhibited by the irradiated methylene
blue-nanogold embedded silicone in this study [27].
The tribological performance of untreated polymers (exposed to the
solvent treatment used in the swell-encapsulation-shrink process)
and polymers encapsulated with toluidine blue O and 2 nm gold
nanoparticles, was evaluated using the surfaces of both the vena cava
and the inner part of the aorta of a sheep [119]. These further studies
demonstrated that neither solvent exposure, nor the encapsulation
of toluidine blue O and 2 nm gold nanoparticles, changed the
static and kinetic friction coefficients of polyurethane and silicone
polymers [119]. This finding holds promise for the potential use of
this antimicrobial technology in medical applications, since patient
comfort during catheter manipulation and catheterisation, in addition
to potential tissue damage caused by friction, is a key concern with
regard to the suitability of the material in clinical applications [119].
Reports indicated a change in the Young’s modulus of both the
silicone and polyurethane polymers upon exposure to the solvent
treatment, although there was no significant further change upon
encapsulation of the dye or the dye and nanogold combination
[25, 28]. However, an investigation into the effect of laser light on
the methylene blue and 2 nm gold nanoparticle embedded silicone
polymeric surfaces demonstrated that there is no change in the elas-
ticity of the material upon irradiation [27]. Moreover, although the
experimental set-up only facilitated relative polymer deformations
no greater than five times its initial length, it is unlikely that polymer
stretching of this magnitude occurs during normal catheter use and
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manipulation [27]. Thus, since no change in the breaking point was
noted within the experimental constraints, it can be concluded that
even if the polymer becomes more brittle upon laser irradiation, it
should not affect its function in medical applications [27].
A further potential concern regarding the use of implanted medical
devices embedded with photosensitiser dyes, is the toxicity of
generated ROS towards host cells upon photoactivation. Despite
its cytotoxicity, in a physiological environment, the half-life of the
ROS singlet oxygen is shorter than 1 µs, with a reported diffusion
distance of 10 - 100 nm [25]. Therefore, it is unlikely that the singlet
oxygen will diffuse far enough to reach host tissue cells near the
catheter device [25]. In addition, epithelial tissue in the vicinity of
the implanted device is a continually shedding surface and hence, if
in the unlikely event, singlet oxygen effected damage to surrounding
epithelium cells, this would be a short-term effect as the cells would
merely be “shed” and “replaced” [25]. Consequently, the toxicity of
ROS towards host cells should not be problematic in the potential
use of photosensitiser encapsulated devices in clinical applications.
It is hoped that this novel antimicrobial material in combination
with a simple laser system can be utilised in the development of
a range of photobactericidal polymeric medical devices including
catheters, endotracheal tubes, stents and so forth. Ultimately, this may
help decrease the prevalence of infection associated with their use,
through the photosensitisation of bacteria contaminating the device
surfaces and the subsequent prevention of biofilm accumulation.
2.3 research aims
This thesis focuses on the photoinactivation of bacteria on surfaces,
primarily through the use of organic photosensitiser dye molecules.
The development of coatings synthesised through the incorporation
of photosensitiser dye molecules and nanoparticles into polymeric
materials, will be examined and their antimicrobial efficacy will
be evaluated. Ultimately, the focus of this thesis is geared towards
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the introduction of light-activated antimicrobial agents into medical
grade polymers, for example silicone, such that these modified poly-
meric surfaces demonstrate efficacious photo-activated self-sterilising
properties. An exploration into the mechanistic detail of the photo-
chemical activity will be achieved, with the aim to shed light on the
interaction between the polymer immobilised photosensitiser dyes
and nanoparticles. It is hopeful that these surfaces can be used in
healthcare applications, to reduce microbial surface contamination
and subsequently, decrease the risk of healthcare-associated infec-
tions.
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L A S E R - A C T I VAT E D A N T I M I C R O B I A L P O LY M E R S ;
C RY S TA L V I O L E T, M E T H Y L E N E B L U E A N D G O L D
N A N O PA RT I C L E - E N C A P S U L AT E D S I L I C O N E
3.1 introduction
HAIs, a worldwide problem, not only results in severe financial
implications for healthcare institutions, but causes patient discom-
fort, the extensive use of antibiotics and prolonged hospital stays.
Unfortunately, in some cases, HAIs can result in patient death. The
U.K. Department of Health (2004) estimated that each year there are
300,000 incidents of HAI in the U.K. [1, 2], translating to a financial
burden of ca. £1 billion on NHS hospitals and an additional 3.6
million patient hospitalisation days [1, 3].
Indwelling polymeric medical devices, for example, endotracheal
tubes, intravascular devices and urinary catheters, are crucial in
the treatment of critically ill patients. However, many HAIs are
associated with their use [4]. Urinary catheters are one of the most
frequently used medical devices and in the U.S. alone, more than 30
million urinary catheters are inserted each year [4]. Recent figures
suggest that urinary tract infections (UTIs) account for ca. 20 % of
all HAIs in England and 80 % of UTIs are associated with urinary
catheterisation [1]. Although the treatment of an individual UTI
is normally relatively inexpensive, due the prevalence of these
infections, they were noted as the most costly single site infection in
the U.K. [3].
Clinical trials focused on decreasing the incidence of UTIs and other
complications have been extensively reviewed, to determine the
efficacy of catheter policies for long-term and short-term bladder
drainage and to continuously update guidelines for clinical practice
[5–10]. Attempts to reduce the risk of UTIs include the use of
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antibiotic prophylaxis, catheter flushes and antibiotic and antiseptic
devices [5–10]. It has been noted that many trials were small or
of poor quality and provided inadequate data to draw reliable
conclusions on the efficacy of the approaches, in terms of reducing
the incidence of UTIs. However, the use of silver alloy catheters
and antibiotic catheters (minocycline/ rifampicin- or nitrofurazone-
coated) have demonstrated a statistically significant reduction in
asymptomatic bacteriuria (the presence of bacteria in urine), in
hospitalised patients catheterised for durations of both less than and
more than one week when a silver alloy catheter was used and less
than one week when an antibiotic catheter was used [10]. No signif-
icant reductions in bacteriuria were reported for cases of long-term
catheterised patients with anti-infective indwelling urinary catheters
[6]. Moreover, despite a decrease in the risk of bacteriuria with silver
alloy or antibiotic-coated catheters in short-term catheterised patients,
their impact on the overall risk of UTIs was inconclusive [10]. Overall,
there is limited evidence that current infection-prevention strategies
help significantly decrease the incidence of UTIs. Moreover, the use
of antibiotic-coated catheters may be detrimental, as exposure of
bacterial populations to antibiotics is likely to increase the prevalence
of drug resistance [11].
Recently, alternative infection prevention strategies have been devel-
oped. One such approach is to use a modified form of PDT - used
in the treatment of tumours, skin infections and conditions [12–16]
- to reduce the risk of device-associated infection. Photosensitisers
can demonstrate bactericidal activity through the generation of
cytotoxic ROS upon photo-activation [12]. Absorption of a photon of
a wavelength within the photosensitiser absorbance range promotes
the dye molecule to an excited singlet state [12, 17]. The molecule in
the excited singlet state can then undergo an intersystem crossing,
a radiationless photochemical process, to a longer lived, lower
energy excited triplet state [12, 17]. This triplet state can undergo
two major photochemical pathways, termed a “type I” or “type II”
photo-process and ultimately both pathways result in the generation
of a range of ROS [12]. The “type I” photochemical pathway involves
the interaction of the triplet state species with surrounding substrate
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molecules, generating radical species [12, 14, 17]. The “type II”
photochemical pathway occurs when the triplet state species interacts
with molecular oxygen in the vicinity, forming the highly reactive,
transient singlet oxygen species [12, 14, 17]. ROS can rapidly kill
bacteria in the vicinity by multiple mechanisms, including oxidative
damage to cellular membranes, intracellular proteins and DNA, such
that the emergence of bacterial resistance is extremely unlikely [12,
18, 19]. Furthermore, mammalian cells show significantly greater
resistance to ROS than bacteria, offering a potential window for
treatment [20].
Photosensitiser dyes such as methylene blue, toluidine blue O
and indocyanine green have been immobilised in medical grade
polymers using a simple “swell-encapsulation-shrink” method and
these materials exhibit photo-activated antimicrobial activity [19,
21–26]. Moreover, despite possessing no inherent antimicrobial
properties, it has been found that the encapsulation of 2 nm gold
nanoparticles in combination with the photosensitiser dye methylene
blue into medical grade polymers, effects a synergistic enhancement
in the light-activated antimicrobial activity of the dye [19, 21, 26].
An electron paramagnetic resonance spectroscopy investigation
indicated that the basis of this enhancement in the photobactericidal
activity is increased generation of methylene blue triplet state, in the
presence of 2 nm gold nanoparticles [25]. An increase in triplet state
production may correlate with an increase in the generation of ROS,
resulting in greater photobactericidal activity [25].
Although research is still in the ‘laboratory investigations’ phase,
results to date have been promising. Studies indicated that these
modified polymeric materials induce the lethal photosensitisation
of both Gram-positive and Gram-negative bacteria upon activa-
tion with short-term laser light irradiation [19, 21–23], or against
Gram-positive bacteria upon activation with longer-term white
light illumination [26]. A study also showed that methylene blue/
nanogold-encapsulated silicone demonstrated efficacy in the reduc-
tion of S. epidermidis biofilm formation under specific laser irradiation
regimes [22]. It is hopeful that these light-activated antimicrobial dye/
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Figure 7: Chemical structures of (a) the triarylmethane photosensitiser dye
crystal violet and (b) the phenothiazine photosensitiser dye methylene blue
nanogold combinations can potentially be incorporated into silicone
catheters for use in medical applications, in which the bactericidal
properties will be activated by laser illumination delivered using an
optical fibre down the device lumen.
This chapter reports on the synergistic enhancement in the light-
activated antimicrobial activity of medical grade silicone coated
with crystal violet in the presence of 2 nm gold nanoparticles and
methylene blue. The crystal violet-coated, methylene blue and
nanogold-encapsulated samples were prepared using a novel two
stage dipping process and the material was characterised using
UV-Vis absorbance spectroscopy, light microscopy and fluorescence
microscopy. Microbiological testing of the crystal violet, methylene
blue and nanogold incorporated silicone was performed using both
Gram-positive and Gram-negative bacteria and a low power 635 nm
laser to activate the antimicrobial properties. Surprisingly, notable
dark kill was seen and this dye-nanogold polymer combination was
shown to be a potent photobactericidal polymer for the destruction
of E. coli.
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3.2 experimental
3.2.1 Chemicals and Substrates
The reagents used in materials synthesis were as follows: Methylene
blue hydrate (Riedel-de Hae¨n, U.K.), crystal violet (Sigma, U.K.), 2
nm gold nanoparticles (2.49 x 10-7 mol L-1, BBI Solutions, U.K.) and
acetone (VWR, U.K.). In all synthetic work carried out, the water used
was deionised (resistivity 15 MΩcm) and the substrate was medical
grade flat silicone sheets (NuSil, Polymer Systems Technology Ltd.,
U.K.). For the extended microbiological testing, the substrate was
commercially available 100 % silicone Foley catheters: 2 way, 30
cc silicone catheter with an opposed eye, (22 Fr, 7.3 mm diameter,
Ru¨sch).
3.2.2 Materials Synthesis
3.2.2.1 System Optimisation - Organic Solvent
Silicone polymer squares (1 cm2) were immersed in crystal violet -
organic solvent solutions (100 ppm crystal violet, 100 % organic sol-
vent) prepared using the following organic solvents: tetrahydrofuran
(THF), toluene, ethyl acetate, hexane, isopropanol, acetone, acetyl
acetone, acetonitrile, methanol, ethanol and butanol. The silicone
sections were allowed to swell under dark conditions for either 24 h
or 72 h. The samples were subsequently removed and allowed to air
dry overnight, after which they were washed (distilled water) and
towel-dried.
3.2.2.2 System Optimisation - Solvent Concentration
Silicone polymer squares (1 cm2) were immersed in crystal violet
solutions (18 ppm crystal violet) made up to the following acetone
: water ratios - 1:0, 8:2, 6:4, 4:6, 2:8 and 0:1 and allowed to swell
under dark conditions for a period of 3 days. The samples were
subsequently removed and allowed to air dry overnight, after which
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they were washed and towel-dried.
3.2.2.3 System Optimisation - Dye Concentration
Silicone polymer squares (1 cm2) were immersed in crystal violet
solutions (in water) made up to the following concentrations, for a
period of 3 days: 1 x 10-1 mol dm-3, 5 x 10-2 mol dm-3, 1 x 10-2 mol
dm-3, 5 x 10-1 mol dm-3, 1 x 10-3 mol dm-3, 5 x 10-4 mol dm-3, 1 x 10-4
mol dm-3, 5 x 10-5 mol dm-3, 1 x 10-5 mol dm-3 and 5 x 10-6 mol dm-3
crystal violet. The samples were subsequently removed and allowed
to air dry overnight, after which they were washed and towel-dried.
3.2.2.4 System Optimisation - Immersion Duration
Silicone polymer squares (1 cm2) were immersed in a crystal violet
solution (0.001 mol dm-3) for varying dipping times extending to 96
h. After each set time period, the corresponding sample was removed
from the dipping solution and allowed to air dry overnight, after
which it was washed (distilled water) and towel-dried.
3.2.2.5 Preparation of Materials for Antimicrobial Testing
A series of samples including the relevant controls, were prepared for
antimicrobial testing:
a) Control samples: Silicone polymer squares (1 cm2) were immersed
in a 9:1 acetone : water swelling solution (72 h, dark conditions).
The polymer sections were subsequently air-dried (24 h), washed
and towel dried.
b) Methylene blue and 2 nm gold nanoparticle encapsulated silicone:
Silicone polymer squares (1 cm2) were immersed in a 9:1 acetone
: nanogold swelling solution saturated with methylene blue (700
mg /L) for 72 h under dark conditions. The polymer sections were
subsequently air-dried (24 h), washed and towel dried.
c) Crystal violet-coated silicone: Silicone polymer squares (1 cm2)
were immersed in a crystal violet solution (0.001 mol dm-3) for 72
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h under dark conditions. The polymer sections were subsequently
air-dried (24 h), washed and towel dried.
d) Crystal violet-coated, nanogold-encapsulated silicone: Silicone
polymer squares (1 cm2) were immersed in a 9:1 acetone :
nanogold swelling solution (72 h, dark conditions). The polymer
sections were subsequently air-dried (24 h), washed and towel
dried, after which they were immersed in a crystal violet solution
(see c for protocol).
e) Crystal violet-coated, nanogold-encapsulated catheters: Silicone
catheter sections (1 cm length, 7.3 mm diamater) were cut along
the length such that 2 flat internal surfaces were exposed. The sec-
tions were immersed in a 9:1 acetone : nanogold swelling solution
(72 h, dark conditions). The catheter sections were subsequently
air-dried (24 h), washed and towel dried, after which they were
immersed in a crystal violet solution (40 oC, 6 hours) that was
continuously stirred using a gyro-rotator. The catheter sections
were subsequently air-dried (24 h), washed and towel dried.
3.2.3 Materials Characterisation
A PerkinElmer Lambda 25 UV-Vis Spectrometer was used to measure
the UV-Vis absorption spectra of the modified silicone polymers used
for microbiology, within the range 400 - 750 nm. A Bruker Platinum
attenuated total reflectance-Fourier transform infrared (ATR-FTIR)
was used to measure the infrared transmittance spectra of the
samples within the range 4000 - 400 cm-1, with an accumulation of 15
scans per sample. Methylene blue and crystal violet were dissolved
in industrial methylated spirits (IMS) and the infrared transmittance
spectra were measured within the range 4000 - 400 cm-1, with an
accumulation of 15 scans per sample.
Flat silicone polymers prepared by immersion in varying concen-
trations of crystal violet solutions, were embedded vertically in
paraffin blocks. 10 µm sections were cut using a microtome and
sections were mounted on Vectabond (Vecta Laboratories, U.K.)
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treated slides for fluorescence imaging. On average, 10 sections
were taken from each of the 10 silicone sheets dipped in increasing
concentrations of crystal violet solution. The sections were imaged
at 10x magnification, using a light microscope (Olympus U.K. Ltd.,
model BH2) with a colour charge-coupled device (CCD) digital
camera (Lumenera, model Infinity 1) and Infinity Capture software
was used for analysis. Fluorescence microscopy was performed on
the thinly sliced crystal violet-coated silicone sections. The samples
were imaged using a cooled scientific-grade 16-bit digital CCD
camera (Princeton Instruments Ltd., Model PIXIS 512) operated by
Win-Spec software, coupled to an inverted fluorescence microscope
(Olympus U.K. Ltd., Model IMT-2). The crystal violet present in the
silicone sections was detected using fluorescence excitation with a
635 nm laser and the samples were imaged using a 10x objective.
Fluorescence was detected using a bandpass filter centred at 660 nm
(Omega Optical Inc., model 660DF30). The use of red wavelength
excitation minimized the background autofluorescence detected
from the polymer itself and is very close to the wavelength used
for irradiation (635 nm). The images were subsequently analysed
using Roper Scientific Software (WinSpec/32) and ImageJ software
(National Institutes of Health, U.S.A.).
3.2.4 Functional Testing
3.2.4.1 Transmission Measurements
A Gentec-EO TPM-300 power meter was used to estimate the trans-
mision of laser power through unmodified and modified medical
grade silicone. A 635 nm laser set to 314 mW was used in the trans-
mission testing and produced a uniform spot size of 2 cm diameter,
corresponding to a fluence rate of 100 mW cm-2. The laser power was
measured before and after placement of a 1.21 cm-2 silicone section
at the detector and the percentage transmission through the polymer
was calculated.
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3.2.4.2 Water Contact Angle Measurements
Equilibrium water contact angle measurements (∼9 µL) on: untreated
silicone, solvent treated (control) silicone, crystal violet-coated sil-
icone, methylene blue and 2 nm gold nanoparticle-encapsulated
silicone and crystal violet-coated nanogold-encapsulated silicone,
were obtained using an FTA 1000 Drop Shape Instrument. The
contact angle measurement for each sample type was taken to be the
average value over >10 measurements, using a droplet of deionised
water dispensed by gravity from a gauge 27 needle and the samples
were photographed side on. The data was analysed using FTA32
software.
3.2.4.3 Leaching Test
The stability of the crystal violet-coated silicone polymers in phos-
phate buffer saline (PBS, Dulbecco A) at 37 oC, was investigated.
Crystal violet-coated silicone sections (1 cm2, as prepared for mi-
crobiology) were immersed in PBS (2.5 mL, 37 oC) for an extended
period of time. The UV-Vis absorbance of the PBS (596 nm, Pharmacia
Biotech Ultrospec 2000) was measured periodically to monitor any
leaching of the crystal violet from the polymer, into the surrounding
solution. A comparison of the absorbance at 596 nm of the PBS with
a crystal violet calibration curve, enabled the determination of the
concentration of crystal violet that was released from the silicone into
the surrounding solution.
3.2.5 Microbiological Investigation
3.2.5.1 Antimicrobial Testing - Flat Polymer Sheets
The following medical grade silicone elastomer samples (1 cm2) were
used in the microbiology experiments: (i) solvent treated silicone
(control), (ii) crystal violet-coated silicone, (iii) crystal violet-coated, 2
nm gold nanoparticle-encapsulated silicone, (iv) methylene blue and
2 nm gold nanoparticle-encapsulated silicone and (v) crystal violet-
coated, methylene blue and 2 nm gold nanoparticle-encapsulated
106
silicone. The samples were left for a period of 3 days prior to use in
the microbiological testing, to ‘sterilise’. The microorganisms tested
were S. epidermidis RP62a and E. coli ATCC 25922. These organisms
were stored at -70 oC in Brain-Heart-Infusion broth (BHI, Oxoid)
containing 20 % (v/v) glycerol and propagated onto either Mannitol
Salt agar (MSA, Oxoid) in the case of S. epidermidis or MacConkey
agar (MAC, Oxoid Ltd.) in the case of E. coli, for a maximum of 2
sub-cultures at intervals of 2 weeks.
BHI broth was inoculated with 1 bacterial colony and cultured in air
at 37 oC for 18 h. The bacterial pellet was recovered by centrifugation
(21 oC, 1771 xg, 4 min), washed in PBS (10 mL) and centrifuged
again to recover the bacteria, which were finally re-suspended in
PBS (10 mL). The washed suspension was diluted 1000-fold to obtain
the inoculum (∼106 cfu /mL). The inoculum in each experiment
was confirmed by plating ten-fold serial dilutions on agar for viable
counts. Triplicates of each polymer sample type were inoculated with
25 µL of the inoculum and covered with a sterile cover slip (22 mm x
22 mm). The samples were then irradiated for ∼13.5 minutes using a
635 nm diode laser (see 3.2.5.2). A further set of samples (in triplicate)
was maintained in the dark for the duration of the irradiation time.
Post irradiation, the inoculated samples and cover slips were added
to PBS (225 µL) in a 50 mL tube and vortexed. The neat suspension
and ten-fold serial dilutions were plated onto the appropriate agar
for viable counts. The plates were incubated aerobically at 37 oC for
24 h (E. coli) or 48 h (S. epidermidis). Each experiment contained 3
technical replicates and the experiment was reproduced three times.
The data was analysed using the Mann-Whitney U test.
3.2.5.2 Laser Specifications for Activation of Antimicrobial Activity
A 635 nm 1.0 W laser (Changchun New Industries Optoelectronics
Technology Co. Ltd., China) coupled to a 1 m long liquid light guide
was used for the microbiological testing and produced a uniform
spot size of 2 cm diameter, corresponding to a fluence rate of 55.7
mW cm-2. Over the ∼13.5 minutes irradiation duration, the total
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incident fluence at the sample was 45 J cm-2.
3.2.5.3 Antimicrobial Testing - Commercial Catheter Sections
Crystal violet-coated, methylene blue and 2 nm gold nanoparticle-
encapsulated (CVMBAu) catheter sections were used in the microbiol-
ogoical testing. The samples were left for a period of 3 days, prior to
antimicrobial testing. The microorganisms tested were E. coli ATCC
25922, S. epidermidis RP62a, MRSA-15, P. mirabilis (clinical strain),
Enterococcus faecalis JH-2 and P. aeruginosa PAO1. These organisms
were stored at -70 oC in BHI broth containing 20 % (v/v) glycerol
and propagated onto BHI Agar (Oxoid Ltd.) for a maximum of 2
sub-cultures at intervals of 2 weeks.
BHI broth was inoculated with 1 bacterial colony and cultured in air
at 37 oC for 18 h. The bacterial pellet was recovered by centrifugation,
washed in PBS (10 mL) and centrifuged again to recover the bacteria,
which were finally re-suspended in the same volume of PBS. The
washed suspension was diluted 1000-fold to obtain the inoculum
(∼106 cfu /mL). The inoculum in each experiment was confirmed by
plating ten-fold serial dilutions on agar for viable counts. Triplicates
of the CVMBAu catheter sections were inoculated with 12.5 µL of the
inoculum and covered with a sterile cover slip (22 mm x 22 mm). The
samples were then irradiated for ∼18 minutes using a 635 nm laser
(see 3.2.5.4). A further set of samples (in triplicate) was maintained in
the dark for the duration of the irradiation time.
Post irradiation, the inoculated samples and cover slips were added
to PBS (112.5 µL) in a 50 mL tube and vortexed. The neat suspen-
sion and ten-fold serial dilutions were plated onto either MSA (S.
epidermidis, MRSA, E. faecalis) or MAC agar (E. coli, P. mirabilis,
P. aeruginosa) agar for viable counts. The plates were incubated
aerobically at 37 oC for 24 h. Each experiment contained 3 technical
replicates and the experiment was reproduced three times. The data
was analysed using the Mann-Whitney U test.
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3.2.5.4 Laser Specifications for Further Antimicrobial Testing
A 635 nm laser (Biomed Ltd, U.K.) set to 130 mW power was used
for the microbiological testing and produced a uniform spot size of 2
cm diameter, corresponding to a fluence rate of 41.4 mW cm-2. Over
the ∼18 minutes irradiation duration, the total incident fluence at the
sample was 45 J cm-2.
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3.3 results and discussion
3.3.1 Materials Synthesis
A modified “swell-encapsulation-shrink” strategy was developed to
incorporate photosensitiser dyes and 2 nm gold nanoparticles into
a medical grade silicone polymer. Previous studies have indicated
that varying dye-polymer combinations require different swelling
conditions [19, 24, 25] and so, in this study, the dipping conditions
were optimised to determine conditions that facilitated a good uptake
of the dye into the silicone polymer. Silicone polymer coupons were
exposed to solutions containing crystal violet under varying condi-
tions to optimise the incorporation procedure. Silicone samples were
immersed in crystal violet swelling solutions prepared using a range
of organic solvents, for up to 72 h. Shown in Figure 8(a) are samples
prepared by immersion in crystal violet/ organic solvent swelling
Figure 8: (a) Crystal violet-incorporated silicone sections prepared by immer-
sion in crystal violet/ organic solvent swelling solutions for either 24 h (im-
mediately post-removal from swelling solution) or 72 h. (air-dried overnight).
Organic solvents used are as follows: 1. THF, 2. toluene, 3. ethyl acetate,
4. hexane, 5. isopropanol, 6. acetone, 7. acetyl acetone, 8. acetonitrile, 9.
methanol, 10. ethanol and 11. butanol. (b) Silicone sections immersed in dif-
ferent crystal violet/ organic solvent swelling solutions (100 % solvent) and
(c) UV-Vis absorbance spectra of crystal violet-encapsulated silicone sections
prepared by immersion in crystal violet/ organic solvent swelling solutions
for 72 h. Note that the spectra are ordered as specified in the legend
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solutions either immediately post-immersion (24 h dip samples), or
after air-drying (72 h dip samples). It is clear that solvents such as
THF, toluene, ethyl acetate and hexane induce significant polymer
swelling. Due to the insolubility of crystal violet in hexane (Figure
8(b), no visible encapsulation of the dye is evident despite extreme
polymer swelling. However, although the dye demonstrates very lim-
ited solubility in both THF and toluene, a significant uptake of dye is
achieved. The study indicated that ethanol, methanol and acetonitrile
solutions resulted in poor uptake of the dye, whereas the use of
ethyl acetate and acetone swelling solutions achieved strong polymer
crystal violet colouration, indicative of the most efficacious uptake of
the dye. Since the use of acetone as a swelling agent for incorporation
of photosensitiser dyes into medical grade polymers has been well
established, with functional testing investigations demonstrating
little resultant effect on the polymeric material [19, 21–25], it was
selected as the preferred solvent for further investigation.
Silicone samples were immersed in solutions comprising of varying
water/ acetone ratios and crystal violet concentrations to explore that
which facilitated the best uptake of the dye. Immersion of the silicone
into either 100 % acetone or 100 % water crystal violet solutions for a
period of 72 hours resulted in bright purple coloured silicone squares,
correlating to an efficacious uptake of the dye. As the volumes of the
acetone and water components of the dipping solution equalised, the
polymer uptake of the dye was less efficient (Figure 9(a)).
The concentration of crystal violet in the dipping solution was
optimised using water as the solvent, since it was found that this
facilitated a good uptake of the dye. Silicone squares were immersed
in crystal violet solutions varying in crystal violet concentration from
1 x 10-1 mol dm-3 to 5 x 10-6 mol dm-3. The uptake of the dye onto
the polymer increased with crystal violet concentration up to 10-3
mol dm-3, after which, the uptake of dye onto the polymer decreased
(Figure 9(b)).
A solution of 1 x 10-3 mol dm-3 crystal violet (in water) was selected
and the silicone was exposed to the chosen crystal violet solution
111
Figure 9: Silicone polymer sections prepared by immersion in: (a) Crystal
violet dipping solutions of varying water : acetone ratios for a period of 72
h, (b) 100 % water crystal violet dipping solutions of varying crystal violet
concentrations for a period of 72 h and (c) 1 x 10-3 mol dm-3 crystal vio-
let dipping solutions for increasing immersion time lengths up to a period
of 96 h. Methylene blue and 2 nm gold nanoparticle-encapsulated silicone
polymers prepared by immersion in crystal violet dipping solutions for in-
creasing immersion time lengths up to a period of 96 h are also shown
for a range of dipping times to further refine the process. A parallel
investigation in which methylene blue-silicone sections were exposed
to the aqueous crystal violet dipping solution (1 x 10−3 mol dm−3) for
a range of dipping times, was also carried out. In both studies, it was
found that the uptake of the dye into the polymer increased with the
immersion duration and a significant uptake of the dye occurred after
as little as 7 h at room temperature (Figure 9(c)). Moreover, as demon-
strated in the cross sectional photograph Figure 10, the uptake of the
crystal violet dye under these conditions was a predominantly surface
process, with no visible dye diffusion through the bulk of the silicone.
A further set of polymers were prepared for antimicrobial testing. The
methylene blue and 2 nm gold nanoparticle-encapsulated silicone
polymer samples were prepared by immersing the silicone polymer
squares into a 9:1 acetone : nanogold swelling solution saturated with
methylene blue, for a period of 72 h. The crystal violet-coated silicone
samples were prepared as described above, by dipping the silicone
into a 1 x 10-3 mol dm-3 crystal violet solution for 72 h. The crystal
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Figure 10: A cross section of the untreated- and methylene blue and 2 nm
gold nanoparticle-encapsulated silicone sections coated with crystal violet
by immersion in a 1 x 10-3 mol dm-3 crystal violet dipping solution for 72 h
violet-coated, nanogold-encapsulated samples were prepared using
a novel two-step process. The first step involved the encapsulation
of 2 nm gold nanoparticles into the silicone by immersion of the
polymer in a 9:1 acetone : nanogold swelling solution, for a period of
72 h. The nanogold-encapsulated silicone was subsequently coated
with crystal violet, using the protocol detailed above. It is thought
that this synthetic route achieves the uniform encapsulation of 2
nm gold nanoparticles throughout the polymer bulk, with visible
concentrated bands of crystal violet dye at the polymer surfaces. A
similar protocol was used to prepare crystal violet-coated, methylene
blue and nanogold-encapsulated samples. However, in the initial dip-
ping step, the 9:1 acetone : nanogold swelling solution was saturated
with methylene blue, resulting in the uniform encapsulation of dye
through the polymer bulk, with concentrated crystal violet bands at
the polymer surfaces (Figure 10).
3.3.2 Materials Characterisation
3.3.2.1 UV-Visible Absorbance Spectroscopy
The UV-Vis absorbance spectra of crystal violet-encapsulated silicone
samples prepared by immersion in a range of crystal violet/ organic
solvent swelling solutions, was measured within the range 400 -
750 nm (Figure 8(c)). The spectra indicate that the use of different
organic solvents to encapsulate the dye within a silicone polymer,
does not affect the main absorption peak position (λ ≈ 588 nm),
or the shoulder peak position (λ ≈ 546 nm). However, varying
the organic solvent impacts on the efficacy of dye uptake into the
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Figure 11: (a) UV-Vis absorbance spectra measured in the range 400 - 750 nm
of crystal violet-coated silicone polymers prepared using a simple dipping
method. The silicone polymers were immersed in crystal violet solutions of
varying concentrations: 1 x 10-1 mol dm-3, 1 x 10-2 mol dm-3, 1 x 10-3 mol
dm-3, 1 x 10-4 mol dm-3 and 1 x 10-5 mol dm-3. (b) UV-Vis absorbance spectra
measured in the range 400 - 750 nm of samples used for microbiological
testing: Methylene blue and nanogold-encapsulated silicone, crystal violet-
coated silicone, crystal violet-coated, nanogold-encapsulated silicone, crystal
violet-coated, methylene blue and nanogold-encapsulated silicone
polymer. It is clear from the absorbance spectra that the use of
ethyl acetate-, acetone- and toluene-crystal violet swelling solutions
result in efficient dye uptake, whereas methanol-, acetonitrile- and
hexane-crystal violet swelling solutions achieve extremely limited
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encapsulation of the dye, within the same dipping time period. This
can be attributed to a combination of two key factors: (i) the degree to
which the solvent induces polymer swelling and (ii) the solubility of
the crystal violet dye in the organic solvent. As shown in Figures 8(a)
and 8(b), although hexane induces significant polymer swelling, the
dye is largely insoluble in the solvent and thus, limited/ no visible
encapsulation of the dye is achieved. Interestingly despite the poor
solubility of crystal violet in both THF and toluene, due to extreme
polymer swelling, significant uptake of the dye is achieved. However,
it is a combination of both good dye-solvent solubility and sufficient
polymer swelling that results in the best uptake of dye, as achieved
using either ethyl acetate or acetone as swelling solvents.
The UV-Vis absorbance spectra of silicone samples immersed for
3 days in crystal violet solutions of varying concentrations, were
measured within the range 400 - 750 nm (Figure 11(a)). When
immobilised in the silicone substrate, the main absorption peak of
crystal violet is at λ ≈ 590 nm and a shoulder peak at λ ≈ 548
nm is also present. Furthermore, the spectra also indicate a slight
variation in the peak maxima with dye concentration. As is clear from
Figure 11(a), increasing the concentration of crystal violet in solution
results in an increased uptake of dye, up to a concentration of ∼5
x 10-3 mol dm-3 crystal violet (not shown on spectra). Surprisingly,
further increase in crystal violet concentration effects a reversal of
this trend, with increasing crystal violet concentrations correlating to
a decreasing uptake of the dye.
The UV-Vis absorbance spectra of silicone samples used in microbi-
ological testing were also recorded. Figure 11(b) shows the spectra
of the crystal violet-coated silicone and the crystal violet-coated,
nanogold-encapsulated silicone and crystal violet-coated, methylene
blue and nanogold-encapsulated silicone. It is clear from the spectra
that the crystal violet peaks across the sample range are similar in
peak intensity and peak form, with both absorption maxima and
shoulder peaks in the same wavelength region. This indicates that
the presence of the nanogold does not change the spectral features.
The figure also shows the absorbance spectra of the methylene
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blue and nanogold-encapsulated silicone. Methylene blue has an
absorption maxima of λ ≈ 652 nm when encapsulated in the silicone
polymer, with a shoulder peak at ∼610 nm. The spectrum also
suggests a second shoulder peak at ∼670 nm. It should be noted
that the UV-Vis absorbance spectra for both the crystal violet-coated,
nanogold-encapsulated silicone sample and the methylene blue/
nanogold-encapsulated silicone sample show no detectable absorp-
tion corresponding to the presence of the gold nanoparticles, in the
visible region of the spectrum. This can be attributed to the small
diameter of the gold nanoparticles used (2 nm), which is below the
limit for surface plasmon resonance for nanoparticle colouration
(∼4 nm) [21]. It was also noted that the absorbance maxima of the
two crystal violet samples were comparable, indicating that the
coating procedure is reproducible and the incorporation of the 2
nm gold nanoparticles does not hinder the uptake of the dye. The
absorbance intensity of the crystal violet-coated, methylene blue and
nanogold-encapsulated silicone differs from the other samples, but
this can be attributed to the incorporation of multiple dyes within the
polymer that demonstrate strong absorbance at similar wavelengths.
3.3.2.2 ATR-FTIR Spectroscopy
The infrared transmittance spectra of the photosensitiser dyes and
dye-encapsulated silicone samples were obtained by ATR. The pho-
tosensitiser dyes methylene blue and crystal violet, were dissolved
in industrial methylated spirits and the solutions were deposited
onto the ATR crystal. The residual solvent was allowed to evaporate,
leaving a thin film of photosensitiser dye. The infrared spectra of
methylene blue showed absorbance bands in the region 1600, 1500
and 1400 cm−1, characteristic of aromatic carbon-carbon bonds
(Figure 12(a)). The infrared transmittance spectra of crystal violet
also shows peaks correlating to aromatic carbon-carbon bonds in
this region, although the absorption is much sharper (Figure 12(b)).
The broad band evident on both the spectra for methylene blue and
crystal violet at around 3400 cm−1 can at least in part, be attributed
to the presence of residual IMS.
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Figure 12: ATR-FTIR transmittance spectra measured within the range 4000
- 400 cm−1 of: (a) Methylene blue in industrial methylated spirits (IMS),
methylene blue-encapsulated silicone (72 h dipping time) and untreated sil-
icone, (b) crystal violet in IMS, crystal violet-coated silicone (96 h dipping
time) and untreated silicone and (c) dye-modified and untreated silicone
samples
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The infrared-transmittance spectra of methylene blue-encapsulated
silicone, crystal violet-coated-silicone, methylene blue encapsulated,
crystal violet-coated-silicone and untreated silicone, were obtained
by ATR. No significant difference in the measured spectra was
evident across the sample range analysed and no peaks correlating
to the presence of either dye was observed (Figure 12(c)). This
can be attributed to the strong absorbance bands of the silicone
substrate, which presumably masks any weak signals from the dye.
The absorbance patterns obtained were expected, due to the relatively
low dye concentrations present in the polymers. The sharp infrared
absorption bands at 2965 cm−1 and 1260 cm−1 can be attributed to
the silicone polymer. It can be suggested that the former indicates
that the silicone polymer is functionalised with sp3-carbon R groups.
This is confirmed by the latter peak at 1260 cm−1, which corresponds
to the Si-CH3 bond infrared absorption. The similarity between
the spectra of all samples analysed - characteristic of that of the
untreated silicone sample - indicated that the solvent treatment did
not detrimentally affect the polymer substrate, in terms of effecting a
chemical change in the silicone polymer.
3.3.2.3 Microscopy
Light microscopy and fluorescence microscopy were used to analyse
the effects of exposing the silicone to varying concentrations of
crystal violet solution, to determine whether the dye concentration
in the dipping solutions can be exploited to adjust the extent of dye
diffusion through the polymer bulk. The silicone samples prepared
by immersion in varying concentrations of crystal violet solution
were analysed using a light microscope with an attached CCD camera
(Figure 13(a)). The concentration dependency on the efficacy of the
uptake of the dye, in addition to the dye distribution within the
polymer, is clearly demonstrated. Immersion of the silicone polymer
into solutions of higher crystal violet concentration resulted in the
distribution of the dye throughout the polymer bulk, with a less
defined dye surface concentration. The dye diffusion through the
polymer bulk decreased with crystal violet concentration. Conversely,
the dye polymer surface concentration increased with the crystal
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Figure 13: (a) Images of thin sections of crystal violet-coated silicone pre-
pared by immersing the polymer in varying crystal violet dipping solution
concentrations. The polymer section imaged is positioned on the upper-right
hand corner of the image and is at an incline. The images were recorded
using a 10x objective and the bar on each image corresponds to 100 µm.
Actual polymer wall-width, 1 mm. (b) CCD false coloured fluorescence mi-
croscopy images of 10 micron thick crystal violet-coated silicone sections,
prepared from polymer samples immersed in increasing concentrations of
crystal violet dipping solution. The polymer analysed is shown on the left
hand side of the images with a 100 micron scale bar on each image and
the fluorescence intensity scale, top, increases from black (background/no
fluorescence) through to white (max. fluorescence). The trace above each flu-
orescence image indicates the fluorescence distribution through the silicone
sample, with peak intensity localised at the outer edge. The image resolution
is 512 x 512 pixels, corresponding to 557 x 557 microns
violet dipping solution concentration up to a solution concentration
of ∼5 x 10-4 mol dm-3, after which the uptake of the dye decreased
with the dipping solution concentration. Immersion of the silicone
into dipping solutions of low crystal violet concentrations such as 5 x
10-6 mol dm-3, resulted in extremely poor uptake of the dye over the
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3 day immersion period.
These polymer samples of varying crystal violet concentration were
subsequently analysed using fluorescence microscopy. The crystal
violet embedded in the thinly sliced silicone sections was excited
using a 635 nm laser and a bandpass filter centred at 660 nm was
used to detect dye fluorescence. The crystal violet fluorescence was
imaged using a CCD and the acquired digital images were used
to analyse the extent of the diffusion of dye through the polymer.
Figure 13(b) shows examples of images obtained using fluorescence
microscopy, displayed in false colour. The silicone sections were
imaged such that roughly one half of the polymer examined is shown
on the left hand side of each image, providing an overview of the
dye diffusion gradient through the polymer. The false colour scale
corresponds to low fluorescence (shown as black) to high fluores-
cence (shown as white). Profile plots were also obtained using ImageJ
software and correlated to a graphical representation of the fluores-
cence distribution through the silicone polymer, shown in false colour.
The trend established using light microscopy was confirmed from
the fluorescence measurements as it was found that silicone exposed
to solutions of higher crystal violet concentrations, resulted in
encapsulation of the dye throughout the polymer bulk. The extent
of the diffusion of dye through the polymer decreased with dye
concentration, such that at lower crystal violet solution concentra-
tions, the uptake of the dye was predominantly a surface process
(Figure 13(b)). It should be noted that the sample prepared for
microbiological testing (1 x 10-3 mol dm-3) demonstrates a substantial
band of dye at the polymer surface, indicated by strong fluorescence,
with a decreasing dye concentration gradient through the polymer,
as shown by the 3D surface plot of the dye fluorescence distribution
through the silicone (Figure 14).
The predominant cause of catheter-associated UTIs in hospitalised
catheterised patients, responsible for two-thirds of reported cases,
is the bacterial contamination of the extraluminal catheter surface
caused by the ascension of bacteria up the urinary tract, along the
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Figure 14: 3D surface plot of the fluorescence distribution through the sili-
cone sample immersed in a 1 x 10-3 mol dm-3 crystal violet dipping solution
(72 h), obtained using CCD false coloured fluorescence microscopy at 10x
magnification
catheter-urethra interface [6, 27]. Estimations suggest that only one-
third of these infections are attributed to microbial contamination of
the intraluminal catheter surface [6, 27], with Gram-negative bacteria
such as E.coli noted as key causative pathogens for these infections
[1]. In potential applications in medical devices such as catheters, the
antimicrobial activity of these modified polymers will be activated
by irradiation down the catheter lumen using an optical fibre, with
the fibre remaining in place for the duration of catheterisation [25].
The antimicrobial properties of the polymer can then be activated
by illuminating the catheter at specific time intervals to kill bacteria
in contact with the catheter surface, to prevent biofilm accumulation.
Consequently, it is key that the polymer used has a substantial
surface dye concentration and low dye bulk concentration to enable
efficacious light delivery through the polymer for activation of the
antimicrobial properties of both the internal and external device
surfaces, thereby increasing the suitability of the system for potential
clinical applications. Light microscopy and fluorescence microscopy
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showed that the desired polymer configuration was achieved by
immersing the silicone samples in a 1 x 10-3 mol dm-3 crystal violet
dipping solution for a period of 72 hours. However, it should be
noted that for potential commercial applications, the lengthy coating
process can be shortened to a few hours by gently heating the
dipping solution to 40 - 50 ◦C, without compromising the strong
polymer surface dye uptake.
3.3.3 Functional Testing
3.3.3.1 Transmission Measurements
A power meter was used to estimate the laser power transmission
through modified and unmodified silicone sections, to determine
whether sufficient irradiation was received at the outer polymer
surface. Results showed that 93 % transmission of laser illumination
was obtained through the unmodified silicone polymer, reducing
upon polymer crystal violet-coating to 69 %. The encapsulation of 2
nm gold nanoparticles within the polymeric matrix did not further
decrease the transmission of laser light through the polymer. How-
ever, silicone samples encapsulated with methylene blue and gold
nanoparticles, post-coated with crystal violet, showed a significantly
reduced transmission of light through the polymer (43 %). This
can be attributed to the methylene blue dye which is encapsulated
through the polymer bulk, dissimilar to the crystal violet which is
predominantly coated at the polymer surface, therefore decreasing
laser transmission through the polymer bulk. Nevertheless, in all
cases significant transmission through the polymer was achieved.
It can be suggested that these polymeric materials are suitable for
application in medical devices, as sufficient laser power is transmit-
ted through the polymer, for light-activation of the antimicrobial
properties of the outer polymer surface.
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Table 1: Average contact angle measurements (o) ± standard deviation of
water on the following silicone polymer surfaces: untreated, solvent treated
(control), methylene blue and 2 nm gold nanoparticle encapsulated (MBAu),
crystal violet-coated (CV), crystal violet-coated, 2 nm gold nanoparticle en-
capsulated (CVAu) and crystal violet-coated, methylene blue and 2 nm gold
nanoparticle encapsulated (CVMBAu)
Silicone Sample Contact Angle (◦) ± Standard Deviation
Untreated 102 ± 1.0
Control 101 ± 1.5
MBAu 100 ± 0.3
CV 100 ± 0.5
CVAu 100 ± 0.5
CVMBAu 102 ± 0.8
3.3.3.2 Water Contact Angle Measurements
The water contact angles of the untreated silicone, in addition to the
treated silicones were measured under laboratory temperature and
lighting conditions. The water contact angle measurements indicated
that the untreated silicone presents a hydrophobic surface (Table 1).
Moreover, it was found that there was there was negligible difference
between the wetting properties of the untreated silicone, when com-
pared to the treated silicones, whether the treatment involved solvent
exposure, dye encapsulation or, encapsulation with a combination of
both dye and gold nanoparticles.
3.3.3.3 Leaching Study
The release of crystal violet from the crystal violet-coated silicone
samples into a pre-heated aqueous solution, was measured spectro-
scopically as a function of time. By comparing the optical density
of the surrounding aqueous solution at 596 nm with a crystal violet
calibration curve, the concentration of crystal violet that leached from
the polymer was established (Figure 15). The figure indicates that the
sample released some crystal violet into solution upon immersion,
although the leaching of dye from the polymer plateaued quickly.
Over a period of more than 300 hours, the leaching of crystal violet
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Figure 15: Leaching of crystal violet dye (ppm) from a crystal violet-coated
silicone polymer into PBS solution at 37 ◦C, was measured as function of
time (hours)
from the crystal violet-coated silicone into the surrounding PBS
solution (which was maintained at 37 ◦C), was < 0.004 ppm, which is
at the detection limit of the spectrometer.
It is anticipated that this technology can be applied to medical
implants such as catheter devices, where the dye-coated catheter
would be illuminated by pulsing a laser through an optical fibre.
Therefore, it is important that the antimicrobial agent, the photosensi-
tiser dye, does not leach from the polymer under aqueous conditions
at 37 oC, since if significant concentrations of the photosensitiser
leach from the polymer under these conditions, this may reduce
the antimicrobial efficacy, in addition to causing concerns for use
in potential clinical applications. The leaching studies carried out,
demonstrated the stability and suitability of these materials for use
in future healthcare applications.
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3.3.4 Microbiological Testing
3.3.4.1 Flat Polymer Sections
In this study, a range of dye-nanogold-embedded polymers were
developed and their photobactericidal properties - activated by a
low power red laser (635 nm) - were investigated, to determine their
antimicrobial efficacy for use in potential applications in indwelling
medical devices. Medical grade silicone polymers were incorporated
with both crystal violet and 2 nm gold nanoparticles to determine
whether similar to the case of methylene blue [19, 21, 26], the 2 nm
gold nanoparticles enhance the photochemical activity of the crystal
violet. Moreover, samples encapsulated with crystal violet, methylene
blue and 2 nm gold nanoparticles were synthesised, to establish
whether the use of multi-dye-nanogold combinations can improve
bacterial kills.
The light-activated antimicrobial activity of a range of modified
silicone samples was tested against a Gram-positive bacterium and a
Gram-negative bacterium, S. epidermidis and E. coli, respectively. The
antimicrobial activity was activated by irradiating the samples using
a 635 nm laser, such that the samples were exposed to an energy dose
corresponding to 45 J cm-2. A control set of samples were stored under
dark conditions for the duration of laser irradiation. The photobacteri-
cidal activity of the following samples were tested: (i) solvent-treated
silicone (control), (ii) crystal violet-coated silicone (CV), (iii) crystal
violet-coated, 2 nm gold nanoparticle-encapsulated silicone (CVAu),
(iv) methylene blue and 2 nm gold nanoparticle-encapsulated silicone
(MBAu) and (v) crystal violet-coated, methylene blue and 2 nm gold
nanoparticle-encapsulated silicone (CVMBAu). It should be noted
that silicone samples encapsulated with 2 nm gold nanoparticles
were not tested as controls, as these were previously shown to lack
bactericidal activity [19].
Figure 16 shows the extent of the antimicrobial activity of the treated
silicone polymers when tested against both Gram-positive and Gram-
negative bacteria. Under dark conditions (∼13.5 minutes incubation at
room temperature), the control sample, MBAu sample and CV sample
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Figure 16: Graph to show the lethal photosensitisation of (a) Staphylococcus
epidermidis and (b) Escherichia coli upon irradiation with a 635 nm laser (45
J cm-2 energy dose, ∼13.5 minutes laser irradiation). Bars on the graphs rep-
resent the: initial inoculum (inoc), control silicone (control), methylene blue
and 2 nm gold nanoparticle-encapsulated silicone (MBAu), crystal violet-
coated silicone (CV) and crystal violet-coated silicone encapsulated with 2
nm gold nanoparticles (CVAu). The  indicates where the bacterial counts
are below the detection limit of 400 cfu/ mL
demonstrated no significant antimicrobial activity against S. epider-
midis. However, some antimicrobial activity was observed in the dark
on the CVAu sample and CVMBAu samples, when tested against
the Gram-positive bacterium (P < 0.01 and P < 0.001 respectively).
The enhanced kill achieved in the dark on the CVMBAu sample was
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statistically significant compared to the CVAu sample (P < 0.001).
Crystal violet is a well-known antiseptic agent and its use for medical
treatments was described as early as 1890 when Stilling noted the an-
timicrobial efficacy of aniline dyes and slightly later, in the beginning
of the 1900s when Churchman noted its effectiveness in the treatment
of superficial skin infections [28–33]. In this experiment however,
such short incubation times were used, that it was impossible to
establish the full extent of the inherent bactericidal activity of the dye.
Importantly, when irradiated with laser light, efficacious antimi-
crobial activity was demonstrated by some samples against both
Gram-positive and Gram-negative bacteria. Irradiation of the CV sam-
ple with a 635 nm laser (∼13.5 min, 55.7 mW cm-2) resulted in a highly
significant lethal photosensitisation of S. epidermidis (1.46 log kill, P <
0.001). Moreover, a substantial enhancement in the photobactericidal
activity of the crystal violet was noted when 2 nm gold nanoparticles
were present (P < 0.001), with bacterial levels reduced below the
detection limit after ∼13.5 minutes of irradiation (> 4 log reduction).
The methylene blue and 2 nm gold nanoparticles-encapsulated sili-
cone samples demonstrated a reduced light-activated antimicrobial
activity compared to the polymers containing crystal violet, although
the kill was still statistically significant compared to the control
silicone (P < 0.001). The ineffective photobactericidal activity of the
MBAu samples compared to previous studies [19, 21, 25], may in part
be attributed to the wavelength of laser light used. Previously, the
antimicrobial activity of MBAu samples was activated using a 660 nm
laser, whereas in this investigation, a 635 nm laser was used and the
wavelength of laser light did not correlate directly to the absorption
maximum of the dye. Interestingly though, as shown in Figure
11(b), the use of a 635 nm laser is a ‘better match’ with the methy-
lene blue-nanogold samples than the crystal violet-nanogold samples.
In common with the experiments using S. epidermidis, we observed a
small but statistically significant reduction in bacterial numbers with
CVAu samples in the dark when tested against E. coli (P < 0.001), but
no kill in either the control silicone or MBAu samples. A small but
statistically significant reduction in bacterial numbers was also noted
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with the CV samples in the dark (P < 0.01). Upon irradiation with red
laser light, there was negligible kill on the control samples, whereas
the MBAu samples and CV samples exhibited some photobacteri-
cidal activity against E. coli (P < 0.001). The lesser susceptibility of
Gram-negative bacteria to PDT is unsurprising, given the increased
complexity of the Gram-negative cell wall [13, 25, 34].
Importantly, a statistically significant enhancement in the antimicro-
bial activity of the crystal violet samples was observed when 2 nm
gold nanoparticles were present (P < 0.001). Both the CVAu samples
and CVMBAu samples induced the greatest lethal photosensitisation
of S. epidermidis and E. coli. These samples exhibited comparable
antimicrobial efficacy, with bacterial numbers reduced to below the
detection limit when tested against S. epidermidis and a ca. 2.6 log
reduction in bacterial numbers when tested against E. coli, upon
irradiation with a 635 nm laser for ∼13.5 min (55.7 mW cm-2). It
should be noted that the presence of methylene blue did not achieve
a further increase in the photo-activated antimicrobial efficacy com-
pared to the crystal violet-coated, nanogold-encapsulated sample.
This can be attributed to the poor photobactericidal efficacy of the
methylene blue dye at the irradiation wavelength used in this study.
It is clear that despite no intrinsic antimicrobial activity [19], the
presence of the 2 nm gold nanoparticles enhances the photoactivated
antimicrobial activity of the triarylmethane dye, crystal violet. This ef-
fect has been reported previously, although only with phenothiazine
dyes [19, 21, 26, 35]. Both CVAu and CVMBAu samples exhibited
comparable exceptional photobactericidal activity, with kills against
E. coli at least 0.4 log greater than previously reported kills for
dye-incoporated silicone polymers prepared using a simple dipping
technique [19, 21]. One study reports a similarly outstanding photo-
sensitisation of both Gram-positive and Gram-negative bacteria on
toluidine blue O and nanogold incorporated polyurethane polymers,
using very short irradiation times [23]. Nevertheless, it should be
noted that in this current investigation, the laser power was reduced
from 1 W as used previously [23], in order to deliver a lower energy
dose over a longer time such that the system is more suitable for
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potential use in medical devices, since a 1 W laser would be too
expensive and potentially dangerous for use in patients.
It is interesting to note that although the wavelength of laser irradia-
tion does not correspond to the absorption maximum wavelength of
either dye, the efficacy of the photobactericidal activity of the CVAu
sample and CVMBAu sample far surpasses that of the MBAu samples
tested. The antimicrobial activity exhibited by these modified poly-
mers stems from the photogeneration of ROS such as singlet oxygen
upon excitation of the photosensitiser molecules and a consideration
of the diffusion of these species may shed light onto the substantial
differences in polymer photosensitisation of bacteria. To roughly ap-
proximate the diffusion distance of the singlet oxygen species within
the polymer, ‘Einstein’s equation for Brownian motion’ for the diffu-
sion of atoms and ions in 1 dimension (Equation 1) can be used.
τ ≈ l
2
2D
(1)
Where ‘l’ is the mean distance travelled by the diffusing species
singlet oxygen, ‘D’ is the diffusion coefficient approximated as that
for molecular oxygen in a PDMS polymer (5.4 × 10-10 m2 s-1 [36])
and ‘τ’ is the lifetime of singlet oxygen generated by the excitation
at 532 nm of crystal violet embedded in the silicone polymer (40 µs).
The diffusion distance of the singlet oxygen species can be estimated
as 0.2 microns. This very short diffusion distance perhaps indicates
why under the same irradiation conditions, the crystal violet-coated,
nanogold-encapsulated silicone polymer and crystal violet-coated,
methylene blue and nanogold-encapsulated silicone polymer are
more effective than the methylene blue and nanogold-encapsulated
polymer, in terms of their photobactericidal activity (assuming a Type
2 photochemical mechanism). Fluorescence microscopy demonstrates
that the crystal violet polymers have concentrated bands of dye very
close to the polymer surface. This theoretically correlates to high
concentrations of ROS produced at the polymer surface, in close
proximity to the bacterial species. Conversely, the methylene blue and
nanogold-encapsulated polymer has a uniform distribution of dye
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throughout the polymeric matrix, but does not present concentrated
bands of methylene blue at the polymer surface. Hence, contrary
to the case of the crystal violet/ nanogold incorporated silicone,
the ROS produced upon irradiation of these polymers may not
be sufficiently close to the polymer surface to initiate an ‘attack’
against colonising bacteria, subsequently leading to its inefficacious
antimicrobial activity under these irradiation conditions.
3.3.4.2 Commercial Catheter Sections
Further microbiological studies were carried out on commercial
catheters modified to incorporate the photosensitiser dyes, crystal
violet and methylene blue, in addition to 2 nm gold nanoparticles.i
The light-activated antimicrobial activity of these samples was
tested against a range of Gram-positive and Gram-negative bacteria,
including those noted as key causative pathogens for UTIs [37].
The samples were tested against the following bacteria: E. coli, S.
epidermidis, MRSA, P. mirabilis, E. faecalis and P. aeruginosa. The
antimicrobial activity was activated by irradiating the samples using
a 635 nm laser, such that the samples were exposed to an energy dose
corresponding to 45 J cm-2 over an irradiation time period of ca. 18
minutes. A control set of CVMBAu samples were stored in the dark
for the duration of laser irradiation.
The extended microbiological testing was carried out to deter-
mine whether the efficacious photobactericidal efficacy activity
demonstrated by the crystal violet-coated, methylene blue and
gold nanoparticle-encapsulated flat medical grade silicone, was
reproducible when the dye-nanogold combination was encapsulated
into commercially available 100 % silicone catheters. Note that
further sample controls were not used in this investigation, since
the principal experimental aim was to confirm the efficacy of the
antimicrobial activity of these samples.
i This study was kindly carried out by Miss Annapaula Correia at the UCL Eastman
Dental Institute, Division of Microbial Diseases
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Figure 17: Lethal photosensitisation of key causative agents of urinary tract
infections by crystal violet-coated, methylene blue and gold nanoparticle-
encapsulated (CVMBAu) commercial catheter surfaces. The antimicrobial ac-
tivity of the materials was activated using a 635 nm laser (45 J cm-2 energy
dose, ∼18 minutes laser irradiation). Bars on the graphs represent the CVM-
BAu catheter sections when stored under dark conditions (purple bar). The
 represents the irradiated CVMBAu catheter sections and indicates where
the bacterial counts are below the detection limit of 400 cfu/ mL. This work
was carried out by Miss Annapaula Correia, Division of Microbial Diseases, UCL
Eastman Dental Institute
Control CVMBAu samples maintained under dark conditions did
not exhibit significant antimicrobial activity, with bacterial numbers
of the order ∼106 cfu /mL (Figure 17). However, upon irradiation
with a low power red laser (ca. 18 minutes), the numbers of all the
bacterial species tested were reduced to below the detection limit (P
< 0.001). The efficacy of this antimicrobial technology when incor-
porated into commercially available catheters against a wide range
of bacteria associated with hospital-acquired infection is extremely
promising. Over exposure to antibiotics has been associated with the
rise of bacterial drug-resistance [11], and infections such as UTIs,
are becoming increasingly difficult to treat. Consequently, it is vital
that an infection-prevention strategy, effective against a wide range
of bacteria, is developed. Due to the non-site specific mechanism by
which the lethal photosensitisation of bacteria occurs, this strategy
circumvents the issue of bacterial resistance to the antimicrobial
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agent [13, 19]. It is also anticipated that in clinical applications, the
possible emergence of crystal violet resistant Gram-positive bacteria
is unlikely, since these microorganisms are extremely susceptible to
PDT. Consequently, the incorporation of this antimicrobial photo-
sensitiser should not add to the ever-increasing problem of bacterial
drug-resistance.
A further cause for concern is the possible effect of the photosensitiser
and photogenerated products on host cell tissue, when regarding
potential applications in urinary catheter devices. Leaching studies
have demonstrated stability of the crystal violet under aqueous
conditions at body temperature and thus, release of the dye upon use
of the device is improbable, reducing the likelihood of subsequent
adverse effects. In addition, it is important that the PDT conditions
used to induce the lethal photosensitisation of bacteria on dye
incorporated polymers, do not induce a similar phototoxic effect
against host cells in the vicinity [25]. Although only a few in-vitro
studies comparing the effects of antimicrobial PDT conditions on
mammalian cells have been conducted, these have indicated the
existence of a therapeutic window in which bacterial cells can be
targeted, without compromising mammalian cells [38]. Both the
irradiation time and photosensitiser concentration sufficient to cause
bacterial cell death, does not effect similar damage to mammalian
cells [20, 25, 38–42]. Moreover, due to the short half life (< 1 µs)
and diffusion distance (10 - 100 nm) of ROS such as singlet oxygen
in a physiological environment, it is unlikely to cause significant
long-term damage to the ‘shedding’ nature of the host epithelium
cells in the environment of the catheter device [19]. In spite of this,
further investigations into the in-vivo safety and photobactericidal
efficacy of modified silicone need to be accomplished, prior to a
clinical evaluation into its suitability for use in medical practice.
3.4 conclusions
This chapter details the successful incorporation of 2 nm gold
nanoparticles, methylene blue and crystal violet dye into medical
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grade silicone, using an innovative two step synthetic route. Ef-
ficacious uptake of the crystal violet dye was achieved without
the use of an organic solvent, resulting in a polymer with even,
concentrated bands of crystal violet on both polymer surfaces, but
no dye distributed in the bulk. This non-uniform dye distribution is
beneficial for potential clinical applications in catheter devices, since
it allows more laser light to pass through the polymer bulk to activate
the photobactericidal properties of the outer surface. Spectroscopic
analysis showed that the presence of 2 nm gold nanoparticles did
not impact on the spectroscopic signature pattern of the crystal
violet dye. Moreover, the modification of the silicone to incorporate
the antimicrobial agents did not significantly change the wetting
properties of the polymer and the dye incorporated polymers were
stable under aqueous conditions at 37 ◦C.
Crystal violet-coated silicone demonstrated significant light-activated
antimicrobial activity against Gram-positive bacteria, although
this effect was more limited when tested against Gram-negative
bacteria. However, the presence of 2 nm gold nanoparticles in
combination with crystal violet was found to dramatically enhance
the lethal photosensitisation of bacteria, such that a > 2.6 log kill
was achieved against Gram-negative bacteria and bacterial numbers
were reduced to below the detection limit, when tested against
S. epidermidis. Comparably efficacious antimicrobial activity was
exhibited by crystal violet-coated, methylene blue and gold nanopar-
ticle encapsulated silicone. Both samples demonstrated exceedingly
efficacious antimicrobial activity against both Gram-positive and
Gram-negative bacteria upon irradiation with a low power laser
for short time periods. Indeed, to our knowledge this is the most
potent laser-activated polymer developed to date, for use in medical
devices. This is even more exciting as it was shown that the crystal
violet-nanogold silicone combination has statistically significant dark
kill of bacteria, even over the short time period (13.5 minutes) of the
experiment. This is the first time that light-activated antimicrobial
polymer combinations have shown dark kill, presumably due to the
intrinsic bactericidal properties of the crystal violet. This opens up
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wider and simple methods of clinical use.
For the first time, significant kill against a wide range of bacteria
noted as causative pathogens for UTIs was accomplished for a light-
activated antimicrobial polymer. Commercial catheters incorporated
with the novel antimicrobial technology, reduced bacterial numbers
to below the detection limit, when irradiated with a low power red
laser for 18 minutes. It is hoped that this novel system may potentially
help reduce the impact of catheter-associated UTIs in clinical practice.
In the next chapter, these crystal violet and nanogold- and crystal
violet, methylene blue and nanogold-incorporated silicone polymers
are tested using a white light source to activate the antimicrobial
properties, to determine whether this potent antimicrobial technol-
ogy can also be used in hospital touch surface applications, to help
maintain low surface microbial contamination levels in healthcare en-
vironments.
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W H I T E L I G H T- A C T I VAT E D A N T I M I C R O B I A L
P O LY M E R S ; C RY S TA L V I O L E T, M E T H Y L E N E B L U E
A N D G O L D N A N O PA RT I C L E - E N C A P S U L AT E D
S I L I C O N E
4.1 introduction
Much research has focused on employing a range of synthetic
strategies to develop both hard and soft antimicrobial surfaces [1–3].
Examples include: deposition of TiO2 or doped-TiO2 films onto
hard surfaces [4–9], silver ion technology [10, 11], copper coated or
incorporated surfaces [12–15], the covalent attachment of quaternary
ammonium salts to polymeric surfaces [16, 17], microbicide-releasing
surfaces [18, 19], in addition to the incorporation of photosensitiser
dyes into polymers [20–32]. The latter, as detailed in Chapter 3, is a
particularly interesting approach since photosensitisers can inactivate
micro-organisms via multiple, conserved targets giving a broad
spectrum of activity and low risk of resistance development.
The previous chapter describes the synthesis, characterisation and
testing of multi-dye-nanogold incorporated antimicrobial polymers
for use in indwelling medical devices such as urinary catheters. The
materials were strategically developed such that concentrated bands
of crystal violet were present on both polymer surfaces, with 2 nm
gold nanoparticles and methylene blue embedded throughout the
polymer bulk. It is thought that the high surface concentration of
dye maximises the antimicrobial activity of these materials, since
the diffusion distance of ROS such as singlet oxygen is very short
(estimated as < 1 micron). The antimicrobial activity of these surfaces
was activated used a low power red laser light and it is anticipated
that in clinical applications an optical fibre can be used to irradiate
the indwelling medical device.
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A two-step synthetic strategy was used to develop the photobacteri-
cidal polymers: a simple dipping step for surface uptake of crystal
violet and a ‘swell-encapsulation-shrink’ technique for encapsulation
of the light-activated antimicrobial combination, methylene blue and
2 nm gold nanoparticles, into the medical grade silicone. The liter-
ature details the antimicrobial potency of photosensitiser dye-based
photobactericidal polymers developed using this synthetic strategy,
with resultant materials inducing the lethal photosensitisation of both
Gram-positive and Gram-negative bacteria upon either short-term
illumination using a laser light source (order of minutes), or over a
slightly longer-term irradiation duration, using a standard hospital
light source to activate the antimicrobial properties of the surfaces
(order of hours) [20–23, 25, 27–32]. Recent research has primarily
been targeted towards the development of potent light-activated
antimicrobial materials for use in medical devices, that require
laser-irradiation to activate the bactericidal properties [20–25, 27].
However, some research on the incorporation of photosensitiser dyes
into polymers for use as a material for touch surfaces in a clinical
environment has been achieved [29–32].
The antimicrobial activity of the crystal violet-methylene blue-
nanogold-incorporated silicone developed in the previous chapter
can also be activated using a standard white hospital light source, as
the light-activated antimicrobial agents present, absorb light across
the visible region of the electromagnetic spectrum. This chapter
reports on the efficacious bactericidal activity of crystal violet-
coated, methylene blue and 2 nm gold nanoparticle incorporated
silicone under both white light illumination and in the dark. The
modified polymers were prepared by use of the two-step dipping
process as detailed in the previous chapter and the materials were
characterised using UV-Vis absorbance spectroscopy. Functional
testing of the material included an examination of the wetting
properties, in addition to an extensive photostability investigation.
Microbiological testing of the material involved a comparison with
previously synthesised photosensitiser-incorporated silicones against
both a Gram-positive and a Gram-negative bacterium, using a white
light source comparable to standard hospital lighting conditions
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to activate the antimicrobial properties of the polymers. The multi-
dye-nanogold incorporated polymer demonstrated the most potent
photobactericidal activity upon white light illumination reported
to this point, for dye-embedded polymers and surprisingly for the
first time, significant dark kill of both S. epidermidis and E. coli was
observed. This latter fact is a significant step-forward for dye-based
antimicrobial surfaces, as it indicates that they can be efficacious
under any lighting conditions.
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4.2 experimental
4.2.1 Chemicals and Substrates
The reagents used in materials synthesis were as follows: Methy-
lene blue hydrate (Riedel-de Hae¨n), crystal violet (Sigma, U.K.),
L-glutathione (Sigma, U.K.), HPLC grade water (Sigma, U.K.), 2
nm gold nanoparticles (2.49 x 10-7 mol L-1, BBI Solutions, U.K.),
HAuCl4.3H2O (Alfa Aesar, U.K.) and acetone (VWR, U.K.). Unless
otherwise specified, in all synthetic work carried out, the water used
was deionised (resistivity 15 MΩcm) and the substrate was medical
grade flat silicone sheets (NuSil, Polymer Systems Technology Ltd.,
U.K.).
4.2.2 Synthesis of Gold Nanoparticles
Gold nanoparticles were kindly provided by Mr William Peveler (Uni-
versity College London) and synthesised using a method adapted
from Luo et al [33]. HAuCl4.3H2O aqueous solution (2 mL, 20 mM)
and L-glutathione (reduced) aqueous solution (0.6 mL, 100 mM) were
added sequentially to HPLC grade (18 MΩ) water (17.4 mL) and
stirred at 500 rpm for 22 hours at 70 oC. The addition of the reagents
resulted in the formation of an orange colour, which faded over time
to a pale yellow.
4.2.3 Materials Synthesis
A series of samples were prepared for microbiological testing and
materials characterisation using a simple two-step dipping method
(Figure 18). NuSil silicone polymer squares (1.21 cm2) were immersed
in a swelling solution for 72 h as described in Table 2. After air-drying
(24 h), the samples were washed and towel-dried, after which selected
samples (see Table 2) were subsequently immersed in a crystal violet
dipping solution (72 h). These samples were then air-dried again,
washed and towel-dried. Gold nanoparticles used in this materials
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Figure 18: Schematic to show preparation of crystal violet-coated, methylene
blue and 2 nm gold nanoparticle-encapsulated sample
Table 2: Dipping conditions for material preparation. Where possible the
samples were maintained under dark conditions
Dipping Solution Control MBAu CV CVAu CVMBAu
9:1 acetone:water y - - - -
9:1 acetone:nanogold y* - y y*
0.001 M CV solution - - y y y
* dipping solution saturated with methylene blue (700 mg L−1)
synthesis were purchased from BBI Solutions.
Samples were prepared for further microbiological testing to com-
pare the use of commercially purchased 2 nm gold nanoparticles
from BBI Solutions, with laboratory synthesised gold nanoparticles
(see Section 4.2.2). A 9:1 acetone : nanogold swelling solution was
prepared using the laboratory synthesised gold colloid. Addition of
the acetone resulted in the formation of a pale yellow precipitate. The
9:1 acetone : nanogold swelling solution was decanted off and the
swelling solution was saturated with methylene blue dye (700 mg/
L), after which silicone polymer squares (1.21 cm2) were immersed in
it for 72 h under dark conditions. The dye/ nanogold incorporated
samples were then air-dried (24 h), washed and towel dried. The
dye-nanogold embedded polymers were subsequently immersed
in a crystal violet solution (0.001 mol dm-3) for 72 h under dark
conditions, after which they were air-dried (24 h), washed and towel
dried.
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4.2.4 Materials Characterisation
The UV-Vis absorption spectra of the treated silicone polymers pre-
pared for microbiological testing were measured using a PerkinElmer
Lambda 25 UV-Vis Spectrometer, within the range 380 - 800 nm. The
infrared absorbance spectra of the same polymers were measured
within the range 4000 - 400 cm-1 with an accumulation of 15 scans
per sample, using a Bruker Platinum ATR-FTIR spectrometer.
Untreated and modified silicone samples were imaged at 40x mag-
nification using a Brunel light microscope (NLSD-120) with a CCD
camera attached and Scope Image Advanced software was used for
analysis. A transmission electron microscope (TEM) was used to
image the 2 nm gold nanoparticle colloid and silicone-embedded
with 2 nm gold nanoparticles. 2 nm gold nanoparticles suspended
in an aqueous solution were drop cast onto lacey carbon films on
300 Mesh Copper Grids (Agar Scientific Ltd.). Grids were cleaned
under an O2/H2 plasma stream for 10 s in a Solarus (Model 950)
Advanced Plasma Cleaning System (Gatan) prior to imaging. High
resolution-TEM (HR-TEM) images were acquired using a Titan
80-300 (FEI) microscope equipped with a monochromator and image
corrector and operated with an accelarating voltage of 300 kV and
FEG of 4.5 kV. Particle size analysis was carried out using ImageJ
software (version 1.40 g, National Institutes of Health, U.S.A.). 5
micron sections of 2 nm gold nanoparticle-encapsulated silicone
polymer were secured onto a 400 Cu mesh lacy carbon film coated
Cu TEM grid (Agar Scientific Ltd.) and imaged using a Jeol 2100 high
resolution transmission electron microcope (HR-TEM) with a LaB6
source operating at an acceleration voltage of 200 kV. Micrographs
were taken on a Gatan Orius CCD with DigitalMicrograph software.
4.2.5 Dye Adherence Testing
The crystal violet-coated and crystal violet-coated, methylene blue
and nanogold-encapsulated silicone samples were wiped rigorously
with a 70% isopropyl alcohol wipe (AZOwipeTM, Synergy Health)
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to determine whether the dye adhered to the sample surface under
standard cleaning regimes.
4.2.6 Sample Photostability Testing
Treated polymer samples were stored in a white light box for an
extended duration. The samples were exposed to intense white
lighting conditions using a white light source (General Electric 28 W
Watt MiserTM T5 2D compact fluorescent lamp) emitting an average
light intensity of 12,500 ± 250 lux at a distance of 16 cm from the
samples.
4.2.7 Wetting Properties
Equilibrium water contact angle measurements (∼9 µL) on: untreated
silicone, solvent treated (control) silicone, crystal violet-coated sil-
icone, methylene blue and 2 nm gold nanoparticle-encapsulated
silicone and crystal violet-coated nanogold encapsulated silicone,
were also obtained. The contact angle measurement for each sample
type was taken to be the average value over > 10 measurements,
using a droplet of deionised water dispensed by gravity from a gauge
27 needle and the samples were photographed side on. The data was
analysed using FTA32 software.
4.2.8 Microbiological Testing
4.2.8.1 Antimicrobial Activity of a Range of Photobactericidal Polymers
A range of medical grade silicone elastomer samples (1.1 cm x 1.1
cm) were used in the microbiology experiments: (i) solvent treated
silicone (control), (ii) crystal violet-coated silicone, (iii) methylene
blue and 2 nm gold nanoparticle-encapsulated silicone, (iv) crystal
violet-coated, nanogold-encapsulated silicone and (v) crystal violet-
coated, methylene blue and nanogold-encapsulated silicone. These
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samples were tested against S. epidermidis RP62a and E. coli ATCC
25922. These organisms were stored at -70 oC in BHI containing 20
% (v/v) glycerol and propagated on either MSA or MAC agar for a
maximum of two sub-cultures at intervals of two weeks.
BHI broth (10 mL) was inoculated with 1 bacterial colony and cul-
tured in air at 37 oC for 18 h with shaking, at 200 rpm. The bacterial
pellet was recovered by centrifugation (21 oC, 1771 xg, 5 min), washed
in PBS and centrifuged again to recover the bacteria, which were
finally re-suspended in PBS (10 mL). The washed suspension was di-
luted 1000-fold to obtain the inoculum (∼106 cfu /mL). The inoculum
in each experiment was confirmed by plating ten-fold serial dilutions
on agar for viable counts. Triplicates of each polymer sample type
were inoculated with 25 µL of the inoculum and covered with a
sterile cover slip (22 mm x 22 mm). The samples were then irradiated
for up to ∼6 hours using a white light source (General Electric 28 W
Watt MiserTM T5 2D compact fluorescent lamp) emitting an average
light intensity of 3,750 ± 250 lux at a distance of 30 cm from the
samples. A further set of samples (in triplicate) was maintained in
the dark for the duration of the irradiation time, whilst an additional
sample set was maintained under dark conditions for up 18 hours.
Post irradiation, the inoculated samples and cover slips were added
to PBS (225 µL) and vortexed. The neat suspension and ten-fold serial
dilutions were plated on the appropriate agar for viable counts. The
plates were incubated aerobically at 37 oC for 24 h (E. coli) or 48 h (S.
epidermidis). Each experiment contained 3 technical replicates and the
experiment was reproduced three times. The Mann-Whitney U test
was used to determine the significance of the following comparisons:
(i) the activity of each of the modified polymers compared to the
control silicone sample when both were incubated in the dark and (ii)
the activity of each of the irradiated modified polymers compared to
the same material incubated in the dark.
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4.2.8.2 Comparison of Use of Two Different Gold Nanoparticles
A range of silicone elastomer samples (1.1 cm x 1.1 cm) were used
in the microbiology experiments: (i) solvent treated silicone (control),
(ii) crystal violet-coated, methylene blue and commercial 2 nm gold
nanoparticle-encapsulated silicone (CVMBAu@BBI) and (iii) crystal
violet-coated, methylene blue and lab synthesised gold nanoparticle-
encapsulated silicone (CVMBAu@Lab). These samples were tested
against S. epidermidis RP62a and E. coli ATCC 25922. These organisms
were stored at -70 oC in BHI containing 20 % (v/v) glycerol and
propagated on either MSA or MAC agar for a maximum of two
sub-cultures at intervals of two weeks.
BHI broth (10 mL) was inoculated with 1 bacterial colony and cul-
tured in air at 37 oC for 18 h with shaking, at 200 rpm. The bacterial
pellet was recovered by centrifugation (21 oC, 1771 xg, 5 min), washed
in PBS and centrifuged again to recover the bacteria, which were
finally re-suspended in PBS (10 mL). The washed suspension was di-
luted 1000-fold to obtain the inoculum (∼106 cfu /mL). The inoculum
in each experiment was confirmed by plating ten-fold serial dilutions
on agar for viable counts. Triplicates of each polymer sample type
were inoculated with 25 µL of the inoculum and covered with a
sterile cover slip (22 mm x 22 mm). The samples were then irradiated
for up to ∼6 hours using a white light source (General Electric 28 W
Watt MiserTM T5 2D compact fluorescent lamp) emitting an average
light intensity of 3,750 ± 250 lux at a distance of 30 cm from the
samples. A further set of samples (in triplicate) was maintained in
the dark for the duration of the irradiation time.
Post irradiation, the inoculated samples and cover slips were added
to PBS (225 µL) and vortexed. The neat suspension and ten-fold serial
dilutions were plated on the appropriate agar for viable counts. The
plates were incubated aerobically at 37 oC for 24 h (E. coli) or 48 h (S.
epidermidis). Each experiment contained 3 technical replicates and the
experiment was reproduced three times. The Mann-Whitney U test
was used to determine the significance of the following comparisons:
(i) the activity of each of the modified polymers compared to the
control silicone sample when both were incubated in the dark and (ii)
148
the activity of each of the irradiated modified polymers compared to
the same material incubated in the dark.
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4.3 results and discussion
4.3.1 Materials Synthesis and Characterisation
4.3.1.1 Synthesis of Gold Nanoparticles
Luminescent gold-thiolate nanoparticles were synthesised using
a method adapted from the literature [33]. When irradiated with
UV light (365 nm), the yellow gold nanoparticle suspension gave
an orange emission, correlating to an emission peak of 636 nm. To
prepare the swelling solution for polymer nanoparticle encapsulation,
nine parts acetone was added to 1 part gold colloid. The addition of
acetone to the nanoparticle suspension resulted in the formation of a
pale yellow precipitate which fluoresced orange under UV-irradiation
(365 nm). It is likely that the fluorescent pale yellow precipate is
the gold-thiolate capping agent and the gold nanoparticles remain
dispersed in solution.
4.3.1.2 Materials Synthesis
The use of a ‘one-step’ or ‘two-step’ dipping strategy to incorporate
photosensitiser dyes and 2 nm gold nanoparticles into medical grade
polymers, has been detailed in the literature [21–23, 25, 27, 29]. As
described in the previous chapter, a ‘two-step’ method was used to
develop a polymer encapsulated with a dual photosensitiser dye
combination, in addition to 2 nm gold nanoparticles. In the first
step, the silicone samples were immersed in a 9:1 acetone : nanogold
swelling solution saturated with methylene blue dye. Upon exposure
to the solvent, the polymer swells enabling the dye molecules to
diffuse through the polymer. When the silicone is removed from
the swelling solution, the residual solvent evaporates resulting in
a dye-incorporated polymer. In the subsequent step, the treated
polymer sections were immersed in a 1 x 10-3 mol dm-3 crystal violet
solution for 72 hours such that the resultant polymer is coated with
a thin layer of crystal violet dye at the polymer surface. Although
the mechanistic details are unclear, it is clear that the crystal violet
dye strongly attaches to the polymer surface under aqueous dipping
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Figure 19: (a) Hospital lighting emission spectrum of a 28-W fluorescent
lamp [34] with UV-Vis spectra of a series of treated silicone polymers over-
layed. The UV-Vis absorbance spectra of methylene blue and nanogold en-
capsulated silicone (blue line), crystal violet-coated, nanogold-encapsulated
silicone (violet line) and crystal violet coated, methylene blue and nanogold
encapsulated silicone (purple line) were measured within the range 380 - 800
nm. The absorbance spectra were scaled to fit the emission spectrum of the
hospital lighting source (y-axis units: mW /nm /1 lm). (b) Crystal violet-
coated nanogold and methylene blue-encapsulated silicone and nanogold
encapsulated silicone samples, prepared using a novel 2-step dipping proto-
col
conditions, as the polymer sections showed no detectable leaching of
crystal violet. Samples incorporated with methylene blue in addition
to crystal violet were a blue-purple colour, whereas those exposed
to just the crystal violet were a more purple hue (Figure 19(b)). It
should be noted that the presence of 2 nm gold nanoparticles did not
affect the sample colouration.
4.3.1.3 UV-Vis Absorbance Spectroscopy
The dye-incorporated samples were analysed using UV-Vis spec-
troscopy within the range 380 - 800 nm and their absorbance spectra
were compared to that of a hospital lighting emission spectrum
similar to that used in the microbiological testing (Figure 19(a)).
From the spectra it is clear that the crystal violet-coated, nanogold-
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encapsulated silicone sample absorbed strongly at 594 nm with a
shoulder peak at 548 nm, whereas the methylene blue encapsulated
in the silicone sample demonstrated a maximum absorption at 651
nm with small shoulder peaks at ∼610 nm and ∼670 nm. The UV-Vis
absorbance signal of the crystal violet-coated, methylene blue and
nanogold encapsulated sample exhibited key peaks from both the in-
dividual samples, with peak maxima in the same wavelength region
at 594 nm and 651 nm and shoulder peaks at 548 nm and 670 nm, cor-
responding to the crystal violet and methylene blue respectively. The
presence of the 2 nm gold nanoparticles affected neither the dye peak
intensity, shape, nor position compared to samples incorporated with
dye only and the UV-Vis spectra of the dye/ nanogold-incorporated
samples demonstrated no detectable absorbance in the visible region
of the spectrum of the gold nanoparticles, as the small diameter of the
nanoparticles used, is below the limit for surface plasmon resonance
(4 nm) [23, 27]. It is also interesting to note that there appears to be
little electronic interaction between the 2 dyes incorporated into the
polymer, since the absorbance spectrum of the multi-dye silicone is
effectively a ‘sum’ of the spectra of the individual dye incorporated
silicones.
The UV-Vis absorbance spectra of gold-thiolate nanoparticles was
measured within the range 300 - 800 nm and demonstrated ab-
sorption at < 500 nm (Figure 20(a)). No peak correlating to surface
plasmon resonance was noted, indicating that these nanoparticles
are small and below the limit for surface plasmon resonance (< 4
nm) [23, 27]. Nine parts acetone was added to the gold nanoparticle
suspension and the solution was left at room temperature to ensure
all precipitation was complete. It has been proposed that the ob-
served pale yellow precipitation is the nanoparticle thiolate capping
polymer. The UV-Vis absorbance spectra of the 9:1 acetone : gold
nanoparticle suspension was measured and it was noted that the
absorption edge at < 500 nm was not evident. This indicates that this
absorption correlated to the nanoparticle thiolate capping polymer,
which precipitated off upon addition of acetone.
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Figure 20: The UV-Vis absorbance spectra measured within the range 300 -
800 nm of: (a) Gold-thiolate nanoparticles dispersed in water (AuNP@GSH)
and gold nanoparticles dispersed in 90 % acetone (AuNP/acetone) and (b)
crystal violet-coated, methylene blue and gold nanoparticle-encapsulated sil-
icone prepared using lab synthesised gold nanoparticles (MBAuCV@LAB)
and commercially acquired gold nanoparticles (MBAuCV@BBI)
Medical grade silicone coated with crystal violet and encapsulated
with methylene blue and gold nanoparticles were synthesised. These
dark purple-coloured samples were prepared using either lab synthe-
sised gold nanoparticles or commercially acquired gold nanoparticles
(BBI). The UV-Vis absorbance spectra of both samples were measured
within the range 300 - 800 nm (Figure 20(b)). It was found that the
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type of gold nanoparticle affected neither the peak shape, nor peak
position, with both samples absorbing strongly at 590 nm and 650
nm, showing characteristic absorption signals of the photosensitiser
dyes crystal violet and methylene blue, respectively.
4.3.1.4 ATR-FTIR Spectroscopy
ATR-FTIR spectroscopy was used to measure the infrared absorbance
spectra of the samples used for microbiological testing. The spectra
(see Chapter 3, section 3.3.2.2) demonstrated no significant difference
across the sample range, or, when compared to a control, untreated
silicone sample, as the strong absorbance bands of the silicone
substrate dominated over any signals due to the dye. The similarity
of the spectra can be attributed to the low concentrations of dye
present in these polymers. However, it can be commented that the
similarity between the spectra indicates that the solvent treatment
process did not cause any significant chemical change in the silicone
polymer across the sample range.
4.3.2 Microscopy
4.3.2.1 Transmission Electron Microscope
TEM images of the commercially acquired 2 nm gold nanoparticles
in solution, are shown in Figure 21(a). The TEM images indicate
that the gold nanoparticles were spherical, mono-dispersed and
nano-crystalline. By analysis of more than 1000 particles, the average
size of the gold nanoparticles was calculated as 2.2 nm, with a narrow
size distribution of 1.1 nm (Figure 21(c)). HR-TEM images of the gold
nanoparticle showed lattice spacings of ∼0.235 nm, correlating with
the (111) plane of fcc gold (Figure 21(b)).
Flat nanoparticle-encapsulated silicone polymers were embedded ver-
tically in paraffin blocks and 5 µm sections were cut using a micro-
tome. The TEM images of these sections at the polymer edge, show
the same crystalline nanostructures, roughly 2 nm in diameter (white
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Figure 21: (a) TEM of commercially acquired gold nanoparticles, (b) HR-
TEM of commercially acquired gold nanoparticle with lattice spacings,
(c) histogram of particle size distribution of commercially acquired gold
nanoparticles determined by TEM and (d) TEM of silicone polymer encap-
sulated with commercially acquired gold nanoparticles
arrows), confirming the presence of the gold nanoparticles in the sili-
cone polymer (Figure 21(d)).
4.3.2.2 Light Microscope
A light microscope with an attached CCD camera was used to analyse
the effects of exposing the silicone to an acetone swelling solution and
the added effect of the incorporation of photosensitiser dyes at 40x
magnification, to determine whether these treatments detrimentally
affect the surface properties of the polymer. As observed in Figure
22(a), the untreated medical grade silicone sample presents a rough
surface at this magnification. Exposure to a 90 % acetone dipping
solution further roughens the polymer surface, with many additional
surface features evident (Figure 22(b)). The acetone exposure induces
polymer swelling, which is exploited to enable nanoparticle diffusion
through the polymer matrix. When removed from the swelling
solution, the residual solvent evaporates and the polymer shrinks.
However, it is possible that the swelling treatment may disorder the
polymer, resulting in the observed increase in surface roughness.
As detailed in Section 4.2.3, the photosensitiser dye crystal violet
can be coated onto medical grade silicone using an aqueous dipping
solution. From Figure 22(c), it is clear that the surface of the crystal
violet-coated polymer is smooth compared to the acetone treated
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Figure 22: Images at 40x magnification of 1.1 cm x 1.1 cm silicone squares:
(a) Untreated silicone, (b) acetone treated silicone, (c) crystal violet-coated
silicone and d) methylene blue and gold nanoparticle-encapsulated, crystal
violet-coated silicone. Note that images (c) and (d) are false coloured to dif-
ferentiate between the non-dye embedded samples (a) and (b)
polymer, closely resembling the untreated silicone surface. This
indicates that the uptake of crystal violet dye does not detrimentally
affect the polymer surface. Surprisingly, despite solvent treatment
used to incorporate the methylene blue and 2 nm gold nanoparticles,
the crystal violet-coated, methylene blue and nanogold-encapsulated
silicone surface is also similar to the untreated silicone surface, under
40x magnification (Figure 22(d)). This bodes well for potential clinical
applications where these surfaces may be used in medical devices,
as it is critical that the surface roughness properties of these devices
are not altered, to prevent increased friction during device insertion
and associated patient discomfort upon their use. It is also important
that the antimicrobial incorporation process does not significantly
increase polymer surface roughness for hospital touch surface ap-
plications. Smooth surfaces are key in a hospital environment since
these hinder bacterial surface adhesion.
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4.3.3 Functional Properties
4.3.3.1 Dye Adherence Testing
The stability of the photosensitiser dye adsorbed on the polymer
surface, was tested to determine its suitability for clinical applications.
The modified polymers were wiped rigorously with a 70 % alcohol
wipe and no visual evidence of dye removal from the treated polymer
surface was observed. This indicates that the modified polymers
should be stable under standard hospital cleaning protocols. This
test is crucial, since despite the potent antimicrobial nature of these
polymers, it is anticipated that surfaces treated by this method will
still undergo the regimented hospital cleaning protocol as an adjunct
infection-control measure and thus, must be stable to robust wiping
using an alcohol-based, anti-infective wipe.
4.3.3.2 Wetting Properties
The wetting properties of a range of untreated and treated silicone
samples were measured under laboratory temperature and lighting
conditions as detailed in Chapter 3. From the water contact angle
measurement data (Table 3), it can be inferred that the untreated
silicone presents a hydrophobic surface and the treatment of the
Table 3: Average water contact angle measurements (o) ± standard devia-
tion, of water on a range of silicone polymers: untreated, solvent treated
(control), methylene blue and 2 nm gold nanoparticle encapsulated (MBAu),
crystal violet-coated (CV), crystal violet-coated, 2 nm gold nanoparticle en-
capsulated (CVAu) and crystal violet-coated, methylene blue and 2 nm gold
nanoparticle encapsulated (CVMBAu)
Silicone Sample Water Contact Angle (◦) ± Standard Deviation
Untreated 102 ± 1.0
Control 101 ± 1.5
MBAu 100 ± 0.3
CV 100 ± 0.5
CVAu 100 ± 0.5
CVMBAu 102 ± 0.8
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polymers to incorporate dyes, dye-nanogold combinations or dye-
dye-nanogold combinations effects negligible differences in the
subsequent wetting properties of the surfaces.
Once a microorganism is within a critical distance of a surface
(usually 1 nm), the net sum of the repulsive and attractive forces
between the microorganism and the surface influences adhesion to
the surface [35]. These forces include electrostatic and hydrophobic
interactions, van der Waals forces and hydrodynamic forces [35].
Since bacteria and inert surfaces tend to be negatively charged,
electrostatic interactions between these surfaces result in repulsion
[35, 36]. It has been suggested that hydrophobic interactions may
dominate the outcome of initial bacterial adhesion to abiotic surfaces
[35], therefore it is crucial that surface modification treatments do
not act to enhance surface hydrophobicity. The water contact angle
measurements indicate that the polymer surface hydrophobicity is
not adversely affected by the antimicrobial incorporation. This is
beneficial in terms of the utilisation of this material in healthcare
applications.
4.3.3.3 Dye Photostability
UV-Vis spectroscopy was employed to investigate the photostability
of the dye incorporated silicone polymers upon exposure to a white
light source - 8W GE lighting (3500 K) - commonly used in U.K.
hospitals (for emission spectrum, see Figure 19(a)). The measured
Table 4: Recommended light intensities for different areas in U.K. healthcare
environments [4, 31]
Environment Light Intensity /lx
Operating theatre 10,000 - 100,000
A & E Examination Room 1,000
Ward corridors 6 100
Typical dental chair* 250
* Measurement performed at UCLH Eastman Dental Hospital
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Figure 23: UV-Vis absorbance spectra measured in the range 400 - 800
nm of: (a) Crystal violet-coated nanogold encapsulated silicone, (b) crystal
violet-coated, methylene blue and nanogold-encapsulated silicone and (c)
methylene blue and nanogold-encapsulated silicone, using a simple dipping
method. The samples were illuminated with a white light source emitting
an average light intensity of 12,500 ± 250 lux at a distance of 16 cm from the
samples
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Figure 24: Rate of photodegradation of modified polymers upon exposure
to white light illumination (32 days, 12,500 lx). The rate is displayed as a
decrease in sample absorbance at the absorbance maxima, over time. Crys-
tal violet has been abbreviated as CV and methylene blue has been abbre-
viated as MB. CV/Si_CV represents the crystal violet peak in the crystal
violet-coated, nanogold encapsulated silicone sample, CVMBAu/Si_CV and
CVMBAu/Si_MB represents the crystal violet and methylene blue peaks
in the crystal violet-coated, methylene blue and nanogold-encapsulated sili-
cone sample respectively and MBAu/Si_MB represents the methylene blue
peak in the methylene blue and nanogold-encapsulated polymer
light intensity at the samples was ∼12,500 lx at a distance of 16 cm
from the light source. The absorbance of the illuminated samples was
measured periodically within the range 400 - 800 nm (Figure 23). The
lighting conditions used in this study were considered in relation to
the brightness of various areas in U.K. healthcare environments, as
recommended by the Department of Health (Table 4) [4] and were
found to be ∼125x more intense than those typically found in hospital
corridors and wards, areas in which microbial contamination is
prevalent. Under these intense irradiation conditions, the photodegra-
dation of the crystal violet was ∼51 % for the crystal violet-coated,
nanogold-encapsulated silicone sample, ∼94 % for the methylene
blue and nanogold-encapsulated silicone sample and ∼81 % for the
crystal violet-coated, methylene blue and nanogold-encapsulated
silicone sample, over the course of up to 29 days (Figure 23(a)-(c)).
The rate of dye photodegradation was determined by plotting
the decrease in the UV-Vis absorbance of the samples at the dye
peak maxima, against the illumination time (Figure 24). The graph
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demonstrates that the rate of dye photodegradation in the multi-
dye-nanogold sample far surpasses that of the same dye in the
dye-nanogold only sample. It is clear from the figure that the rate
of photodegradation of crystal violet in the crystal violet/nanogold
sample is almost linear and there is greater photostability of the
dye in this sample, compared to the crystal violet incorporated in
the crystal violet/methylene blue/nanogold sample where there
is a relatively smooth, exponential rate of degradation of the dye.
It can be speculated that the discrepancy can be attributed to the
presence of multiple dyes within the polymer interacting with each
other upon photo-excitation. This leads to the formation of dye-dye
bonds (Type I pathway), rather than undergoing a cyclic Type II
photochemical pathway, wherein the dye molecule interacts with
and transfers energy to molecular oxygen, generating singlet oxygen
species, returning the dye molecule to its ground electronic state.
It should also be noted that the crystal violet-coated silicone sam-
ples were less susceptible to photodegradation than the methylene
blue-encapsulated samples (> 90 % photodegradation, 18 days,
Figure 24). Moreover, it was found that contrary to the methylene
blue-encapsulated silicone samples (Figure 23(c)), there is only a very
slight shift in the crystal violet absorbance maximum upon illumi-
nation for extensive time periods indicating that the photochemical
activity is not effecting a substantial change in the photosensitiser
structure. This minor ‘right-shift’ effect was evident in the crystal
violet peak of both the crystal violet-coated, nanogold encapsulated
silicone samples and the crystal violet-coated, methylene blue and
nanogold-encapsulated silicone samples and became noticeable with
an increase in illumination duration of > 30 days. Nevertheless,
due to the high light intensities used in this study, the observed
photodegradation should not pose a problem in practical clinical
applications, for example in hospital wards and corridors which have
less intense lighting conditions, as photodegradation will occur over
a longer timescale (years).
It is anticipated that the degradation of these dyes correlates to the
light-flux levels and thus, the samples tested indicate strong stability
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and suitability for these antimicrobial surfaces to be employed in a
clinical environment such as hospital wards and corridors. In these
environments, it is expected that these photo-activated polymers
would maintain potency for several years (based on light-flux levels
used).
4.3.4 Bactericidal Properties
In this chapter, the antimicrobial activity of multi-dye, nanogold-
encapsulated silicone sample systems are presented and compared
to a series of other dye and dye-nanogold embedded silicones.
The samples were tested against a Gram-positive bacterium and
a Gram-negative bacterium, S. epidermidis and E. coli, respectively.
The antimicrobial activity of these modified medical grade silicone
polymers, was promoted by exposure of the samples to a white
hospital light source; a compact fluorescent lamp, which emits light
across the visible region of the spectrum and is similar to those
commonly found in U.K. hospitals. In all experiments, a control
sample set was maintained under dark conditions for the same
period of time as the samples exposed to light and in a further
experiment, a sample set was incubated under dark conditions for
an extended time period. The antimicrobial activity of the following
samples was compared to that of a control, solvent-treated silicone
sample: (i) crystal violet-coated silicone (CV), (ii) crystal violet-coated,
nanogold-encapsulated silicone (CVAu), (iii) methylene blue and
nanogold encapsulated silicone (MBAu) and (iv) crystal violet-coated,
methylene blue and nanogold-encapsulated silicone (CVMBAu).
Exposure of these samples to a white light source emitting an average
light intensity of 3,750 ± 250 lux at a distance of 30 cm from the
samples, resulted in the lethal photosensitisation of both bacteria,
as demonstrated in Figure 25((a)-(c)). Under dark conditions for
incubation times of 3 h, the MBAu sample exhibited no statistically
significant kill of S. epidermidis when compared to the control silicone
sample. However, all crystal violet-coated silicone samples demon-
strated statistically significant (P < 0.001) bacterial kills compared to
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Figure 25: Viable counts of bacteria after incubation on modified silicone
polymers exposed to white light illumination: (a) S. epidermidis (3 h illumina-
tion), (b) E. coli (3 h illumination) and (c) E. coli (6 h illumination). The white
light source emitted an average light intensity of 3,750 ± 250 lux at a dis-
tance of 30 cm from the samples. The  indicates that the bacterial numbers
were reduced to below the detection limit of 400 cfu
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Figure 26: Viable counts of E. coli from the surface of samples incubated
at 20 oC for 18 h under dark conditions. The  indicates that the bacterial
numbers were reduced to below the detection limit of 400 cfu
the control silicone sample, ranging from a 0.76 log reduction in bac-
terial numbers with CV alone to a 1.9 log kill with CVMBAu, within
3 hours of contact time in the dark (Figure 25(a)). Upon illumination
with white light (3 h), all dye-incorporated samples demonstrated
strong light-activated antimicrobial activity, with statistically signifi-
cant kills compared to the same dye-incorporated samples stored in
dark conditions for an equivalent time period (P < 0.001). The crystal
violet-coated silicone sample types encapsulated with 2 nm gold
nanoparticles exhibited the most efficacious light-activated activity
against S. epidermidis, with bacterial numbers reduced below the
detection limit within 3 h.
Microbiological testing also demonstrated that these novel photo-
activated antimicrobial surfaces show significant antimicrobial
activity against a Gram-negative bacterium, under dark conditions.
When tested against E. coli, all crystal violet-coated silicone samples
demonstrated statistically significant bactericidal activity against E.
coli upon incubation in the dark for 3 hours (Figure 25(b); P < 0.01
(CV) and P <0.001 (CVAu, CVMBAu)), with increased antimicrobial
activity exhibited when incubated for 6 hours and 18 hours (Figure
25(c) and Figure 26). The efficacy of the bactericidal activity against
E. coli demonstrated by these surfaces varied across the sample range.
As with S. epidermidis, the CVMBAu sample resulted in the greatest
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reduction in bacterial numbers of up to 1.49 log, when incubated for
time periods of up to 18 hours in the dark. The CVAu sample also
showed strong antimicrobial activity, resulting in up to 0.66 log kills
against E. coli when in contact with the modified silicone surface
for up to 18 hours. The MBAu sample demonstrated no statistically
significant activity against E. coli despite an extended incubation in
dark conditions, when compared to the control silicone sample.
The nanogold attributed enhancement in the lethal photosensitisation
of Gram-negative bacteria on photosensitiser-incorporated silicone
under conditions of white light illumination, was also examined.
All modified silicone samples exhibited photo-activated bactericidal
activity against E. coli. Although statistically significant kills were
achieved in all cases for the treated silicone samples when compared
to the corresponding samples under dark conditions (P < 0.001), the
extent to which the lethal photosensitisation of E. coli was achieved
by these surfaces varied greatly across the sample range tested. The
modified sample that demonstrated the least bactericidal activity
compared to the silicone control upon activation with a white hospi-
tal light source, was the methylene blue and nanogold-encapsulated
silicone, with limited kills achieved even after 6 hour illumination.
The CV sample demonstrated stronger photo-activity than the
MBAu samples, although the presence of 2 nm gold nanoparticles
significantly enhanced the bacterial kills achieved on the crystal
violet-coated silicone surfaces, by a factor of > 1.15 log.
The novel multi-dye-nanogold silicone samples not only demon-
strated potent bactericidal activity under dark conditions, but these
samples also induced the lethal photosensitisation of E. coli, with
bacterial numbers reduced by > 2.1 log upon 3 hours exposure
to white light and reduction to below the detection limit within 6
hours of white light illumination. These multi-dye samples utilise a
greater proportion of light emitted from the white light source, with
sample absorbance within the region 475 - 700 nm (see Figure 19).
Consequently, there is greater potential for the generation of ROS -
the cytotoxic species that initiate multi-site attack against bacteria -
since dye excitation can occur over a greater range of wavelengths
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due to the multiple dyes incorporated in the silicone.
Contrary to previously synthesised materials, we have developed
and reported here potent photobactericidal polymers that also
demonstrate significant dark kill, predominantly against the Gram-
positive bacterium, S. epidermidis, but also against the Gram-negative
bacterium, E. coli. This has been achieved by incorporating the tri-
arylmethane photosensitiser dye, crystal violet, into the nanogold or
methylene blue and nanogold encapsulated silicone, by use of a novel
two-step dipping strategy. Although the anti-infective properties of
crystal violet were first discovered in the 1890s by Stilling, it was
Churchman (1912) who noted the selective action of the dye against
Gram-positive bacteria [37–40]. Crystal violet has since been used as
a treatment for infected wounds and superficial skin infections, with
clinical trials testing its efficacy as a treatment for MRSA infections
[41, 42] and was an important topical antiseptic, before modern
drugs replaced it [40]. The use of crystal violet as a treatment for
skin conditions such as superficial wounds, fungal infections and
infected scabies was recommended by the World Health Organisation
for inclusion in ‘The Interagency Emergency Health Kit’ [43]. The
photo-activated antimicrobial effect of crystal violet on Porphyromonas
gingivalis has also been investigated using a rat model with a subcuta-
neous abscess, to determine the antimicrobial efficacy of this system
in vivo, for potential applications in clinical periodontal therapy [42].
Results indicate that crystal violet coating the silicone samples signif-
icantly increases the susceptibility of the Gram-positive bacterium, S.
epidermidis, within 3 hours. A statistically significant, but more lim-
ited increase in sensitivity was demonstrated by E. coli, although this
effect required longer incubation times (18 hours). Interestingly, the
results suggest that the encapsulation of gold nanoparticles into the
silicone sample enhances not only the light-activated antimicrobial
properties, but the inherent antimicrobial properties of crystal violet.
It can be speculated that there may be an interaction between the dye
molecules and the gold nanoparticles that enhance its antimicrobial
action. A similar effect has recently been noted in the literature, with
regard to antibiotics and gold nanoparticles, in which the binding
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of antibiotics to spherical gold nanoparticles effects an enhancement
in antimicrobial activity [44–46]. The results of this study show that
this potential crystal violet-nanoparticle interaction also increases the
sensitivity of the Gram-negative bacterium, E. coli, towards the dye
(Figure 26). Following this reasoning, it can be further speculated
that dye-dye interactions transpire, perhaps on the surface of the
gold nanoparticles, since silicone samples embedded with methylene
blue and gold nanoparticles in addition to crystal violet, consistently
demonstrate greater efficacy in terms of their antimicrobial activ-
ity, compared to the sum kill of samples incorporated with only
methylene blue and gold nanoparticles or crystal violet and gold
nanoparticles.
The microbiological testing indicates that the crystal-violet incor-
porated samples outperform the methylene blue and nanogold-
encapsulated samples under both dark conditions and white light
illumination. It can be speculated that the increased efficacy in the
photo-activated kill is due to the high concentration of crystal violet
accumulated on the sample surfaces [27]. It has previously been
estimated that the ROS, singlet oxygen, has a very short diffusion dis-
tance of around 0.2 microns within the polymer [27]. Consequently,
in the case of the MBAu sample, since the dye is distributed relatively
evenly throughout the polymer, the dye encapsulated within the
polymer bulk is redundant with respect to the exhibited antimicrobial
activity. Only dye embedded near the polymer surface will act in
the photosensitisation of bacteria, as only the ROS generated near
to the polymer surface, rather than that generated within the bulk,
will act to photo-damage bacteria. With high concentrations of
photosensitiser on the crystal violet-coated polymer surfaces, there
is a greater probability of the generation of cytotoxic ROS within
range of ‘attack’ against bacteria colonising the surface, subsequently
contributing to the increased bacterial kills. It should also be noted
that crystal violet at the polymer surface may also contribute to the
dark kill exhibited by these samples, since the bacteria are in direct
contact with high surface concentrations of the antimicrobial agent.
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Figure 27: Viable counts of bacteria after incubation on modified silicone
polymers exposed to white light illumination: (a) S. epidermidis (200 minutes
illumination) and (b) E. coli (6 h illumination). The white light source emitted
an average light intensity of 3,750 ± 250 lux at a distance of 30 cm from the
samples. The  indicates that the bacterial numbers were reduced to below
the detection limit of 400 cfu
4.3.4.1 Further Microbiological Testing
The photo-enhanced antimicrobial activity of crystal violet-coated,
methylene blue and nanogold encapsulated medical grade silicone
prepared using lab synthesised gold nanoparticles (CVMBAu@Lab),
was compared to that of crystal violet-coated, methylene blue and
commercial gold nanoparticle-encapsulated silicone samples (CVM-
BAu@BBI). The antimicrobial efficacy of both samples was measured
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relative to a solvent-treated control silicone polymer and all samples
samples were tested against both a Gram-positive bacterium, S.
epidermidis and a Gram-negative bacterium, E. coli using a white
hospital light source to activate the photocatalytic kill mechanism.
An additional sample set was stored under dark conditions, for the
duration of illumination.
Microbiological testing indicated that both the CVMBAu@BBI sam-
ples and CVMBAu@Lab samples achieved significant kills against
S. epidermidis, when stored under dark conditions for 200 minutes
(P < 0.001). The CVMBAu@BBI sample reduced bacterial numbers
by 1.20 log, whereas the CVMBAu@WP sample resulted in a 1.17
log decrease in bacterial numbers and it was found that there was
no statistically significant difference in the antimicrobial activity of
these two samples (Figure 27(a)). Exposure to a standard compact
fluorescent hospital lamp induced the lethal photosensitisation of S.
epidermidis within 200 minutes, reducing bacterial numbers to below
the detection limit.
Similarly, when tested against E. coli, both samples demonstrated
efficacious antimicrobial activity under dark conditions, decreasing
viable bacterial numbers by 0.66 log within 6 hours (P < 0.001),
with no statistically significant difference in the bactericidal activ-
ity between the samples (Figure 27(b)). White light illumination
enhanced bacterial kills, resulting in the photo-activated reduc-
tion of bacterial numbers to below the detection limit on both
surfaces (P < 0.001). Overall, it was observed that the use of lab
synthesised gold nanoparticles did not inhibit, or impact on the
potency of the lethal photosensitisation of bacteria on surfaces incor-
porated with this dye-dye-nanogold antimicrobial surface technology.
This comparative study of the photo-enhanced antimicrobial activity
of crystal violet-coated, methylene blue and 2 nm gold nanoparticle-
encapsulated silicone sections is of critical importance. The use of
commercially acquired 2 nm gold nanoparticles hindered progress
since the stability of gold nanoparticles in the purchased gold
colloid was poor and nanoparticle precipitation was observed in
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several batches of the gold nanoparticle suspension. Preliminary
microbiological testing indicated that the antimicrobial efficacy of
these samples was comparable to dye only-encapsulated silicone,
with no synergistic enhancement in activity attributed to gold
nanoparticles exhibited. Moreover, despite very low concentrations
of gold nanoparticles used in the dipping solutions - 10 % nanogold
in dipping solution, ca. 1 mL dipping solution per 1.21 cm2 silicone
sample - these nanoparticles presented some financial implications
for the commercial viabilty of these surfaces, at a cost of £160.97 per
100 mL [47].
The gold-thiolate nanoparticles were synthesised at a cost of < £10
per 100 mL - nanogold concentrations used ‘as synthesised’ - deeming
this antimicrobial technology financially accessible for widespread
use in a host of surface applications. Furthermore, these nanoparticles
demonstrated stability in solution over prolonged periods of time,
with no evidence of nanoparticle precipitation. Nevertheless, one
concern regarding the use of these lab synthesised gold nanoparticles,
was the presence of the fluorescent thiolate capping polymer. In PDT
applications where it is imperative that the antimicrobial combination
results in efficacious triplet state yields, the presence of a species that
encourages gold nanoparticle fluorescence may be detrimental, as it
can impact on the subsequent enhancement in the generation of the
dye triplet state attributed to the nanogold. However, it was found
that addition of acetone to the gold colloid effects the precipitation of
thiolate-capping polymer, resulting in suspension of non-fluorescent
gold nanoparticles. This was confirmed by UV-Vis spectroscopy of
the gold nanocolloid with and without the presence of acetone, in
addition to excitation to fluorescence of these solutions using a hand
help UV lamp.
It is anticipated that these bactericidal surfaces can be employed in
hospitals for use in touch surfaces, including but not limited to: tablet
and mobile phone covers and screen protectors, computer keyboards,
hand-dryers and paint films, to help maintain low bacterial levels
and hence, potentially reduce the risk of the spread of infection. In
addition, as detailed in Chapter 3, it is envisaged that this technology
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can also be applied for use in medical devices such as catheters,
however, a low power laser irradiation system will be required for
these applications.
These novel samples demonstrate efficacious antimicrobial activity
when tested against both Gram-positive and Gram-negative bacteria,
commonly associated with nosocomial infection. Moreover, illumi-
nation with a white light source similar to that typically found in a
hospital setting resulted in a strong enhancement in the antimicrobial
activity. The intensity of the white light source used to activate
the photobactericidal properties of these polymers was ∼15x that
typically found in hospital ward corridors and ∼3x that found in
Accident and Emergency examination rooms (see Table 4) [4, 31].
Consequently, the photobactericidal activity of these surfaces would
be most efficacious in examination rooms where the light intensity
is higher, however, it is anticipated that significant kills can still
be achieved in areas of lower light intensity if the irradiation time
is prolonged. Moreover, in these experiments, very high bacterial
loads (∼32,920 cfu /cm2 E. coli, ∼51,147 cfu /cm2 S. epidermidis) were
used to test the potency of these antimicrobial polymers, whereas
on hospital surfaces, the bacterial loads on contaminated surfaces
are considerably lower (up to an equivalent of 3,060 cfu /cm2 with
average values of < 100 cfu /cm2) [48–51].
4.4 conclusions
This chapter outlines the development of potent light-activated
antimicrobial surfaces that also demonstrate effective dark kill using
polymers incorporated with multi-dye-nanogold combinations. Using
a standard hospital white light source to activate the photobacterici-
dal properties, these efficacious antimicrobial surfaces induced the
lethal photosensitisation of S. epidermidis in just 3 hours and of E. coli
in just 6 hours, with bacterial numbers reduced to below the detection
limit. The multi-mechanism antimicrobial activity proves attractive
for use in potential hospital surface applications, as low bacterial
levels will be maintained under non-optimal lighting conditions (i.e.
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at night, or when lights are dimmed), with a boost in antimicrobial
activity achieved with increasing illumination intensity. The use of lab
synthesised gold nanoparticles provides an inexpensive alternative to
previously used commercial gold nanoparticles, without detracting
from the efficacy of photobactericidal activity, increasing the viability
of this antimicrobial strategy for use in both touch surfaces and
indwelling devices.
Further work on these antimicrobial materials should include an ex-
amination of the efficacy of the bactericidal activity of these surfaces
in a clinical environment. However, although these surfaces induce
the lethal photosensitisation of high surface contamination levels of
both Gram-positive and Gram-negative bacteria, the demonstrated
dark kill levels are efficacious, but their activity can be improved.
In the next chapter, an investigation into the development of ‘dual-
mechanism’ antimicrobial surfaces will be pursued, in which novel
antimicrobial dye-nanoparticle combinations will be incorporated
into medical grade silicone. The aim of this study is to develop
surfaces that achieve potent dark-activated antimicrobial activity
against key hospital pathogens, that also demonstrate efficacious
photosensitisation of bacteria.
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W H I T E L I G H T- A C T I VAT E D A N T I M I C R O B I A L
P O LY M E R S ; C RY S TA L V I O L E T A N D Z I N C O X I D E
N A N O PA RT I C L E - E N C A P S U L AT E D S I L I C O N E
5.1 introduction
Despite rigid hygiene protocols in place, the transfer of bacteria
within hospital environments is a substantial issue and can lead to
the contraction of HAIs. These infections are a significant financial
burden to healthcare institutions, often markedly extending the
length of hospital stay and causing additional discomfort and pain
to the patient. The use of antimicrobial surfaces is an important
infection-control strategy and can disrupt the cyclic transmission of
bacteria in healthcare environments.
Chapter 4 describes the synthesis of potent white light-activated
antimicrobial surfaces for use in hospital touch surface applications,
as a strategy to decrease the incidence of associated infection. A
simple two-step dipping process was used to incorporate crystal
violet, methylene blue and 2 nm gold nanoparticles into medical
grade silicone polymers and this method can easily be upscaled for
commercial production. White hospital light illumination of these
polymers achieved significant antimicrobial activity with > 4 log
reductions in bacterial numbers within 6 hours when tested against
E. coli and within 3 hours when tested against S. epidermidis. More-
over, for the first time, these light-activated antimicrobial surfaces
demonstrated substantial kill against E. coli under dark conditions.
Although significant kills under dark conditions were documented
in the previous chapter, these were achieved over an 18 hour time
period. This chapter focuses on the development of ‘dual-mechanism’
antimicrobial surfaces that induce the lethal photosensitisation of
bacteria and also demonstrate rapid, efficacious bactericidal activity
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under dark conditions, such that low bacterial surface contamination
levels can be effectively maintained in healthcare environments, even
under low illumination conditions. Such surfaces would demon-
strate versatile antimicrobial properties, with a minimal risk of the
development of bacterial resistance, due to the multi-mechanism
mode of bacterial attack. In this chapter, the development of these
surfaces is described and was achieved through the incorporation
of photosensitiser dyes in combination with nanoparticles with
documented bactericidal properties, such as zinc oxide nanoparticles,
into medical grade silicone.
Zinc oxide is a naturally occurring metal oxide; it is inexpensive,
has a high thermal conductivity and a wide band gap (3.36 eV)
lending itself to a large range of commercial applications from
paint pigmentation to field effect transistors, gas sensors and in
photovoltaics. Zinc oxide is generally considered to be safe and
has widespread use as a food additive [1], in food packaging [2]
and in skin ointments. In fact, it is commonly used to treat nappy
rashes [3, 4] and also widely used in sunscreen products as it is an
effective block of ultraviolet (UV) radiation [3, 5]. Recently, zinc oxide
nanoparticles have attracted heightened research interest in terms of
their bactericidal activity. They exhibit antibacterial properties against
a range of both Gram-positive and Gram-negative bacteria through
a cytotoxic mechanism, in addition to showing activity against high-
temperature and -pressure resistant spores and fungal pathogens
[6–10]. It has been suggested that the mechanism by which zinc oxide
nanoparticles demonstrate antimicrobial activity may involve the
accumulation of nanoparticles in the outer membrane or cytoplasm
of bacterial cells, or may be attributed to the generation of ROS [10].
Reports have also indicated that zinc oxide nanoparticles may disrupt
or damage bacterial cell membranes, resulting in the leakage of in-
tracellular components, or cause oxidative stress [11, 12]. Zinc oxide
nanoparticles also demonstrate an enhanced antimicrobial efficacy
when compared to bulk zinc oxide [7, 9]. This can be attributed to
the high surface area to volume ratio of nanoparticles [7]. Moreover,
it has been observed that there exists a size dependency on the
antimicrobial activity of the zinc oxide nanoparticles, with decreasing
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nanoparticle size effecting greater bactericidal effectiveness [6, 9, 10].
Since nanoparticulate zinc oxide is insoluble in most solvents, in
order to disperse the nanoparticles, large excesses of surfactant are
often added. However, the presence of surfactant can reduce perfor-
mance. To overcome these adverse effects and obviate the need for
excess surfactant, a synthetic organometallic route to zinc oxide via
hydrolysis of zinc alkyl groups in the presence of non-hydrolysable
zinc carboxylates can be used [13, 14]. Recently, it has been noted
that the use of zinc di(octyl) phosphinate surface groups enhances
solubility of the nanoparticles, improving their catalytic performance
in methanol synthesis [15]. The resultant small zinc oxide nanoparti-
cles (3 - 4 nm) are easily dispersed in toluene and consequently, can
be encapsulated into polymers using a simple swelling strategy.
In this chapter, the use of a two-stage dipping approach to incorporate
zinc oxide nanoparticles in combination with a commercially avail-
able photosensitiser dye, crystal violet, into medical grade silicone, is
reported. In addition to characterisation by UV-Vis absorbance spec-
troscopy and X-ray photoelectron spectroscopy (XPS), TEM was used
to analyse the nanoparticle embedded polymer and demonstrated
evidence of nanoparticle incorporation. The antimicrobial activity of
the crystal violet-coated, nano zinc oxide-encapsulated polymer was
tested against both Gram-negative and Gram-positive bacteria ubiq-
uitous in healthcare settings and a white light source comparable to
standard hospital lighting conditions was used to enhance the antimi-
crobial properties of the novel material. Significant kill was achieved
against both bacteria under dark conditions, with a substantial en-
hancement in bactericidal activity demonstrated upon white light il-
lumination.
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5.2 experimental
5.2.1 Chemicals and Substrates
The reagents used in materials synthesis were as follows: Crystal
violet (Sigma, U.K.) and toluene (Fisher Scientific, U.K.). Diethyl zinc
(Aldrich, U.K.) was used in nanoparticle synthesis. In common with
many other organometallic compounds, it is pyrophoric and must be
handled with appropriate precautions. Solvents used in nanoparticle
synthesis were distilled from sodium, degassed by performing at
least three freeze-pump thaw cycles and stored under nitrogen. In all
synthetic work carried out, the water used was deionised (resistivity
15 MΩcm) and the substrate was medical grade flat silicone sheets
(NuSil, Polymer Systems Technology Ltd., U.K.).
5.2.2 Materials Synthesis
5.2.2.1 Preparation of Dipping Solutions
Swelling solutions were prepared as specified. Di(octyl)phosphinic
acid (DOPA-H) [15], zinc bis(di(octyl) phosphinate) ([Zn(DOPA)2])
[16, 17] and di(octyl)phosphinic acid-capped zinc oxide nanoparticles
(ZnO, 5:1 ZnO : DOPA-H) [18] that were synthesised as described
in the literature [15–18] and were kindly provided by Mr Jonathan
Weiner (Imperial College London, U.K.), were dispersed in toluene (1
mg/ mL) to prepare separate swelling solutions. The solutions were
left for 24 h (RT) to ensure complete dissolution. A crystal violet dip-
ping solution (aqueous, 0.001 mol dm−3) was also prepared.
5.2.2.2 Synthesis of Antimicrobial Polymers
A series of samples, including the relevant controls, were prepared
for antimicrobial testing. Medical grade silicone polymer squares
(1.21 cm2) were immersed in toluene swelling solutions (24 h) or
aqueous swelling solutions (72 h) as described in Table 5:
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Table 5: Dipping conditions for material preparation. Silicone samples
were immersed in: Toluene (control), di(octyl)phosphinic acid in toluene
(DOPA-H), zinc bis(di(octyl) phosphinate) in toluene ([Zn(DOPA)2]), toluene
dispersed di(octyl)phosphinic acid-capped zinc oxide nanoparticles (ZnO),
0.001 mol dm−3 crystal violet in water (CV) and ZnO nanoparticles followed
by crystal violet (CVZnO)
Solution Control DOPA-H [Zn(DOPA)2] ZnO CV CVZnO
Toluene y - - - - -
DOPA-H* - y - - - -
[Zn(DOPA)2]* - - y - - -
nano ZnO* - - - y - y
0.001 M CV - - - - y y
* solution made up to concentration of 1 mg/ mL
The samples removed from the toluene solutions were air-dried for
48 h, whereas the samples removed from the aqueous solutions
were air-dried for 24 h. All samples were subsequently washed
and towel-dried, after which selected samples (see Table 5) were
immersed in a crystal violet dipping solution (72 h). These samples
were then air-dried, washed and towel-dried. Where possible, the
samples were maintained under dark conditions both during and
after synthesis.
5.2.3 Materials Characterisation
A PerkinElmer Lambda 25 UV-Vis spectrometer was used to measure
the UV-Vis absorption spectra of the modified silicone polymers
used for microbiology, within the range 250 - 1100 nm (full range
not shown). The UV-Vis absorption spectra of: di(octyl)phosphinic
acid-capped zinc oxide nanoparticles, di(octyl)phosphinic acid and
bis(di(octyl) phosphinate) dispersed in separate toluene solutions,
was also measured within this range.
X-ray diffraction (XRD) was carried out using an X’Pert Pro diffrac-
tometer (PANalytical B.V., The Netherlands) and X’Pert Data
Collector software, version 2.2b. The instrument was used in the
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theta/theta reflection mode, fitted with a nickel filter, 0.04 rad Soller
slit, 10 mm mask, 1/4 o fixed divergence slit, and 1/2 o fixed antiscat-
ter slit. The di(octyl)phosphinic acid-capped zinc oxide nanoparticle
sample was analysed using a 0.0042 o step size, at a scanning speed
of 0.028 o s-1. A Bruker Platinum ATR-FTIR was used to measure
the infrared transmittance spectra of di(octyl)phosphinic acid-capped
zinc oxide nanoparticles, within the range 4000 - 400 cm-1 with an
accumulation of 15 scans per sample. XPS was carried out using a
Thermo K-Alpha spectrometer using monochromated Al Kα radia-
tion. Di(octyl)phosphinic acid-capped zinc oxide nanoparticles and
crystal violet-coated, zinc oxide nanoparticle-encapsulated silicone
samples were analysed and survey scans were collected in the range
0 - 1200 eV. High resolution scans (0.1 eV) encompassing the principal
peaks of Zn (2p), Si (2p), O (1s), N (1s) and C (1s) were collected at
a pass energy of 50 eV. For all samples, high-resolution scans were
calibrated to adventitious carbon at 284.8 eV.
Nanoparticles dispersed in toluene were drop-cast onto 300-mesh,
holey carbon-coated copper or gold film TEM grids (Agar Scientific).
A sample of the nanoparticle encapsulated polymer was cut by
microtome to a thickness of ca. 5 µm and secured onto a TEM grid.
Samples were imaged at an operating voltage of 200 kV on a JEOL
JEM 2100F microscope. The HR-TEM images were recorded by an
80-300 TITAN (FEI) equipped with a monochromator, operated at
300 kV. Digital images were analysed for particle sizing using ImageJ
software (version 1.46r, National Institutes of Health, U.S.A.).
5.2.4 Functional Testing
5.2.4.1 Inductively Coupled Plasma - Optical Emission Spectroscopy
Inductively Coupled Plasma - Optical Emission Spectroscopy (ICP-
OES) was measured on a PerkinElmer Optima 2000 DV. ZnO
embedded silicone samples (1.1 x 1.1 x 0.1 cm) were left immersed
in deionised water (2 mL) for a set time period (1 day, 7 days, 21
days). Samples were diluted to 5 mL and the zinc concentration
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was determined against a calibration curve prepared using Merck
Certipur ICP multi element standard solution IV.
5.2.5 Sample Photostability Testing
Treated polymer samples were stored in a white light box for an
extended duration. The samples were exposed to intense white
lighting conditions using a white light source (General Electric 28 W
Watt MiserTM T5 2D compact fluorescent lamp) emitting an average
light intensity of 6,200 ± 250 lux at a distance of 16 cm from the
samples.
5.2.6 Microbiological Investigation
The following silicone elastomer samples (1.21 cm2) were used
in the microbiology experiments: (i) solvent treated silicone
(control), (ii) crystal violet-coated silicone (CV), (iii) zinc oxide
nanoparticle-encapsulated silicone (ZnO), (iv) di(octyl) phos-
phinic acid-encapsulated silicone (DOPA-H), (v) zinc bis(di(octyl)
phosphinate-encapsulated silicone ([Zn(DOPA)2]) and (vi) crystal
violet-coated, zinc oxide nanoparticle-encapsulated silicone (CVZnO).
These samples were tested against S. aureus NCTC 8325-4 and E. coli
ATCC 25922. These organisms were stored at -70 oC in BHI broth
containing 20 % (v/v) glycerol and propagated on either MSA or
MAC agar for a maximum of two sub-cultures at intervals of two
weeks.
BHI broth (10 mL) was inoculated with 1 bacterial colony and cul-
tured in air at 37 oC for 18 h with shaking at 200 rpm. The bacterial
pellet was recovered by centrifugation (21 oC, 1771 xg, 5 min), washed
in PBS and centrifuged again to recover the bacteria, which were
finally re-suspended in PBS (10 mL). The washed suspension was di-
luted 1000-fold to obtain the inoculum (∼106 cfu /mL). The inoculum
in each experiment was confirmed by plating ten-fold serial dilutions
on agar for viable counts. Triplicates of each polymer sample type
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were inoculated with 25 µL of the inoculum and covered with a
sterile cover slip (22 mm x 22 mm). The samples were then irradiated
for up to ∼6 hours using a white light source (General Electric 28 W
Watt MiserTM T5 2D compact fluorescent lamp) emitting an average
light intensity of 3,750 ± 250 lux at a distance of 30 cm from the
samples. A further set of samples (in triplicate) was maintained in
the dark for the duration of the irradiation time.
Post irradiation, the inoculated samples and cover slips were added
to PBS (225 µL) and vortexed. The neat suspension and ten-fold serial
dilutions were plated on the appropriate agar for viable counts. The
plates were incubated aerobically at 37 oC for 24 h (E. coli) or 48 h
(S. aureus). Each experiment contained 3 technical replicates and the
experiment was reproduced three times. The Mann-Whitney U test
was used to determine the significance of the following comparisons:
(i) the activity of each of the modified polymers compared to the con-
trol silicone sample when both were incubated in the dark and (ii) the
activity of each of the irradiated modified polymers compared to the
same material incubated in the dark.
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5.3 results
5.3.1 Material Synthesis
Silicone samples incorporated with dye- and dye-nanoparticle com-
binations were prepared using a simple dipping procedure (Figure
28(a)-(b)) [19]. Zinc oxide nanoparticles (Figure 28(c)) were encap-
sulated into medical grade silicone using a “swell-encapsulation”
shrink strategy, which exploits the swelling of polymers induced by
contact with certain organic solvents [19–21]. The silicone polymers
were immersed into a 100 % toluene swelling solution made up to
1 mg/ mL of zinc oxide nanoparticles, prepared according to the
previously published route [18]. Analogous to the mechanism by
which dyes and gold nanoparticles are encapsulated into polymers
[19–21], exposure of the silicone polymer to toluene induced con-
siderable polymer swelling, enabling the diffusion of the zinc oxide
Figure 28: (a) Photograph of the zinc oxide nanoparticle-encapsulated
silicone sample and the crystal violet-coated, zinc oxide nanoparticle-
encapsulated silicone sample. (b) Cross sectional photograph of the zinc
oxide nanoparticle-encapsulated, crystal violet-coated silicone sample. The
sample dimensions are 1.1 x 1.1 x 0.1 cm. (c) Diagram to show zinc oxide
nanoparticle with di(octyl)phosphinic acid capping ligands
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nanoparticles through the silicone matrix. The resulting zinc oxide
nanoparticle-encapsulated polymer was colourless in appearance.
Crystal violet was coated onto medical grade silicone and zinc
oxide nanoparticle-encapsulated silicone by immersing the respective
polymers in an aqueous crystal violet solution made up to 0.001 mol
dm-3, for 72 h (Figure 28). The mechanism of attachment is as yet
unknown, but it has been found that it is a predominantly surface
process at this concentration [19], with the purple dye adhering to
the silicone surface and not distributed through the polymer bulk
(see Figure 28(b)).
5.3.2 Materials Characterisation
5.3.2.1 UV-Vis Absorbance Spectroscopy
The UV-Vis absorbance spectra of toluene swelling solutions and
selected treated silicone samples were measured within the range
250 - 1100 nm. The dispersed zinc oxide nanoparticle solution
demonstrated a characteristic shoulder at 350 nm [15], whereas the
capping agent solution and [Zn(DOPA)2] exhibited no significant
absorption in this region (Figure 29(a)). Using a Tauc plot - a plot
of (ahv)2 against energy (eV), where ‘a’ is the absorbance of the
zinc oxide nanoparticles [22] - the band onset of the nanoparticle
suspension was estimated at 3.53 eV (Figure 29(a), inset), indicating
that the zinc oxide nanoparticle is a UV photocatalyst (< 385 nm)
and thus should not exhibit significant light-activated antimicrobial
activity when illuminated with a white hospital lighting source.
UV-Vis absorbance spectroscopy was also used to examine some
of the materials prepared for microbiological testing (Figure 29(b)).
The zinc oxide nanoparticle-encapsulated silicone sample showed no
UV-Vis absorbance signal at 350 nm, characteristic of the nanopar-
ticles. This can be attributed to low nanoparticle concentrations in
the polymer, in addition to the significant UV-Vis absorption signal
of the silicone substrate in the region 250 - 350 nm. The UV-Vis
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Figure 29: (a) UV-Vis absorbance spectra of toluene dispersed
di(octyl)phosphinic acid-capped zinc oxide nanoparticles (ZnO NP),
di(octyl)phosphinic acid in toluene (DOPA-H) and zinc bis(di(octyl) phos-
phinate) ([Zn(DOPA)2]) in toluene. Inset: Tauc plot to determine band gap
of di(octyl)phosphinic acid-capped zinc oxide nanoparticles. The band onset
of the 3 - 4 nm zinc oxide nanoparticles was calculated as 3.53 eV. (b) UV-Vis
absorbance spectra of modified samples used for microbiological testing:
Solvent treated silicone (control), crystal violet coated-silicone (CV), zinc
oxide nanoparticle encapsulated-silicone (ZnO) and crystal violet-coated,
zinc oxide nanoparticle-encapsulated silicone (CV-ZnO)
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absorbance signals of both the crystal violet coated- and crystal
violet coated, zinc oxide nanoparticle-embedded silicone samples
were similar in peak shape and position and characteristic of the
crystal violet dye, with absorbance maxima at λ ≈ 590 nm and a
shoulder peak at λ ≈ 545 nm. This indicates that the presence of
the zinc oxide nanoparticles does not affect the position of spectral
features, suggesting that there is no electronic interaction between
the zinc oxide nanoparticles and crystal violet dye. Figure 29(b)
also indicates that the concentration of crystal violet in the zinc
oxide nanoparticle-embedded silicone is greater than that in the
crystal violet coated-silicone. It can be speculated that this is due
to the swelling treatment prior to dye coating, used to incorporate
the zinc oxide nanoparticles, disordering the polymer surface and
creating a greater surface area for uptake of the dye. This increased
uptake of the dye may effect a more efficacious antimicrobial activ-
ity consequent to a greater concentration of bactericidal agent present.
5.3.2.2 X-Ray Diffraction
The di(octyl)phosphinic acid-capped zinc oxide nanoparticles were
analysed using XRD and compared to a reference spectrum (Figure
30(a)). The nanoparticle sample examined corresponds to zinc oxide,
with all the reference peaks correlating to that of the reference
spectrum for the zinc oxide wurtzite structure. Two broad peaks
were also present at ca. 12o 2θ and 21o 2θ. XRD analysis of the
di(octyl)phosphinic acid showed a series of sharp peaks in this
region (Figure 30(b)), confirming that these peaks can be attributed
to amorphous DOPA-H on the surface of the zinc oxide nanoparticle.
5.3.2.3 ATR-FTIR Spectroscopy
The infrared transmittance spectra of the di(octyl)phosphinic acid-
capped zinc oxide nanoparticles and the silicone encapsulated with
the zinc oxide nanoparticles were obtained by ATR (Figure 31). The
IR spectra of the zinc oxide nanoparticles showed sharp peaks at 1050
cm-1 and 1130 cm-1 and a broad band at 3400 cm-1 correlating to the
P-O bonds and the O-H bond respectively, in the di(octyl)phosphinic
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Figure 30: (a) XRD of di(octyl)phosphinic acid-capped zinc oxide nanopar-
ticles. The red lines reference the zinc oxide nanoparticle peaks against the
ZnO wurtzite structure (reference lines from PDF 036-1451, ICDD PDF4+
database). * indicates that these peaks are assigned to DOPA-H. (b) XRD of
di(octyl)phosphinic acid
acid capping ligand (Figure 31(a)). A sharp peak at ca. 2900 cm-1 was
also observed and corresponds to the long alkyl chain in the nanopar-
ticle capping group. The IR spectrum of the silicone embedded
with the zinc oxide nanoparticles was characteristic of the spectrum
for the silicone polymer (Figure 31(b)). The spectrum showed no
evidence of nanoparticle encapsulation and this can be attributed to
the strong signal obtained for the silicone polymer, in addition to the
low concentration of nanoparticles encapsulated within the polymer.
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Figure 31: ATR-FTIR transmittance spectra measured within the range 4000 -
400 cm-1 of (a) di(octyl)phosphinic acid-capped zinc oxide nanoparticles and
(b) silicone encapsulated with di(octyl)phosphinic acid-capped zinc oxide
nanoparticles
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Figure 32: XPS spectra of di(octyl)phosphinic acid-capped zinc oxide
nanoparticle to show (a) Zn scan, (b) P scan, (c) O scan and (d) C scan
5.3.2.4 X-Ray Photoelectron Spectroscopy
XPS of the di(octyl)phosphinic acid-capped zinc oxide nanoparticles
showed a doublet in the Zn (2p) region corresponding to zinc in
ZnO and an asymmetric peak in the P (2p) region, correlating to the
overlapping P 2p3/2 and P 2p1/2 components typical of phosphorus
in phosphate, as found in the nanoparticle capping ligand (Figure
32(a)-(b)). It should be noted that a Zn (3s) peak was observed in the
P (2p) region and peaks in the O (1s) region and C (1s) region were
also present (Figure 32(c)-(d)).
XPS of the crystal violet-coated, zinc oxide nanoparticle encapsulated
silicone polymer showed evidence of nanoparticle encapsulation
(Figure 33). As observed in the XPS spectra of the zinc oxide nanopar-
194
Figure 33: XPS spectra of crystal violet-coated, zinc oxide nanoparticle-
encapsulated silicone to show (a) Zn scan, (b) O scan, (c) C scan and (d)
N scan
ticles, a doublet in the Zn (2p) region corresponding to zinc in ZnO
was identified, confirming the presence of zinc oxide nanoparticles
within the polymer. Peaks in the O (1s) region, and C (1s) region Si
(2p) region and N (1s) region were also present, correlating to the
presence of the nanoparticle, polymer and crystal violet dye (N peak).
5.3.2.5 Transmission Electron Microscopy
The zinc oxide nanoparticle powder was dispersed in toluene to
form a dilute solution and drop cast onto TEM grids. The TEM
images (Figure 34) show well separated, small, spherical nanopar-
ticles with no evidence of agglomeration. Size analysis showed an
average nanoparticle diameter of 3.3 nm (± 1.1 nm). HR-TEM images
showed the particles to be crystalline with lattice spacings correlating
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Figure 34: (a) TEM of zinc oxide nanoparticles with di(octyl) phosphinate
capping ligands, (b) HR-TEM of zinc oxide nanoparticle with lattice spac-
ings, (c) histogram of particle size distribution of zinc oxide nanoparticles
as synthesised, determined by TEM and (d) TEM of silicone polymer encap-
sulated with zinc oxide nanoparticles with di(octyl) phosphinate capping
ligands
with Wurtzite ZnO. Each nanoparticle was composed of a single
crystalline domain, a result of the nucleation controlled growth
and the prevention of oriented attachment by the strongly bound
di(octy)phosphinate ligand.
TEM analysis of the zinc oxide nanoparticle embedded polymer edge
demonstrated evidence of nanoparticle encapsulation, with visible
crystallographic planes present (Figure 34(c)). Lattice spacings of 0.28
nm were observed correlating to the (100) plane of hexagonal ZnO.
5.3.3 Functional Properties
5.3.3.1 Material Stability
In order to elucidate the stability of the zinc oxide nanoparticles
within the polymer, ICP-OES was used to determine whether zinc,
either in nanoparticulate form or other zinc species, leached from the
polymer under aqueous conditions. Samples of silicone embedded
with zinc oxide nanoparticles were immersed in de-ionised water and
the concentration of zinc that leached into solution was measured af-
ter 1 day, 7 days and 21 days. It was found that small traces of zinc
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were released into solution (up to 0.0025 mg per zinc sample), but
these leaching effects plateaued with time (Figure 35).
Figure 35: Leaching of zinc from ZnO encapsulated silicone polymer into
de-ionised water at RT, determined by ICP-OES, measured as function of
time (days)
5.3.3.2 Material Photostability
UV-Vis spectroscopy was used to examine the photostability of crystal
violet and crystal violet-coated, zinc oxide nanoparticle-encapsulated
silicone polymers upon exposure to a white light source. The samples
were illuminated and the dye absorbance was measured periodically
within the range 400 - 750 nm (Figure 36). As in the previous Chapter
(Section 4.3.3.3), the white light source - 8 W GE lighting (3500 K) -
was similar to that commonly used in U.K. hospitals and the lighting
intensity used in this investigation was considered in relation to
the brightness of various areas in U.K healthcare environments,
as recommended by the Department of Health (Table 4) [22]. In
this study, the lighting intensity used, ∼6,200 lx, was ∼62x more in-
tense than that typical of hospital corridors and wards (ca. 200 lx) [22].
Under these intense lighting conditions, the crystal violet-coated
silicone sections demonstrated suitable photostability (Figure 36(a)-
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Figure 36: UV-Vis absorbance spectra measured in the range 400 - 750 nm
of (a) crystal violet-coated silicone and (b) crystal violet-coated, zinc oxide
nanoparticle-encapsulated silicone. The samples were illuminated with a
white light source emitting an average light intensity of 6,200 ± 250 lux
at a distance of 16 cm from the samples
(b)). The rate of dye photodegradation was determined by plotting
the decrease in the UV-Vis absorbance of the samples at the dye
peak maxima, against the illumination time (Figure 37). The rate
of photodegradation of both the crystal violet-coated silicone and
crystal violet-coated, zinc oxide nanoparticle-encapsulated silicone is
linear in form, showing a smooth, gradual decrease in dye intensity
as a function of illumination time. The photodegradation of the
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Figure 37: Rate of photodegradation of modified polymers upon exposure to
white light illumination (99 days, 6,200 lx). The rate is displayed as a decrease
in sample absorbance at the crystal violet absorbance maxima, over time.
Crystal violet has been abbreviated as CV and the zinc oxide nanoparticles
have been abbreviated as ZnO. CV_Silicone represents the crystal violet peak
in the crystal violet-coated silicone sample and CVZnO_Silicone represents
the crystal violet peak in the crystal violet-coated, zinc oxide nanoparticle-
encapsulated silicone sample
crystal violet-coated silicone polymers was ca. 72 % over a period of
99 days. Over the same period of time, the crystal violet-coated, zinc
oxide-encapsulated polymer resulted in a 52 % photodegradation of
the crystal violet dye, suggesting that the presence of the nanoparti-
cles may stabilise the dye with respect to photodegradation.
It is expected that the rate of dye photodegradation linearly correlates
with the lighting intensities used in the investigation. Previously
(Chapter 4, Section 4.3.3.3) it was noted that over a period of 29
days, a 50 % photodegradation of crystal violet was observed for the
crystal violet-coated, 2 nm gold nanoparticle-encapsulated silicone,
upon illumination with a 12,500 lx light source. Here, the crystal
violet-coated, zinc oxide nanoparticle samples demonstrate an appar-
ent enhanced photostability, indicating a 27 % photodegradation of
crystal violet within 47 days, using a 6,200 lx white light source. It is
possible to draw conclusions about the relative photostability of the
two dye-nanoparticle systems, by accounting for the light intensity
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received at the sample over a specific time period. However, it should
be noted that a more rigorous comparison of the photostability
of the two dye-nanoparticle systems explored in these chapters
can only be achieved by investigating the photostabilities of the re-
spective samples in a direct study, using the same illumination source.
The crystal violet-coated, zinc oxide-encapsulated samples demon-
strate strong photostability over a prolonged time period using
intense illumination conditions. These samples demonstrate suitabil-
ity for use as photo-activated antimicrobial surfaces in healthcare
environments, where the lighting conditions in hospital wards and
corridors are ca. 62x less intense than that investigated in this study. It
is anticipated that under ambient lighting conditions, these samples
should maintain potency for several years.
5.3.4 Microbiological Testing
The antimicrobial activity of a series of modified medical grade
silicone samples was determined using representative Gram-positive
and Gram-negative bacteria, S. aureus and E. coli, respectively, both
of which are commonly found in healthcare environments. For each
experiment, a set of samples were illuminated with a white hospital
light source (28 W), emitting an average light intensity of 3,750 lux
at a distance of 30 cm from the samples, whilst a parallel set were
stored under dark conditions for the same duration. Although the
white light intensity used in this investigation is approximately three
times that found in a typical A & E examination room [22], the
microbial loads used in these experiments are far greater than those
typically found in a clinical environment (∼45,529 cfu cm−2 used in
this investigation, compared to 6 3,060 cfu cm−2 with average values
of < 100 cfu cm−2 in a clinical environment [23–27]).
The light-activated and intrinsic bactericidal activities of the
following samples were tested: (i) solvent-treated silicone, (ii)
crystal violet-coated silicone (CV), (iii) di(octyl) phosphinic acid-
capped zinc oxide nanoparticle-encapsulated silicone (ZnO), (iv)
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Figure 38: Graph to show the viable counts of bacteria after incubation on
modified silicone polymers exposed to white light illumination: (a) S. aureus
(1 h illumination), (b) E. coli (3 h illumination) and (c) E. coli (6 h illumina-
tion). The white hospital lighting source emitted an average light intensity
of 3,750 ± 250 lux at a distance of 30 cm from the samples. DOPA refers to
di(octyl)phosphinic acid, the nanoparticle capping ligand. The  indicates
where the bacterial counts were reduced to below the detection limit of 400
cfu
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di(octyl)phosphinic acid encapsulated silicone (DOPA-H), (v) zinc
bis(di(octyl) phosphinate-encapsulated silicone ([Zn(DOPA)2]) and
(vi) crystal violet-coated, di(octyl) phosphinic acid-capped zinc oxide
nanoparticle encapsulated silicone (CVZnO). This range of samples
was tested to deduce whether it was the ZnO nanoparticle, free
capping agent or the ZnO-bound capping agent, that contributed
to the antimicrobial activity. Samples were also coated with crystal
violet dye to establish whether this enhances bacterial kills and if
there exists a similar synergistic enhancement in the antimicrobial
activity as previously established with crystal violet, methylene blue
and gold nanoparticle combinations encapsulated into medical grade
polymers [19–21, 23].
Figure 38 shows the antimicrobial efficacy of a range of treated
silicone samples when inoculated with either S. aureus or E. coli for
up to 6 hours (Figure 38). Under dark conditions (1 h incubation at 20
oC), neither the ZnO sample, nor the DOPA-H sample demonstrated
significant activity against S. aureus. However, the [Zn(DOPA)2]
sample induced a statistically significant reduction in staphylococcal
numbers (P < 0.001) in the dark. The CVZnO sample significantly
reduced the number of viable S. aureus on the sample surface (P <
0.001), with enhanced bacterial kills compared to the sample contain-
ing CV alone. This can be attributed to the higher concentration of
crystal violet at the sample surface, due to the pre-swelling treatment
in toluene used to encapsulate the ZnO nanoparticles. Illumination
of these samples using a standard hospital lighting source for just
1 hour, resulted in the lethal photosensitisation of S. aureus on the
CV sample (1.69 log kill), with a marked increase in antimicrobial
activity on the CVZnO sample (P < 0.001, 3.36 log kill).
A correlation has been noted in the literature between the decreasing
size of the zinc oxide nanoparticle and its bactericidal efficacy [6, 9,
10]. In this study, small 3 - 4 nm ZnO nanoparticles were incorporated
into the polymer. These polymers exhibited antimicrobial activity
against E. coli, with a statistically significant reduction in bacterial
numbers (1.41 log) following incubation for 6 hours in the dark (P
< 0.001, Figure 38). ICP-OES studies indicated that small traces of
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zinc species leached from the polymer when left in aqueous solution
for extended periods. However, previous research has shown that
leached Zn2+ ions are unlikely to contribute to the antimicrobial
activity [10].
Illumination of the ZnO sample resulted in enhanced antimicrobial
activity with a 1.9 log reduction in bacterial numbers for the same
incubation duration. No antimicrobial activity was observed on the
DOPA-H and [Zn(DOPA)2] samples either under dark conditions
or with white light illumination for 3 hours. CV samples demon-
strated a limited, but statistically significant bactericidal activity
when tested against E. coli (0.72 log kill, 6 h illumination). This
discrepancy between the efficacy of PDT against Gram-positive
bacteria and Gram-negative bacteria can be attributed to differences
in their cell wall structures [19]. Gram-negative bacteria have both
inner and outer phospholipid bilayer cell membranes, whereas
Gram-positive bacteria have only a single inner phospholipid bilayer
cellular membrane surrounded by peptidoglycan, which acts as
an ineffective barrier against PDT. It has also been noted that the
inherent bactericidal efficacy of crystal violet against Gram-negative
bacteria is more limited [19]. However, the dual-combination CVZnO
sample exhibited potent photobactericidal activity against E. coli,
with bacterial numbers reduced by 2.16 log within 3 hours of white
light illumination and by at least 4.25 log within 6 hours (below
detection limit, P < 0.001). This suggests a synergistic effect in
the activity of the triarylmethane dye when ZnO nanoparticles are
present, as an enhancement in bacterial kill was noted, that surpassed
the kills expected if they were caused by an additive effect.
Overall, the results indicate that the ZnO samples demonstrate a
stronger bactericidal efficacy against the Gram-negative bacterium,
E. coli, than the Gram-positive bacterium, S. aureus. Conversely, the
CV samples exhibit a more efficacious antimicrobial activity against
S. aureus. Crystal violet is known to exhibit antimicrobial activity
against Gram-positive bacteria and is used in the treatment of
superficial wounds and some skin infections [28–32]. Consequently,
this novel ZnO-dye combination creates an antimicrobial surface on
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medical grade silicone, effective against both E. coli and S. aureus.
The CVZnO sample demonstrates superior antimicrobial efficacy,
inducing the lethal photosensitisation of both S. aureus and E. coli,
with high reductions in viable bacterial numbers achieved after only
1 hour and 6 hours illumination, respectively. Moreover, significant
kills were also observed under dark conditions and importantly,
a highly significant reduction in E. coli numbers (1.70 log) was
recorded with CVZnO after 6 hours incubation. These samples
achieved a 1.16 log greater reduction in bacterial numbers when
tested against E. coli under dark conditions (6 hours), compared
to the dual photosensitiser dye-gold nanoparticle system described
in the previous chapter. It is clear that the antimicrobial activity of
the novel zinc oxide nanoparticle, dye-coated silicone samples is
more efficacious than other dye-nanoparticle samples investigated,
however, the photobactericidal activity demonstrated by these sam-
ples is comparable to that demonstrated by a previously tested
multi-dye-nanogold-encapsulated silicone (Chapter 4), with both
samples reducing bacterial numbers to below the detection limit
within 6 hours illumination.
To validate the antimicrobial efficacy of these surfaces, the exhibited
photobactericidal activity of these surfaces was compared to other
antimicrobial systems published in the literature. Limited data has
been published on the development of photobactericidal polymers.
One system details the synthesis of protoporphyrin- and zinc
protoporphyrin-grafted nylon fibres using a white light source of in-
tensities ranging from 10,000 - 60,000 lux, to activate the antimicrobial
properties [33]. When tested against S. aureus these samples induced
the lethal photosensitisation of bacteria within 30 minutes, reducing
bacterial numbers to 5.6 % on the zinc protoporphyrin sample at a
light fluence of 40,000 lx [33], however, no antimicrobial activity was
observed when tested against E. coli at this light fluence [33].
Other visible light photo-active antimicrobial surfaces include tita-
nia, silver-loaded titania, nitrogen-doped titania and silver-loaded
nitrogen-doped titania thin films, on glass surfaces [22, 34]. Titania
coatings demonstrated negligible antimicrobial activity upon irradi-
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ation with white light for 12 h, when tested against EMRSA-16 [22].
Titania is a UV-active photocatalyst and so, this poor photo-activity
can be attributed to the limited proportion of UV light present in the
white light source [22]. Silver-doped titania-coatings demonstrated
an enhanced photocatalytic effect, reducing bacterial numbers by ca.
2.5 log [22]. Moreover, when tested against E. coli, silver-doped titania
samples demonstrated efficacious bacterial kills, even under dark
conditions, reducing bacterial numbers to below the detection limit
within 6 hours [22]. Silver-loaded nitrogen-doped titania samples
demonstrated enhanced light-activated kill rates, reducing bacterial
levels to below the detection limit within 5 hours at a light fluence
of 1,000 lx, although less efficacious antimicrobial acitivity was noted
under dark conditions [34]. When tested against MRSA however,
these samples only effected a 2 log reduction in bacterial numbers
upon irradiation for 5 hours [34]. Copper surfaces have also attracted
much attention in terms of their efficacious antimicrobial activity,
with thin films of copper and copper oxide on glass surfaces reducing
bacterial numbers to below the detection limit within 30 minutes
and 1 hour, when tested against E. coli and S. aureus respectively, in
a laboratory investigation [35]. The use of copper surfaces in hospital
touch surface applications, has also effected a significant reduction
in microbial surface contamination levels in clinical trials [24, 25],
impacting on the incidence of hospital-acquired infections [36].
Some of these antimicrobial systems demonstrate poor antimicrobial
efficacy compared with the crystal violet-coated zinc oxide nanopar-
ticle encapsulated silicone reported here [22, 33]. However, other
systems exhibited comparable, or enhanced antimicrobial activity
[34, 35]. The use of thin film antimicrobial coatings, or copper sur-
faces however, presents a substantial financial burden to healthcare
institutions. Existing furnishings would have to be replaced with
the antimicrobial equivalent and U.K. hospitals that are part of the
Private Finance Initiative scheme would also be required to pay an
upfront ‘30 year lifetime cost’ for new furnishing installations. The
use of an antimicrobial polymer that can be retrofit onto existing
furnishings presents a promising, inexpensive alternative for use as
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an infection-control mechanism.
It is anticipated that this crystal violet-zinc oxide-polymer technol-
ogy can be utilised to develop antimicrobial surfaces for use, chiefly
in healthcare environments, but also in everyday applications such
as keyboards, mobile phone and tablet covers and kitchen surfaces.
Although this novel material has been developed for use in touch sur-
faces rather than implanted medical devices, it is crucial that these
surfaces are non-toxic and contact with them does not effect adverse
reactions. With the widespread use of zinc oxide nanoparticles in the
cosmetics and food industry, their toxicity has been extensively stud-
ied in a number of reports. The toxicity of nanoparticles depends on
a number of factors including their size, shape, route of administra-
tion and dosage [37]. Nano zinc oxide is generally believed to be safe,
with investigations concluding that zinc oxide nanoparticle penetra-
tion through the skin is negligible and through other routes of admin-
istration zinc oxide only showed toxic effects at high doses (> 100 µg/
mL) [38–40]. Similarly, crystal violet poses a low toxicity risk and was
used as a topical antiseptic before its use was superseded by mod-
ern drugs [41]. The World Health Organisation also recommended its
inclusion in the ‘Interagency Emergency Health Kit’ [42] and clinical
trials have investigated its efficacy as a potential treatment against
MRSA [43, 44]. Consequently, the use of this antimicrobial combina-
tion in these novel dual mechanism antimicrobial surfaces, should not
present a risk to users and should maintain low surface bacterial lev-
els, reducing the likelihood of the spread of infections in a hospital
environment.
5.4 conclusion
Highly efficacious antimicrobial surfaces encapsulated with 3 - 4
nm zinc oxide nanoparticles and coated with crystal violet dye,
have been synthesised using a straightforward and simple two stage
dipping process. These materials demonstrated strong photostability
upon extensive illumination with a white hospital light source. For
the first time, TEM analysis was used as a technique to confirm
the incorporation of nanoparticles into the silicone polymer, with
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visible lattice spacings matching those as determined from TEM
micrographs of the drop cast nanoparticle suspension.
These efficacious antimicrobial materials present ideal surfaces for
use in healthcare environments and demonstrated strong bacteri-
cidal activity via a novel-dual mechanism approach, utilising PDT
in combination with the inherent antimicrobial properties of zinc
oxide nanoparticles. The resultant polymer, a potent bactericidal
surface, achieved a 3.4 log reduction in bacterial numbers within
an hour, when tested against Gram-positive bacteria and reduced
bacterial numbers to below the detection limit within 6 hours against
Gram-negative bacteria, upon illumination with a white light source.
Significant kills against both Gram-positive and Gram-negative
bacteria were also achieved under dark conditions within the same
time period.
The principal aim of this thesis is to detail the development of
potent antimicrobial polymers that utilise multiple mechanisms of
bacterial attack to maintain low surface bacterial contamination
levels in healthcare environments. Up to this point, there has been a
strong emphasis on the development of photobactericidal polymers
incorporated with photosensitiser dyes and nanoparticles. How-
ever, to advance materials development, an understanding of the
underpinning photophysics is key. The next chapter presents an in-
vestigation into the photochemical properties of photosensitiser dye-
and photosensitiser dye and nanoparticle-encapsulated polymers,
to gain insight into the mechanism of the photobactericidal activity
demonstrated.
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P H O T O E X C I TAT I O N O F P H E N O T H I A Z I N E A N D
T R I A RY L M E T H A N E P H O T O S E N S I T I S E R D Y E S
E N C A P S U L AT E D I N M E D I C A L G R A D E S I L I C O N E
6.1 introduction
This thesis has detailed the development of novel photosensitiser and
nanoparticle-encapsulated polymers, that exhibit efficacious antimi-
crobial activity against key pathogens associated with HAIs through
a light-activated mechanism. It has also been noted in Chapters 3 and
4, that the photobactericidal activity of photosensitiser dyes is sig-
nificantly enhanced through interactions between the dye molecule
and 2 nm gold nanoparticles. This synergistic enhancement has been
observed in polymers incorporated with either methylene blue [1, 2]
or crystal violet [3, 4]. It is critical that the photochemistry of these
dye- and dye-nanoparticle-encapsulated polymers is explored, to
gain an understanding of the photochemical mechanism by which
antimicrobial activity is achieved, such that this technology can be
refined to develop more potent antimicrobial polymers.
As detailed in the literature and in previous chapters, photobac-
tericidal polymers pose as attractive candidates for use as an
infection-control strategy in healthcare environments. These poly-
mers can be synthesised by incorporating photosensitiser dye
molecules and nanoparticles into polymers, using a simple dipping
approach. Photosensitisers used include methylene blue, toluidine
blue O and crystal violet and these dye-incorporated polymers
have induced the lethal photosensitisation of both Gram-positive
and Gram-negative bacteria, with samples demonstrating strong
antimicrobial efficacy under both laser irradiation and also, under
standard hospital lighting conditions [1–11]. The utilisation of this
photochemical kill approach reduces the risk of bacterial resistance,
consequent to the non-site-specific mode of attack. The photosensi-
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tiser dyes used in this strategy are cheap and commercially available
and the method of incorporation is easy to upscale on an industrial
level. Consequently, these novel polymers are ideal candidates for
use as antimicrobial surfaces in hospitals, as a means to help decrease
the risk of infection.
The polymers demonstrate antimicrobial activity predominantly by a
light-activated mechanism: photosensitiser dyes immobilised in the
polymers absorb light, resulting in the transition of an electron from
the delocalised pi orbital in the dye molecule, to a pi* antibonding
orbital; an excited singlet state. This electron can then undergo an
intersystem crossing, such that the dye molecule is in the slightly
lower energy, longer-lived excited triplet state [12, 13]. The triplet
state molecule can return to its ground state by undergoing a variety
of radiative or radiationless processes, including phosphorescence,
intersystem crossing and vibrational relaxation [13].
The triplet state dye molecule can also undergo two categories of pho-
tochemical processes, termed a ‘Type I’ and ‘Type II’ mechanism. The
Type I mechanism involves one-electron redox processes that occur
between the excited triplet state dye molecule and any molecule with
the appropriate redox potential; in this context, proteins, unsaturated
lipids, DNA etc. on the target cell [14]. The Type II mechanism
involves an energy transfer process between the excited triplet state
dye molecule and molecular oxygen in the vicinity, resulting in
the generation of singlet oxygen species [14]. Highly electrophilic,
singlet oxygen rapidly reacts with electron-rich substrates such as
unsaturated hydrocarbons, amines, sulfides and phenols which are
abundant in cell membrane proteins, lipids and in DNA [15–18].
Electronically excited triplet state photosensitiser molecules can
undergo both types of photochemical pathways and the efficacy of
each mechanism is dependent upon the triplet state energy level,
the triplet photosensitiser oxidation-reduction potentials, in addition
to the surrounding substrate and oxygen concentrations and their
corresponding reaction rates with the excited triplet state dye [14].
Collectively, the two photoprocesses result in the generation of a
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wide range of cytotoxic ROS upon photo-excitation, including singlet
oxygen and superoxide radicals, which subsequently generate super-
oxide anions and hydroxyl radicals [12, 14]. It is these generated ROS
which initiate a non-site specific attack against bacteria in the vicinity,
damaging bacterial intracellular proteins, cellular membranes and
DNA, hence reducing the risk of the development of resistance to
this antimicrobial strategy [12].
In this chapter, the photochemical properties of these polymers are
examined, in order to gain insight into the mechanism of photo-
bactericidal activity demonstrated. Low temperature time-resolved
electron paramagnetic resonance (TR-EPR) spectroscopy was used
to compare and investigate the properties of the photoexcited
triplet states of a series of dye-incorporated polymers. Subsequently,
time-resolved near infrared singlet oxygen (TRNIR-1O2) phospho-
rescence experiments were carried out (emitted at 1270 nm), to
determine whether the photo-excited triplet states undergo a ‘Type
II’ photochemical pathway. These techniques were also used to
investigate the photochemical properties of a crystal violet and
nanogold-incorporated polymer, to gain an understanding into the
enhanced light-activated antimicrobial activity noted when 2 nm
gold nanoparticles are present (refer to Chapters 3 and 4).
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6.2 experimental
6.2.1 Chemicals and Substrates
The reagents used in materials synthesis were as follows: Methylene
blue hydrate (Riedel-de Hae¨n, U.K.), crystal violet (Sigma, U.K.),
acridine orange (hemi-acetate zinc salt, Fisher, U.K.), toluidine blue O
(Sigma, U.K.), malachite green (oxalate salt, Sigma, U.K.), 2 nm gold
nanoparticles (kindly provided by Mr William Peveler) and acetone
(VWR, U.K.). In all synthetic work carried out, the water used was
deionised (resistivity 15 MΩcm). For the TR-EPR experiments, the
substrate was commercially available 100 % silicone Foley catheters:
BRILLANT AquaFlate 2 way, 10 cc silicone catheter with an opposed
eye, (12 Fr, 4 mm diameter, Ru¨sch). For the extended TRNIR-1O2
phosphorescence experiments, the substrate was medical grade flat
silicone sheets (NuSil, Polymer Systems Technology Ltd., U.K.).
6.2.2 Materials Synthesis and Characterisation
6.2.2.1 Polymer Synthesis for Singlet Oxygen Measurements
Liquid MED-4950 (Polymer Systems Technology Ltd) was combined
with a crosslinking agent (Polymer Systems Technology Ltd) in a 1:1
ratio and an excess (4 - 5 g) was spread into a channel on a clean
glass surface. The system was centrifuged for 5 minutes (1100 rpm,
60 mbar vacuum) and any excess was removed. The polymer was
cured at 150 oC for 6 minutes after which it was allowed to cool and
subsequently, was cut into 1 cm x 3 cm strips.
6.2.2.2 Polymer Modification
Methylene blue, toluidine blue O and acridine orange were incorpo-
rated into the silicone catheter polymer using a ‘swell-encapsulation-
shrink technique’. The silicone catheters were immersed in a 9:1
acetone : water swelling solution made up to a concentration of
0.002 moldm-3 dye. The samples were allowed to swell in the dark
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under room temperature conditions for 24 h, after which they were
removed and air-dried in the dark (24 h). Residual dye was removed
by gently washing the samples in water and the towel-dried samples
were stored under dark conditions.
Crystal violet and malachite green were incorporated into the silicone
catheter polymer using a simple dipping process [3]. The silicone
samples were immersed in dye solutions (0.002 moldm-3) made up
in water for 24 h, after which they were removed and air-dried under
dark conditions (24 h). Residual dye was washed off using water and
the samples were towel-dried and stored under dark conditions.
6.2.2.3 Polymer Modification For Extended Photochemical Investigations
For crystal violet and nanoparticle incorporation into silicone catheter
samples or medical grade flat sheets, samples were immersed in a
9:1 acetone : nanogold swelling solution for 72 hours. The samples
were subsequently air-dried, washed and towel-dried, after which
they were immersed in a crystal violet solution (0.001 moldm-3) for
72 h. Residual dye was washed off using water and the samples were
towel-dried and stored under dark conditions.
6.2.2.4 Materials Characterisation
A PerkinElmer Lambda 25 UV-Vis Spectrometer was used to measure
the UV-Vis absorption spectra of the modified silicone polymers,
within the range 400 - 750 nm.
6.2.3 Photochemical Activity Investigations
6.2.3.1 Time-resolved Electron Paramagnetic Resonance Spectroscopy
A Bruker E580 pulsed EPR spectrometer operating at X-band fre-
quencies (9 - 10 GHz / 0.3 T) was used to record the time-resolved
EPR spectra of acridine orange-, crystal violet-, malachite green-,
methylene blue- and toluidine blue O- incorporated silicone catheter
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samples, under aerobic conditions and in the air-equilibrated
solid phase. TR-EPR spectra of crystal violet-coated and crystal
violet-coated, 2 nm gold nanoparticle-encapsulated silicone catheter
samples were also recorded under the same conditions. A Surelite
broadband OPO system within the operating range 410 - 2550 nm,
pumped by a Surelite I-20 Q-switched Nd:YAG laser with 2nd and
3rd harmonic generators (20 Hz, pulse length: 5 ns) was used to
achieve a pulsed laser excitation at a wavelength within the range of
the dye absorption, with the energy at the sample approximately 10
mJ per pulse. An Oxford Instruments CF935O flow cryostat was used
to cool the sample using liquid helium and an Oxford Instruments
ITC 503 temperature controller was employed to control the tempera-
ture (50 K). EPR spectra were simulated using the EasySpin toolbox
[19] in MATLABTM.
Figure 39: Experimental setup of the luminescence spectroscopy used for the
time-resolved detection of near infrared singlet oxygen phosphorescence
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6.2.3.2 Singlet Oxygen Measurements
The singlet oxygen studies were carried out in the air-equilibrated
solid phase and as shown in Figure 39. A thermoelectrically cooled
photomultiplier (H10330-45, Hamamatsu Photonic Ltd.) was used for
the detection of singlet oxygen at 1270 nm (1O2 quantum efficiency:
3 %, rise time: 0.5 ns). A range of lenses from the cuvette, in addition
to a long-pass and a band-pass filter centred at 1270 nm (Infrared
Engineering Ltd.) on the cuvette holder, were used to detect the
1O2 phosphorescence signal. A Nd:YAG laser (Lumanova, GmbH),
operating at 532 nm (repetition rate: 3kHz, pulse length: 2ns) was
used to irradiate the acridine orange-, crystal violet-, crystal violet
and nanogold-, malachite green-, methylene blue- and toluidine blue
O- incorporated silicone samples that were placed in a 1 cm square
quartz cuvette. A PC-mounted multiscaler board (model MSA-300,
Becker-Hickl, Germany) with a pre-amplifier (Becker-Hickl) was
used as the photon counting system and provided a resolution of 5
nm/ channel. The time-resolved 1O2 phosphorescence measurements
were executed by the multiscalar board (100,000 laser pulses over a
30 s integration time). After the 1O2 phosphorescence of the samples
was measured, the data was analysed using the curve fitting tool in
MATLABTM.
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6.3 results and discussion
6.3.1 Material Synthesis and Characterisation
Commercially available catheters were used for the TR-EPR exper-
iments whereas a laboratory prepared, or commercially available
medical grade silicone flat sheets were used for the singlet oxygen
measurements. This discrepancy is consequent to the requirements
of the different experimental apparatus.
Simple dipping processes were used to incorporate a range of
photosensitiser dyes into the silicone substrates. The phenothiazine
dyes: methylene blue (MB), toluidine blue O (TBO) and acridine
orange (AO) were incorporated into the polymers using a “swell-
encapsulation-shrink” technique, in which the polymers were
immersed into 90 % acetone dipping solutions. Exposure to the or-
ganic solvent causes the polymer to swell, enabling the dye molecules
to diffuse through the polymeric matrix. Upon removal from the
swelling solution, the residual solvent evaporates and the polymer
shrinks back to its previous dimensions, leaving dye molecules
trapped within its matrix [1, 2, 6–8]. Conversely, the triarylmethane
dyes crystal violet (CV) and malachite green (MG) were incorporated
into the polymers using aqueous-based dye solutions due to the high
affinity of the dyes for the polymer, such that polymer swelling was
unnecessary. These dipping processes facilitated a good polymer
uptake of the various dyes (Figure 40). The “swell-encapsulation-
shrink” technique resulted in the uniform encapsulation of dye
throughout the bulk, whereas the aqueous-based dipping strategy
results in polymers with a strong surface dye uptake and minimal
dye diffusion through the polymer bulk [3, 4].
A set of samples were also prepared for extended photochemical
characterisation experiments, to determine the effects of nanoparticle
incorporation on the embedded dye triplet state production and
subsequent singlet oxygen yields. A two-step dipping method
was used to incorporate crystal violet or, crystal violet and gold
nanoparticles into medical grade silicone catheters and flat polymer
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Figure 40: UV-Vis absorbance spectra of silicone incorporated with: (a) tolu-
idine blue O (TBO), (b) acridine orange (AO), (c) methylene blue (MB), (d)
crystal violet (CV) and (e) malachite (MG), measured within the range 400 -
750 nm
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sheets. Crystal violet-coated samples were pre-treated with a solvent
dipping step (9:1 acetone : water solution) to ensure that all samples
were exposed to the same dipping treatment, to standardise the
incorporation of dye in the subsequent step. Crystal violet and
nanoparticle-incorporated samples were prepared by immersion of
the polymer into a 9:1 acetone : nanogold swelling solution. The
nanoparticle-encapsulated samples were subsequently dipped in a
crystal violet solution for dye incorporation. The resultant crystal
violet coated-silicone samples were encapsulated with 2 nm gold
nanoparticles (CVAu sample).
The UV-Vis absorbance spectra of the dye incorporated silicone
polymers, prepared by immersion in dye solutions for 24 h, were
measured within the range 400 - 750 nm. All the dye-incorporated
silicones demonstrated strong absorption in the visible region of the
spectrum (Figure 40), with absorption signals characteristic of the dye
molecules. With the exception of the acridine orange-embedded poly-
mer, the dye-encapsulated samples demonstrate strong absorbance
bands at longer wavelengths, typically near or in the ‘red region’ of
the spectrum. Toluidine blue O-encapsulated silicone demonstrates
a maximum absorbance at 620 nm with shoulder peaks at λ ≈ 578
nm and λ ≈ 510 nm. The UV-Vis absorbance signal of acridine
orange-encapsulated silicone exhibits a peak maximum at 502 nm,
with a lower wavelength, small shoulder peak at λ ≈ 475 nm; whereas
the signal for methylene blue-encapsulated silicone shows a sharp
absorbance maximum at λ ≈ 653 nm, with a shoulder peak at ∼610
nm. The spectrum also suggests second and third shoulder peaks at
∼548 nm and ∼509 nm respectively.
The final two spectra are those of the triarylmethane dyes, crystal
violet and malachite green. The crystal violet-encapsulated sample
demonstrates a strong absorbance at λ ≈ 600 nm, with a sharp
shoulder peak at 547 nm. The absorbance spectrum for the malachite
green-encapsulated sample shows an intense peak at 625 nm, with a
shoulder at 582 nm and overall, this sample absorbs more strongly
than the other samples examined. It should be noted that the UV-Vis
absorbance spectra of the photosensitiser dyes in solution were
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comparable in form to their polymer-embedded analogues, however,
across all dyes studies, there was a shift in peak position, which
can be attributed to interactions between the dye molecule and its
immediate environment.
6.3.2 Photosensitiser Dye-Encapsulated Silicone
6.3.2.1 Time-Resolved Electron Paramagnetic Resonance Spectroscopy of
Photosensitiser Dye Encapsulated-Polymers
Suitable dyes for consideration in the development of photobacterici-
dal polymers should exhibit: i) strong absorption in the visible region
of the electromagnetic spectrum, ii) a high intersystem crossing yield
for efficient production of the corresponding triplet state and iii)
a long triplet lifetime to allow for the reaction with surrounding
molecules such as molecular oxygen. Here, low temperature TR-
EPR spectroscopy was used to detect paramagnetic species upon
photoexcitation of medical grade silicone embedded with either
phenothiazine (methylene blue, acridine orange, toluidine blue O) or
triarylmethane (crystal violet, malachite green) photosensitiser dyes,
under aerobic conditions (see Figure 40 for structures).
TR-EPR allows the determination of the zero-field splitting (ZFS)
parameters of the dye triplet state and the values of non-equilibrium
populations of the triplet sublevels. The ZFS parameters - D and
E - describe the magnetic dipolar interaction between the two
unpaired electrons (Figure 41). These parameters are directly related
to the singly occupied molecular orbitals and in turn, correlate
to the electron density on the excited state and they depend on
the conformation and the protonation state of the dye. The ZFS
parameter D is a measure of the dipolar spin-spin interaction and
it is proportional to the inverse third power of the average distance
between the unpaired triplet electrons. Therefore it provides an
estimate of the extent of the electron delocalisation in the excited
state molecule. The ZFS parameter E depends on the deviation of
the spin-spin interaction from axial symmetry and it is related to
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Figure 41: Adapted from Chapter 2, a Jablonski diagram representing pro-
cesses upon photoexcitation of a photosensitiser dye. The ground state pho-
tosensitiser molecule (S0) absorbs a photon of energy and is promoted to an
excited singlet state (S1). The excited singlet state molecule can undergo var-
ious photoprocesses, including the radiative release of energy (fluorescence)
or intersystem crossing (ISC) to the excited triplet state (T1), which is split
into three triplet sublevels, Tx, Ty, Tz. The triplet state molecule can release
energy as radiation (phosphorescence) or undergo further photoprocesses.
Shown also are D and E, the zero field splitting parameters, which describe
the magnetic dipolar interaction between the two unpaired electrons
molecular shape and symmetry. Non-equilibrium populations of the
spin sublevels characterise the photophysical path leading to the
triplet state formation which, in the present case, is the intersystem
crossing from the excited singlet state.
The spectra obtained (Figure 42) show that the TR-EPR signals of
dyes with analogous molecular structures are comparable in form
and typical of spin-polarised (i.e. non-Boltzmann populated) triplet
states of aromatic molecules, but they differ in detail and intensity.
The spectrum of each of the five samples was simulated using
EasySpin software in MATLABTM to obtain the relative populations
of the three triplet sublevels px : py : pz and |D| and |E|. Note that
the modulus is given since the sign of the ZFS parameters cannot
be directly derived from the TR-EPR spectra. An isotropic g value
equal to the free electron g value (gx : gy : gz = 2.0023) was used in the
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Figure 42: Low temperature TR-EPR spectra of silicone catheters encapsu-
lated with: TBO (blue), AO (red), MB (cyan), CV (fuschia) and MG (green),
under aerobic conditions. The simulated spectra are superimposed onto the
experimental data (black line). A and E stand for absorption and emission,
respectively
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simulations.
The triplet states of the phenothiazine dyes and the triarylmethane
dyes have similar ZFS parameters (see Table 6). Interestingly, this sug-
gests that in the latter dye group, the spin density is mostly localised
over adjacent rings rather than spread over the entire molecule. More-
over, the similarity between the ZFS parameters within members
of the same dye group implies that chemical variability has little
influence on the distribution of the unpaired triplet electrons within
the delocalised system. However, the relative sublevel populations
give inverse polarisation patterns for the phenothiazine dyes com-
pared to the triarylmethane dyes (see Table 6). This inversion can
be rationalised in two alternative ways: either the change in the
molecular geometry - planar as opposed to propeller-like - influences
the sign of the ZFS parameters (they have been assumed to be
both positive in the simulations), or it changes the population rates
without affecting the sign of ZFS parameters.
Inspection of Figure 42 shows that the quality (signal-to-noise ratio,
S/N) of the spectra largely varies within both dye groups, despite
similarities in triplet sublevel populations (Table 6). This variability
can be accounted for as follows: i) some dyes have lowered triplet
yield (i.e. intersystem crossing efficiency) or ii) the intersystem
crossing process for these dyes is more isotropic, leading to a less
polarised spin system. Within the phenothiazine dye group, acridine
orange displays the worst S/N and it should be noted that compared
to the other two phenothiazine dyes examined, acridine orange is the
only dye lacking a sulphur atom in its structure. From quantum me-
chanical considerations, it is known that ‘heavy atoms’ significantly
enhance the intersystem crossing efficiency. The above mentioned
considerations hold for malachite green, which within the triaryl-
methane dye group, displays the worst S/N. In effect, malachite
green lacks a nitrogen atom in its structure compared to crystal violet.
Since the signal intensity in TR-EPR spectra depends on differences
in triplet sublevel populations and only relative populations can
be extracted from spectra simulation, spectra with a similar shape
may share relative sublevel population differences, whilst the net
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polarisation (absolute populations) can be different. Therefore, it
is difficult to assess whether a more isotropic intersystem crossing
process is responsible for the observed S/N in acridine orange and
malachite green.
6.3.2.2 Singlet Oxygen Measurements
Illumination of the dye incorporated polymers effects interesting
photochemical consequences. As confirmed using low temperature
TR-EPR spectroscopy, laser excitation results in the promotion of
the polymer-embedded dye molecule to an excited triplet state. One
photochemical pathway that the triplet state dye molecule undergoes
is a ‘Type II’ photoprocess, whereby molecular oxygen in the vicinity
collides with the immobilised triplet state molecule. Energy transfer
occurs between the triplet excited state of the encapsulated dye and
an O2 molecule, relaxing the dye molecule to its ground state and
concurrently generating singlet oxygen species (1O2). The reaction is
feasible since O2 has a triplet ground state, with low-lying excited
states and thus, low energy (22 kcal mol-1) is needed to produce the
highly oxidative species, singlet oxygen [13]. A minor proportion of
these 1O2 molecules decay by emission of a photon at 1270 nm and
this 1O2 phosphorescence can be used to gain information about the
kinetics of 1O2 production and decay [15].
To establish whether the dye-embedded silicone samples examined in
this study undergo a ‘Type II’ photoprocess, the samples were excited
at 532 nm and the production of 1O2 was measured through the time-
resolved detection of near infrared 1O2 phosphorescence, emitted at
1270 nm. Equation 2 can be used to describe the key factors that de-
termine the concentration of singlet oxygen concentration, [O2(a1∆g)]
[15]:
[O2(a1∆g)]t = [3sens∗]0
k
O2
∆ [
3O2]
kTd + k
O2
q [3O2]
τ∆
τT − τ∆
(e−t/τT −e−t/τ∆) (2)
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Figure 43: The time-resolved near infrared phosphorescence of the singlet
oxygen, emitted at 1270 nm, of photosensitiser dyes embedded in a silicone
polymer. TBO (black line), MB (blue line), CV (purple line), AO (orange line)
and MG (green line)
Where kO2∆ is the rate constant of energy transfer between the
excited triplet state of the photosensitiser and molecular oxygen,
kTd is the rate constant of the photosensitiser’s triplet state decay
by oxygen-independent processes, kO2q is the rate constant for the
photosensitiser’s triplet state decay by quenching with molecular
oxygen, τT is the photosensitiser triplet state lifetime and τ∆ is the O2
(a1∆g) lifetime [15].
As dictated by Equation 2 and shown in Figure 43, [O2 (a1∆g)] is zero
at time t = 0, after which the signal grows to a maximum, correlating
to a steep rise in 1O2 production upon laser excitation of the silicone
encapsulated dye, preceding a more gentle decay. 1O2 is a transient
species; it rapidly reacts with other molecules and this results in a
decrease in the 1O2 signal as a function of time. Analysis of the data
demonstrates that the 1O2 signal detected can be broken down into
two main components with lifetimes τ1 and τ2. Using equation 2, it
can be suggested that τ1 corresponds to collisional quenching of 1O2
with other species such as the polymer matrix (τ∆), whereas the latter
component with a shorter lifetime, τ2, correlates to the 1O2 rise time,
which is proportional to the decay of the dye triplet state and mainly
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determined by quenching by molecular oxygen (τT). The calculated
lifetimes, τ1 and τ2 are similar across the samples investigated, al-
though both τ1 and τ2 are comparatively shorter for the crystal violet
sample (Table 6). It should also be noted that in contrast to crystal
violet samples, Table 6 shows comparable τ2 for the samples where
the dye is embedded, suggesting the 1O2 quenching mechanism may
be similar i.e. quenching within the polymeric matrix.
The TRNIR-1O2 measurements also provide information on the rel-
ative 1O2 production of the dye-incorporated polymers under air-
equilibrated solid phase conditions. Using the integrated signal for
the time-resolved detection of near infrared 1O2 phosphorescence, in
addition to the UV-Vis absorbance data, the relative singlet oxygen
quantum yields were calculated using equation 3:
I = κ x P x Φ∆ x (1− 10-A) (3)
Where I is the time-integrated 1O2 phosphorescence peak intensity,
κ and P are constants that have been equated to ‘1’, Φ∆ is the 1O2
quantum yield and A is the UV-Vis absorbance peak intensity. The
calculated Φ∆ indicated that the photosensitiser dye toluidine blue O,
generates the greatest number of 1O2 molecules per photon absorbed
by the photosensitiser molecule. The calculated Φ∆ were normalised
against this value and it was found that:
Φ∆TBO > Φ∆AO > Φ∆MB > Φ∆CV > Φ∆MG
The TRNIR-1O2 phosphorescence experiments enable us to gain
key information about the photoprocesses upon laser excitation,
in addition to consolidating findings obtained through TR-EPR
measurements. Overall, these findings are in strong agreement with
observations attained through low temperature TR-EPR measure-
ments. In particular, the TRNIR-1O2 phosphorescence measurements
indicate that the photo-excited malachite green sample 1O2 yields
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are negligible. This finding is analogous to that determined from
the TR-EPR measurements, which show poor malachite green triplet
state S/N. Note that the UV-Vis absorbance signal of the malachite
green sample was at least 3x greater than that observed for the
other dyes investigated. TRNIR-1O2 phosphorescence measurements
of a range of samples of varying malachite green concentration,
indicated that the poor 1O2 yield noted was not a concentration effect,
potentially attributable to dimerisation of the embedded dye, since
all malachite green-embedded samples examined - synthesised by
varying the polymer exposure time to the malachite green dipping
solution - exhibited negligible 1O2 yields.
One discrepancy however, is the unusually high calculated acridine
orange 1O2 quantum yield, which is in contrast to the poor TR-EPR
signal obtained for the same sample. It can be hypothesised that the
high 1O2 yield is related to better energy coupling with molecular
oxygen orbitals, resulting in efficient 1O2 production upon photo-
excitation, despite poor triplet state yields. It should be noted that as
shown in Figure 40, the acridine orange first excited singlet state has
the highest energy among the considered molecules. Alternatively, it
can be suggested that the poor TR-EPR acridine orange triplet signal
can be attributed to small population differences between the triplet
sub-levels, rather than reflect on the triplet state generation upon
photo-excitation.
TRNIR-1O2 phosphorescence measurements for the phenothiazine
and triarylmethane photosensitiser dyes in solution, showed a differ-
ing trend in 1O2 quantum yields compared to polymer-embedded
dyes:
Φ∆TBO > Φ∆MB > Φ∆AO > Φ∆MG ≈ Φ∆CV
Here, acridine orange shows a poor 1O2 quantum yield relative to
that found in the polymer investigation. It can be hypothesised that
when free in solution, triplet state deactivation pathways such as
vibrational relaxation, or collisional quenching by other substrate
molecules may become favourable, resulting in a more limited
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1O2 generation. Alternatively, although not explored within the
constraints of this investigation, it should also be noted that the dye
triplet state generation in solution phase may not be comparable to
that in solid phase. In solution, interactions between dye molecules
may occur, for example, pi-stacking effects and dimerisation, that may
hinder triplet state production and subsequently lead to reduced 1O2
quantum yields. Moreover, upon photo-excitation, rotor molecules
such as crystal violet can form twisted intramolecular charge transfer
(TICT) states, rather than undergo intersystem crossing into the
triplet state [20], resulting in negligible observed 1O2 yields (Φ∆(CV)
normalised = 0). However, as noted earlier, polymer-encapsulation
of crystal violet results in comparatively enhanced 1O2 yields and
this can be attributed to the viscosity dependent behaviour of the
formation of TICT states [20].
Overall, the TR-EPR studies and TRNIR-1O2 phosphorescence
measurements indicate that photosensitiser dyes such as toluidine
blue O or methylene blue are ideal candidates for light-activated
antimicrobial agents, as they yield efficient triplet-state production
and 1O2 generation. However, one drawback associated with the
use of these dyes is as follows. As noted in Chapter 3, the diffusion
distance of 1O2 is very short (< 1 micron). Since the phenothiazine
dye-polymer incorporation strategy results in the uniform dispersion
of dye through the polymer bulk, rather than a controlled surface
dye uptake - unlike in the case of crystal violet - the relative surface
dye concentration is low. Subsequently, it can be suggested that the
photo-generation of ROS at the polymer surface is limited compared
to crystal violet-encapsulated samples, where the ROS is generated
predominantly at the sample surface. This may provide insight as
to why despite poor 1O2 quantum yields upon photo-excitation,
crystal violet samples result in enhanced bacterial kills compared to
methylene blue samples in microbiological testing.
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6.3.3 Photosensitiser Dye and Gold Nanoparticle-Encapsulated Silicone
6.3.3.1 Time-Resolved Electron Paramagnetic Resonance Spectroscopy of
Photosensitiser Dye and Nanoparticle Encapsulated-Polymers
Potent photobactericidal surfaces have been developed by incor-
porating photosensitiser dyes into medical grade polymers [6,
8]. Microbiological testing observations indicate that this light-
activated antimicrobial activity can be further enhanced by the
additional incorporation of 2 nm gold nanoparticles. The resultant
dye-nanoparticle-incorporated surfaces achieve the lethal photosen-
sitisation of bacteria under both laser and white light illumination
conditions, reducing bacterial numbers to below the detection limit
[1–4]. Using TR-EPR as a tool to investigate the mechanism of pho-
tochemical activity, it was established that the incorporation of 2 nm
gold nanoparticles into methylene blue-encapsulated PVC catheters,
resulted in a 38 % increase in the dye triplet state production [7].
Here, TR-EPR spectroscopy was used to detect photo-generated
paramagnetic species present in CV- and CVAu-encapsulated silicone
catheters following laser excitation (∼590 nm) and determine whether
a similar enhancement in triplet state production is observed for
this dye. Both samples were prepared using a standardised proto-
col, to ensure there were no differences in crystal violet concentration.
TR-EPR spectra recorded under aerobic conditions of CV- and CVAu-
encapsulated silicone catheters at 50 K, showed signals typical of
spin-polarised triplet states of aromatic molecules, comparable in de-
tail (Figure 44(a)), but differing in intensity (Figure 44(b)). The spectra
of both samples were simulated using an isotropic g value equal to
the free electron g value (gx : gy : gz = 2.00232), ZFS parameters |D| =
1650 MHz and |E| = 350 MHz and relative populations px : py : pz = 0
: 0.46 : 0.54, indicating that the triplet states are localised on the same
species, crystal violet. Note that despite differences in crystal violet
concentrations in the two TR-EPR studies, the parameters used to
simulate the CV- and CVAu-encapsulated catheters were as reported
in Table 6 (Section 6.3.2.1).
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Figure 44: Low temperature TR-EPR spectra of CV (blue) and CVAu (red)
encapsulated silicone catheters showing: (a) peaks aligned with simulated
spectra superimposed onto the experimental data (black line) and (b) scales
aligned for a direct comparison of signal intensity. A and E stand for absorp-
tion and emission, respectively
Despite no change in the ZFS parameters or relative populations of
the triplet state sublevels - suggesting that electronic structure of the
triplet state was unchanged - the presence of 2 nm gold nanoparticles
resulted in a significant increase in intensity of the crystal violet
triplet state signal (40 %). This triplet state enhancement, attributed
to the presence of 2 nm gold nanoparticles, is comparable to that
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reported previously for methylene blue and nanogold-encapsulated
PVC catheters [7] and indicates that this effect is not observed for
phenothiazine dyes only.
6.3.3.2 Singlet Oxygen Measurements - Crystal Violet and Crystal Violet
and Gold Nanoparticle-Incorporated Silicone
To determine whether the increased dye triplet state production,
correlates to enhanced 1O2 yields, TRNIR-1O2 phosphorescence
measurements of CV- and CVAu-encapsulated silicone were recorded
under air-equilibrated solid phase conditions (Figure 45). Results
indicated that the presence of 2 nm gold nanoparticles increased the
1O2 quantum yield of crystal violet samples (Φ∆(CV) = 0.83, when
normalised against Φ∆(CVAu)), although both τ1 (42.79 and 43.65)
and τ2 (1.41 and 1.99) are similar for the CV- and CVAu- silicone
samples.
The TR-EPR studies and TRNIR-1O2 phosphorescence measurements
corroborate findings from microbiological testing that indicate that
the 2 nm gold nanoparticles effects a synergistic enhancement on the
Figure 45: The time-resolved near infrared phosphorescence of the singlet
oxygen, emitted at 1270 nm of CV (dark purple line) and CVAu (violet line)
encapsulated silicone polymer
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photochemical activity of the photosensitiser dye, crystal violet. These
studies demonstrate that the observed increased triplet state pro-
duction correlates to a greater concentration of the photo-generated
ROS 1O2, ultimately achieving the observed enhanced bacterial kills,
compared to dye only-encapsulated polymers [3, 4].
It should also be noted that the increased photochemical activity
of the dye, associated with interactions between the dye and gold
nanoparticles, has further implications. It can be rationalised that
increased dye triplet state production in the presence of gold
nanoparticles means that lower concentrations of dye can be used to
achieve the significant lethal photosensitisation of bacteria, compared
to dye-only embedded silicones. This may be beneficial in medical
device applications where concerns may arise regarding toxicity of
high concentrations of dye present on the device surface in contact
with patient epithelial cells.
6.4 conclusion
TR-EPR and TRNIR-1O2 phosphorescence studies provided insight
into the underpinning photochemical mechanism of dye- and dye-
nanogold encapsulated silicone polymers. The latter demonstrated
that with the exception of malachite green, which overall exhibits
poor photochemical activity, the triplet states of a range of phe-
nothiazine and triarylmethane dyes are deactivated by a Type II
photochemical pathway, resulting in the generation of the highly
reactive species, 1O2.
The photochemical characterisation also shed light onto the underly-
ing photophysical mechanism effecting an enhancement in bacterial
kills upon light-activation, as observed in the microbiological testing.
The spectroscopic techniques demonstrated that crystal violet-gold
nanoparticle interactions result in signficant enhancements in
dye triplet state production and subsequently, greater 1O2 yields.
The findings confirm that the additional incorporation of 2 nm
gold nanoparticles aids and increases the efficacy of the lethal photo-
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sensitisation of bacteria induced by the dye embedded in the polymer.
Using this knowledge, more effective photobactericidal polymers
can be developed with light-activated antimicrobial functionality.
The modification process can be manipulated to incorporate antimi-
crobial agents that achieve bacterial kills via multiple mechanisms,
potentially targeting both Type I and Type II triplet state deactivation
pathways, such that greater kills can be achieved by the photo-
generation of a wide range of ROS. These design tactics will result in
the development of polymers with enhanced rates of bactericidal ac-
tivity. Optimisation by the current empirical approach is not effective
as a long-term strategy and a mechanistic understanding is critical to
underpin future advances in the development of bactericidal surfaces
for use in healthcare technologies. Moreover, the strategic design
of nanoparticles such that the modified surfaces exhibit additional
antimicrobial functionality under dark conditions is also key, in the
development of more potent antimicrobial surfaces for healthcare
environments and this will be explored further in the next chapter.
238
R E F E R E N C E S
[1] S. Perni, C. Piccirillo, J. Pratten, P. Prokopovich, W.
Chrzanowski, I. P. Parkin, and M. Wilson. “The antimicrobial
properties of light-activated polymers containing methylene
blue and gold nanoparticles.” In: Biomaterials 30 (2009), pp. 89–
93.
[2] S. Perni, C. Piccirillo, A. Kafizas, M. Uppal, J. Pratten, M. Wil-
son, and I. P. Parkin. “Antibacterial Activity of Light-Activated
Silicone Containing Methylene Blue and Gold Nanoparticles of
Different Sizes.” In: Journal of Cluster Science 21 (2010), pp. 427–
438.
[3] S. Noimark, M. Bovis, A. J. MacRobert, A. Correia, E. Allan, M.
Wilson, and I. P. Parkin. “Photobactericidal polymers; the in-
corporation of crystal violet and nanogold into medical grade
silicone.” In: RSC Advances 3 (2013), pp. 18383–18394.
[4] S. Noimark, E. Allan, and I. P. Parkin. “Light-activated an-
timicrobial surfaces with enhanced efficacy induced by a dark-
activated mechanism.” In: Chemical Science 5 (2014), pp. 2216–
2223.
[5] S. Perni, P. Prokopovich, I. P. Parkin, M. Wilson, and J. Prat-
ten. “Prevention of biofilm accumulation on a light-activated
antimicrobial catheter material.” In: Journal of Materials Chem-
istry 20 (2010), pp. 8668–8673.
[6] S. Perni, P. Prokopovich, C. Piccirillo, J. Pratten, I. P. Parkin,
and M. Wilson. “Toluidine blue-containing polymers exhibit
potent bactericidal activity when irradiated with red laser
light.” In: Journal of Materials Chemistry 19 (2009), pp. 2715–
2723.
[7] S. Noimark, C. W. Dunnill, C. W. M. Kay, S. Perni, P.
Prokopovich, S. Ismail, M. Wilson, and I. P. Parkin. “Incorpora-
tion of methylene blue and nanogold into polyvinyl chloride
catheters; a new approach for light-activated disinfection of
239
surfaces.” In: Journal of Materials Chemistry 22 (2012), pp. 15388–
15396.
[8] S. Perni, J. Pratten, M. Wilson, C. Piccirillo, I. P. Parkin, and
P. Prokopovich. “Antimicrobial Properties of Light-activated
Polyurethane Containing Indocyanine Green.” In: Journal of
Biomaterials Applications 25 (2011), pp. 387–400.
[9] A. J. T. Naik, S. Ismail, C. Kay, M. Wilson, and I. P. Parkin. “An-
timicrobial activity of polyurethane embedded with methylene
blue, toluidene blue and gold nanoparticles against Staphy-
lococcus aureus; illuminated with white light.” In: Materials
Chemistry and Physics 129 (2011), pp. 446–450.
[10] C. Piccirillo, S. Perni, J. Gil-Thomas, P. Prokopovich, M. Wilson,
J. Pratten, and I. P. Parkin. “Antimicrobial activity of methy-
lene blue and toluidine blue O covalently bound to a modified
silicone polymer surface.” In: Journal of Materials Chemistry 19
(2009), pp. 6167–6171.
[11] S. Ismail, S. Perni, J. Pratten, I. Parkin, and M. Wilson. “Effi-
cacy of a Novel Light-Activated Antimicrobial Coating for Dis-
infecting Hospital Surfaces.” In: Infection Control and Hospital
Epidemiology 32 (2011), pp. 1130–1132.
[12] S. Noimark, C. W. Dunnill, and I. P. Parkin. “Shining light on
materials - A self-sterilising revolution.” In: Advanced Drug De-
livery Reviews 65 (2013), pp. 570–580.
[13] I. J. MacDonald and T. J. Dougherty. “Basic principles of photo-
dynamic therapy.” In: Journal of Porphyrins and Phthalocyanines
5 (2001), pp. 105–129.
[14] C. S. Oliveira, R. Turchiello, A. J. Kowaltowski, G. L. Indig,
and M. S. Baptista. “Major determinants of photoinduced cell
death: Subcellular localization versus photosensitization effi-
ciency.” In: Free Radical Biology and Medicine 51 (2011), pp. 824–
833.
[15] A. Jimenez-Banzo, X. Ragas, P. Kapusta, and S. Nonell. “Time-
resolved methods in biophysics. 7. Photon counting vs. analog
time-resolved singlet oxygen phosphorescence detection.” In:
Photochemical & Photobiological Sciences 7 (2008), pp. 1003–1010.
240
[16] A. Michaeli and J. Feitelson. “Reactivity of singlet oxygen to-
ward amino-acids and peptides.” In: Photochemistry and Photo-
biology 59 (1994), pp. 284–289.
[17] J. L. Ravanat, P. Di Mascio, G. R. Martinez, M. H. G. Medeiros,
and J. Cadet. “Singlet oxygen induces oxidation of cellular
DNA.” In: Journal of Biological Chemistry 275 (2000), pp. 40601–
40604.
[18] X. S. Zhang, B. S. Rosenstein, Y. Wang, M. Lebwohl, and H.
C. Wei. “Identification of possible reactive oxygen species in-
volved in ultraviolet radiation-induced oxidative DNA dam-
age.” In: Free Radical Biology and Medicine 23 (1997), pp. 980–
985.
[19] S. Stoll and A. Schweiger. “EasySpin, a comprehensive soft-
ware package for spectral simulation and analysis in EPR.” In:
J. Magn. Reson. 178 (2006), pp. 42–55.
[20] M. A. Haidekker and E. A. Theodorakis. “Environment-
sensitive behavior of fluorescent molecular rotors.” In: Journal
of Biological Engineering 4 (2010).
241
7
U V- L I G H T- A C T I VAT E D A N T I M I C R O B I A L
P O LY M E R S : F U N C T I O N A L I S E D G O L D - T I TA N I A
A N D T I TA N I A N A N O PA RT I C L E - E N C A P S U L AT E D
S I L I C O N E
7.1 introduction
The development of light-activated antimicrobial polymers for use in
healthcare applications to decrease the incidence of HAIs, has been ex-
amined in this thesis. These photobactericidal polymers, synthesised
through the incorporation of photosensitiser dyes and nanoparticles
into medical grade silicone, have been developed for both medical
device applications (Chapter 3, laser light-activation) and hospital
touch surface applications (Chapters 4 and 5, white light-activation)
and the mechanism of light-activated antimicrobial activity has been
examined using spectroscopic techniques (Chapter 6). This chapter
focuses on the development of versatile antimicrobial surfaces that
achieve rapid kills under both dark and UVA illumination condi-
tions, for both medical device and hospital touch surface applications.
Photosensitiser dye-nanoparticle antimicrobial technology has
demonstrated great potential, for use in antimicrobial surfaces in
both medical devices [1–6] and hospital touch surface applications
[7–11]. Although these surfaces rapidly kill both Gram-positive
and Gram-negative bacteria under laser-activation conditions, upon
white light-activation, similar kills are achieved over far longer time
periods (Chapters 3 - 5). One drawback associated with the use of
these surfaces is that it is difficult to achieve rapid kills over large
areas; laser technology is not practical for use in the sterilisation
of large touch surfaces commonly found in hospital environments.
This chapter details the development of potent antimicrobial surfaces
incorporated with oleic acid-functionalised titania and gold-doped
titania nanoparticles, that achieve rapid bacterial kills in both UVA
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Figure 46: Schematic of the mechanism of the photocatalytic properties of
TiO2 adapted from [12]
illuminated and dark conditions. In cases where devices are fre-
quently used and rapid surface sterilisation is preferable, polymers
incorporated with UV-activated photocatalytic nanoparticles may
prove more suitable.
Titania, TiO2, is inexpensive, robust and is widely used in range
of applications including: as a white pigment, in cosmetics and
sunscreen and as a ‘builder’ in vitamin tablets [13]. It is also an
efficient photocatalyst under UV irradiation conditions [13, 14] and
this well established property has been exploited in the development
of self-cleaning windows and for drinking water sterilisation [12,
15–18]. Due to its wide band gap (3.2 eV for anatase TiO2), in order
to activate its photocatalytic properties, < 385 nm irradiation is
required. A schematic of the photocatalytic properties of TiO2 is
shown in Figure 46 and is detailed as follows: Upon absorption
of photons of energy greater than the band gap energy, a valence
band electron is promoted to the semiconductor conduction band
producing electron-hole pairs [13, 14]. These electron-hole pairs can
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interact with adsorbed water and molecular oxygen at the surface
of TiO2, forming highly reactive radical species such as HO·2, HO
−
2 ,
OH· and superoxide anions [14, 19]. The photo-generated radicals
subsequently participate in redox reactions for the degradation of
organic pollutants and the killing of bacteria and viruses [20–23].
Similar to other light-activated antimicrobial agents, for example
photosensitiser dyes, the species photogenerated on the TiO2 surface
have an active role in the destruction of bacterial cell outer mem-
branes, resulting in leakage of cell minerals, proteins and genetic
material, ultimately leading to cell death [22–26].
The modification of TiO2 with gold nanoparticles, Au/TiO2 systems,
has been widely studied for environmental applications, for example
water splitting [27] and the degradation of organic dye pollutants
[28–30]. It has been proposed previously for similar systems that the
presence of gold results in improved charge separation and combined
with plasmon induced properties, these Au/TiO2 systems are poten-
tially efficient as visible-active photocatalysts [31–33]. However, there
has been little research into the development of Au/TiO2 materials
for antimicrobial surface applications. In one laboratory investigation,
gold-capped TiO2 nanoparticle solutions synthesised using a sol-gel
route exhibited an enhanced antimicrobial activity compared to TiO2
nanoparticle solutions under room lighting conditions, achieving
the photo-destruction of Gram-negative bacteria at a slighly lower
nanoparticle concentration (E. coli) [34]. Conversely, conflicting
observations have been noted when Au/TiO2 systems have been
tested against Gram-positive bacteria, although these experiments
were carried out using different irradiation conditions [34, 35]. Fu
et al [34] reported similar inhibition rates in the growth of Bacillus
megaterium for both TiO2 nanoparticle and Au/TiO2 nanoparticle sys-
tems, whereas in the case of the latter, under UVA-irradiation it was
observed that the antimicrobial activity of the Au/TiO2 nanoparticle
system was reduced compared to that of the pure TiO2, in the killing
of Bacillus subtilis [35].
This chapter details the development of novel UV-activated photobac-
tericidal polymers, prepared by using a “swell-encapsulation-shrink”
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strategy to incorporate TiO2 and Au/TiO2 nanoparticles into com-
mercially available medical grade silicone. Raman, XRD, XPS and
TEM were used to characterise the TiO2 and Au/TiO2 nanoparticles
and the relative photocatalytic activity of these nanoparticles was
compared by investigating their efficacy in the photo-destruction of
stearic acid, upon exposure to UV-irradiation. Using a UVA source
(365 nm) to activate the photobactericidal properties of the materi-
als, the antimicrobial activity of TiO2 nanoparticle- and Au/TiO2
nanoparticle-encapsulated silicone polymers was tested against S.
aureus and E. coli, representative Gram-positive and Gram-negative
bacteria commonly found in hospital environments. Unprecedented
kills were achieved when these surfaces were tested against S. aureus,
with bacterial numbers reduced by at least 3 log within 15 minutes,
under dark conditions. Although only a limited ‘dark kill’ effect
was observed when these samples were tested against E. coli, UVA
illumination for 95 minutes reduced bacterial numbers to below
the detection limit. To our knowledge, this is the first report of
bacterial kill under dark conditions from a titanium dioxide modified
silicone polymer and this demonstrated antimicrobial activity can be
attributed to the surface functionalisation of the nanoparticles used.
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7.2 experimental
7.2.1 Chemicals and Substrates
The reagents used in materials synthesis were as follows: Toluene
(Fisher Scientific, U.K.), titanium (IV) oxysulfate (Sigma-Aldrich,
U.K.), free hydrated sulphuric acid (Aldrich, U.K.), potassium hy-
droxide (Fisher Scientific, U.K.), chloroauric acid (Alfa Aesar, U.K.),
oleic acid (Aldrich, U.K.) and triethylamine (Sigma-Aldrich, U.K.).
Unless otherwise specified, in all synthetic work carried out, the
water used was deionised (resistivity 15 MΩcm) and the substrate
was medical grade flat silicone sheets (NuSil, Polymer Systems
Technology Ltd., U.K.).
7.2.2 Materials Synthesis
7.2.2.1 Synthesis of TiO2 nanoparticles
TiO2 nanoparticles were kindly provided by Professor Jawwad Darr
and produced using a continuous hydrothermal flow synthesis
(CHFS) route. The pilot scale CHFS system used is as detailed in
the literature [36, 37]. The precursors were carried into a confined
jet reactor under controlled-flow conditions, by four industrial
diaphragm type chemical dosing pumps (Milton Roy, Primeroyal
K). In the reactor, the precursors were mixed concurrently with
supercritical water, at temperature and pressure conditions of 400
oC and 24.1 MPa respectively. Type K thermocouples were used to
monitor the temperature of the system at different points. The actual
temperature at the reactor point, in the mixing of supercritical water
and the precursor solutions, was 307 oC. A custom built electrical
heater arrangement (Watlow Cast X 2000, maximum thermal output
24 kW) was used to reach supercritical conditions for the water and
a back-pressure regulator in the system (BPR, Swagelok KHB series),
was adjusted using a PID algorithm, to maintain pressure conditions.
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In the TiO2 nanoparticle synthesis each of the precursors, titanium(IV)
oxysulfate (TiOSO4, 0.2 M) with free hydrated sulphuric acid and
potassium hydroxide (KOH, 0.4 M) were pumped separately at 150
mL min−1 into a T-piece, before meeting the flow of supercritical
water. The flow-rate of supercritical water was adjusted to 300 mL
min−1. The formed TiO2 nanoparticles were rapidly quenched and
cooled using an external cooling system (outer jacket through which
water flowed at 100 L min−1 and an inlet temperature of 15 oC). The
nanoparticles were collected as a slurry, centrifuged and washed
three times with deionised water (10 MΩ) until the pH was neutral.
The nanoparticles were subsequently dried in a freeze-drier (Virtis
Genesis 35XL) by slowly heating under vacuum (100 mTorr) from -60
to 25 oC over a period 24 h.
7.2.2.2 Deposition of gold nanoparticles on TiO2
Gold nanoparticles were deposited onto the titania following a
procedure adapted from the literature, by Mr Joseph C. Bear [38].
Chloroauric acid (HAuCl4, 30 mg), 1 % sodium citrate solution (30
mL) and de-ionised water (120 mL) were refluxed for 4 h at 110
oC. 50 ml of the purple gold colloid was subsequently stirred with
1 g of TiO2 nanoparticles and sodium chloride (5.8 g, NaCl) was
added suddenly, resulting in the precipitation of Au metal onto the
TiO2 particles. The purple precipitate (Au/TiO2) was then filtered,
repeatedly washed with de-ionised water (10 MΩ), centrifuged and
lyophilized.
7.2.2.3 Functionalisation of TiO2 and Au/TiO2 nanoparticles
TiO2 and Au/TiO2 nanoparticles were functionalised following a pro-
cedure adapted from the literature, by Mr Joseph C. Bear [39]. TiO2
or Au/TiO2 nanoparticles (1 g) were heated to 80 oC in excess oleic
acid (120 mmol, 38.1 mL) over a period of 24 hours, with a catalytic
amount of triethylamine (8 mmol, 1.12 ml) added to encourage ester
formation between the titanol groups on the nanoparticle surface and
the oleic acid. The nanoparticles were subsequently precipitated with
ethanol and centrifuged at 2500 xg, before dispersion in toluene. Note
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Figure 47: Schematic to show preparation of TiO2 and Au/TiO2 encapsu-
lated silicone samples
that the nanoparticles were precipitated and re-dispersed in toluene
three times, to remove excess surfactant.
7.2.2.4 Preparation of Antimicrobial Polymers
A series of silicone samples were prepared for microbiological testing.
Swelling solutions were prepared in which oleic acid functionalised-
TiO2 or Au/TiO2 nanoparticles were dispersed in toluene. The
toluene-based swelling solutions were made up to a concentration of
20 mg/ mL nanoparticles. Medical grade silicone polymer coupons
(1.21 cm2) were immersed in toluene, oleic acid functionalised
TiO2 nanoparticles dispersed in toluene or Au/TiO2 nanoparticles
dispersed in toluene and allowed to swell for 48 h. The samples were
subsequently removed from the toluene swelling solutions, air-dried
(48 h), washed and towel-dried. Where possible, the samples were
maintained under dark conditions. An overview of the materials
synthesis is presented in Figure 47.
7.2.3 Materials Characterisation
A PerkinElmer Lambda 25 UV-Vis spectrometer was used to measure
the UV-Vis absorption spectra of the toluene-based nanoparticle
swelling solutions and the modified silicone polymers used for
microbiology, within the range 250 - 1100 nm (full range not shown).
Samples for TEM were prepared by drop-casting a suspension of
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nanoparticles in hexane solvent onto a 400 Cu mesh holey carbon
film TEM grid (Agar Scientific Ltd). Samples were imaged using a
JEOL 2100 HR-TEM with a LaB6 source, operating at an acceleration
voltage of 200 kV with an Oxford Instruments XMax EDX detector,
running AZTEC software. TEM images were recorded on a Gatan
Orius CCD.
XRD was performed using a Bruker-Axs D8 (GADDS) diffractometer.
The instrument operates with a Cu X-ray source, monochromated
(Kα1 and Kα2) and a 2D area X-ray detector with a resolution of
0.01o. TiO2- and Au/TiO2-nanoparticulate films were analysed with
a glancing incident angle (θ) of 5 o. The diffraction patterns obtained,
were compared with ICDD database standards. Raman spectra
of TiO2 and Au/TiO2 nanoparticles and nanoparticle-embedded
polymers were obtained using a Renishaw Raman System 1000,
calibrated using a Silicon standard. XPS was carried out using a
Thermo Scientific K-alpha spectrometer with monochromated Al Kα
radiation, a dual beam charge compensation system and constant
pass energy of 50 eV (spot size 400 µm). Survey scans were collected
in the range 0 - 1200 eV. High-resolution scans (0.1 eV) were used
for the principal peaks of Ti (2p), O (1s), Au (4f) and C (1s) and
all spectra were calibrated against adventitious carbon (C1s, 284.8 eV).
7.2.4 Functional Properties
7.2.4.1 Wetting properties
Equilibrium water contact angle measurements (∼ 5 µL) on: untreated
silicone, solvent treated (control) silicone, TiO2-encapsulated silicone
and Au/TiO2-encapsulated silicone, were recorded using an FTA
1000 Drop Shape Instrument at room temperature conditions. The
contact angle measurement for each sample type was taken to be the
average value over > 5 measurements, using a droplet of de-ionised
water dispensed by gravity from a gauge 27 needle and the samples
were photographed side on. The data was analysed using SURFTENS
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software (V. 4.5).
7.2.4.2 Photocatalytic testing of the TiO2 and Au/TiO2 nanoparticles
The photo-activity of the functionalised titania nanoparticles and
functionalised gold-modified-titania nanoparticles was determined
by the photo-oxidation of a model organic pollutant, octadecanoic
(stearic) acid. TiO2 or Au/TiO2 nanoparticle films (0.8 mg) were
prepared by drop-casting a concentrated solution of nanoparticles
made up in toluene onto a borosilicate glass substrate, after which
the samples were allowed to dry such that the residual solvent
evaporated. A thin layer of stearic acid solution in chloroform (0.05
M) was subsequently dip-coated onto the coated-glass substrate
samples. The samples were then irradiated using a blacklight-blue
(BLB) lamp (Vilber Lourmat, 365 nm, 2 x 8 W, 1.2 mW cm−2) and the
photodegradation of the acid was monitored using a Perkin Elmer
RX-I Fourier transform infrared (FTIR) spectrometer.
7.2.5 Microbiological Testing
The following silicone elastomer samples (1.21 cm2) were used in the
microbiology experiments: (i) solvent treated silicone (control), (ii)
oleic acid functionalised-TiO2 encapsulated silicone (TiO2) and (iii)
gold deposited, oleic acid functionalised-TiO2 encapsulated medical
grade silicone (Au/TiO2). Immediately prior to microbiological
testing, all samples were pre-irradiated for 18 hours using a 365 nm
UV light source (BLB, Vilber Lourmat, 365 nm) emitting an average
light intensity of 1.8 mW cm−2 at a distance of 10 cm from the
samples, after which they were maintained under dark conditions
(24 h). The samples were subsequently tested against S. aureus 8325-4
and E. coli ATCC 25922. These organisms were stored at -70 oC in
BHI broth containing 20 % (v/v) glycerol and propagated on either
MSA or MAC agar for a maximum of two sub-cultures at intervals of
two weeks.
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BHI broth (10 mL) was inoculated with 1 bacterial colony and cul-
tured in air at 37 oC for 18 h with shaking at 200 rpm. The bacterial
pellet was recovered by centrifugation (21 oC, 1771 xg, 5 min), washed
in PBS and centrifuged again to recover the bacteria, which were
finally re-suspended in PBS (10 mL). The washed suspension was di-
luted 1000-fold to obtain the inoculum (∼106 cfu /mL). The inoculum
in each experiment was confirmed by plating ten-fold serial dilutions
on agar for viable counts. Triplicates of each polymer sample type
were inoculated with 20 µL of the inoculum and covered with a
sterile cover slip (22 x 22 mm). The samples were then irradiated for
the required time period using a 365 nm UV light source emitting an
average light intensity of 1.8 mW cm−2 at a distance of 10 cm from
the samples. A further set of samples (in triplicate) was maintained
in the dark for the duration of the irradiation time.
Post irradiation, the inoculated samples and cover slips were added
to PBS (180 µL) and vortexed. The neat suspension and ten-fold serial
dilutions were plated on the appropriate agar for viable counts. The
plates were incubated aerobically at 37 oC for 24 h (E. coli) or 48 h
(S. aureus). Each experiment contained 3 technical replicates and the
experiment was reproduced three times. The Mann-Whitney U test
was used to determine the significance of the following comparisons:
(i) the activity of each of the modified polymers compared to the
control silicone sample when both were incubated in the dark and (ii)
the activity of each of the irradiated modified polymers compared to
the same material incubated in the dark.
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7.3 results and discussion
7.3.1 Materials Synthesis
7.3.1.1 Nanoparticle Synthesis and Functionalisation
A CHFS route was used to synthesise titania nanoparticles and
subsequently, using a modified Turkevich synthesis, gold addition
was achieved on the titania nanoparticles. The latter synthetic route
relies on the formation of gold on the added nanoparticle surface,
after precipitation with salt. The presence of titania nanoparticles
provides a lower energy surface on which the gold can grow, rather
than undergoing Ostwald ripening as they are precipitated. Due to
the presence of citrate ligands on the Turkevich synthesised gold,
the nanoparticles are stabilised by electrostatic interactions and thus,
because of a lowering of surface charge, they are susceptible to salt
flocculation.
The titania and gold-modified-titania nanoparticles were function-
alised according to the method proposed in the literature [39]. The
functionalisation step was achieved to add sterically stabilising oleic
acid to the nanoparticle surface. Some of the oleic acid added, weakly
binds to the nanoparticle via Van der Waals interactions and the
remainder undergoes esterification reactions with titanol groups
present on the nanoparticle surface.
7.3.1.2 Materials Synthesis
Silicone samples were embedded with TiO2 nanoparticles or Au/TiO2
nanoparticles using a simple one-step “swell-encapsulation-shrink”
strategy, as used to incorporate a range of photosensitiser dyes and
nanoparticles into medical grade polymers [1–8]. Medical grade sili-
cone coupons were immersed in toluene swelling solutions made up
to a concentration of 20 mg/ mL of titania or Au/TiO2 nanoparticles
for a period of 48 hours. The toluene induced substantial polymer
swelling, enabling the diffusion of the nanoparticles through the
polymer bulk. Upon removal from the swelling solution, the titania-
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modified samples were allowed to air-dry for at least 48 hours prior
to washing, to ensure complete evaporation of residual solvent and
the solvent-treated polymers shrunk to their previous dimensions
over this time period.
It should be noted that contrary to previous work involving the
incorporation of dyes and nanoparticles into medical grade polymers
[1–8], some of which has been detailed in previous chapters, here,
the encapsulation of neither the TiO2 nanoparticles, nor the Au/TiO2
nanoparticles impacted on polymer colouration. This is an attractive
property in terms of future commercialisation of this technology for
antimicrobial surface technology applications, where strong material
colouration may be detrimental.
Figure 48: UV-Vis absorbance spectra of a toluene treated silicone polymer
(black line), a TiO2-encapsulated silicone polymer (blue line) and a Au/TiO2-
encapsulated silicone polymer (red line). Inset: Tauc plot constructed us-
ing nanoparticle solution data to determine band gap of TiO2 nanoparti-
cles (blue line) and Au/TiO2 nanoparticles (red line). The band onset of the
TiO2 nanoparticles was calculated as 3.33 eV and the band onset of Au/TiO2
nanoparticles was calculated at 3.18 eV
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7.3.2 Materials Characterisation
7.3.2.1 UV-Vis Absorbance Spectroscopy
UV-Vis absorbance spectroscopy was used to examine the toluene
dispersed TiO2 and Au/TiO2 nanoparticle solutions, as well as the
nanoparticle-encapsulated silicone polymers (Figure 48). Using the
UV-Vis data of the toluene dispersed TiO2 and Au/TiO2 nanoparti-
cles, a Tauc plot was constructed - (ahv)1/2 as a function of photon
energy hv, where ‘a’ is the absorbance of the nanoparticles [40] - to
estimate the nanoparticle band onset. The data indicates that the
deposition of gold onto the modified-titania nanoparticle shifts the
band onset towards the visible region of the spectrum (3.18 eV for
Au/TiO2 compared to 3.33 eV TiO2).
The UV-Vis absorbance spectra of the TiO2- and Au/TiO2-
encapsulated silicone polymers were recorded and compared to
the absorbance spectrum of an untreated control silicone polymer.
The absorbance spectra provide evidence of nanoparticle encapsu-
lation within the polymer, since as demonstrated by Figure 48, the
band edge of the TiO2 and Au/TiO2-encapsulated silicone polymers
is noticeably red shifted, with respect to that of the control silicone
polymer.
7.3.2.2 Transmission Electron Microscopy
The TiO2 and Au/TiO2 nanoparticle powders were dispersed in
hexane to form a dilute solution and drop cast onto TEM grids.
The TEM images (Figure 49) showed polydisperse populations of
crystalline nanoparticles, dominated by anatase titania in both the
case of the TiO2 and Au/TiO2 nanoparticle samples. Size analysis
showed an average nanoparticle diameter of 11 ± 4.7 nm for the
TiO2 nanoparticles and 11 ± 4.4 nm for the Au/TiO2 nanoparticles.
HR-TEM images showed the particles to be highly crystalline, with
lattice spacings of 0.34 nm and 0.33 nm (49(b) and 49(d)). Using the
Bragg equation (see XRD data, Section 7.3.2.3), it was determined that
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Figure 49: (a) TEM of oleic acid functionalised TiO2 nanoparticles, (b) HR-
TEM of oleic acid functionalised TiO2 nanoparticles, (c) TEM of Au/TiO2
nanoparticles and (d) HR-TEM of Au/TiO2 nanoparticles
Table 7: Energy-dispersive X-ray spectroscopy data for TiO2 and Au/TiO2
samples
Sample Element Line Type k factor Wt% σWt% Atomic %
TiO2 O K series 1.181 47.29 0.32 72.87
Ti K series 0.635 52.71 0.32 27.13
Au/TiO2 O K series 1.181 51.61 0.64 77.00
Ti K series 0.635 45.45 0.61 22.65
Au M series 1.012 2.94 0.60 0.36
these lattice spacings correspond to the (101) planes of anatase titania.
255
Figure 50: X-Ray diffraction pattern of: (a) TiO2 and (b) Au/TiO2 showing
distinctive peaks of anatase TiO2. Reference lines from ICSD collection code:
154610
TEM analysis also indicated that the size and shape of the TiO2
nanoparticles are unaltered by neither the gold deposition, nor the
oleic acid functionalisation processess. It can be suggested that in the
case of the former, this is possibly due to the small quantities of Au
(ca. 0.36 %, Table 7) that is surface bound.
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7.3.2.3 X-Ray Diffraction
The TiO2 and Au/TiO2 nanoparticle samples were analysed using
XRD (Figure 50). The XRD data supported the TEM analysis and the
diffraction pattern showed prominent peaks at 25.3, 37.9, 48.0, 54.1,
55.0 and 62.4o 2θ, corresponding to anatase TiO2 (ICSD collection
code: 154610). The Scherrer equation [41] was used to estimate the
size of individual nanoparticles, by correlating the particle linear di-
mension with the diffraction pattern peak breadth:
L =
K λ
B cos θ
(4)
where L is the particle linear dimension, K is the Scherrer constant,
B is a measure of the peak broadening, full-width at half-maximum
(FWHM) and λ represents the wavelength of the incoming X-rays [42].
Using the Scherrer equation (Equation 4), the average nanoparticle
diameter was estimated as 11.1 nm for the TiO2 nanoparticles and
10.0 nm for the Au/TiO2 nanoparticles. It should be noted that
these approximated values are in good agreement to those obtained
by TEM analysis (11.2 nm and 10.9 nm, respectively). The peak
broadness compared to that of bulk anatase TiO2, can be attributed
to the small crystallite size. It should also be highlighted that as
expected, the deposition of gold onto the TiO2 nanoparticle surface
effected no discernible change in XRD peak positions.
TiO2- and Au/TiO2 nanoparticle-encapsulated polymer samples
were also analysed using XRD. Analysis of the measured diffraction
patterns showed no difference between that of the control silicone
samples and either nanoparticle-encapsulated sample. It can be
suggested that this is due to the low quantities of nanoparticles
present in the polymer, such that the encapsulated nanoparticle
concentrations are below that detectable using XRD.
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Figure 51: Raman spectra of the (a) TiO2 and (b) Au/TiO2 nanoparticle
samples [43]. (c) Raman spectra of: A) control solvent-treated silicone, B)
TiO2-encapsulated silicone, C) TiO2-encapsulated silicone irradiated with
UV light (365 nm, 18 h), d) Au/TiO2-encapsulated silicone and e) Au/TiO2-
encapsulated silicone irradiated with UV light (365 nm, 18 h)
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7.3.2.4 Raman Spectroscopy
Raman spectroscopy was used to analyse the TiO2 and Au/TiO2
nanoparticle samples. Both measured nanoparticle spectra showed
characteristic Raman signals for titania at 146.7 and 636.7, 396 and
512.5 cm−1 and these peaks can be assigned as the Eg, B1g and
A1g modes of the anatase phase [43]. As expected, no discernible
shift in Raman peak was noted between the TiO2 and Au/TiO2
nanoparticle samples, as the gold is deposited on the nanoparticle
surface. Moreover, no characteristic peak for gold was observed in
the spectrum of the Au/TiO2 sample (Figure 51(b)).
Raman spectra of TiO2- and Au/TiO2-encapsulated silicone were
measured and compared to that of a control silicone sample. No
significant difference was noted across the sample range and the
spectra were comparable to that of the control silicone sample. The
polymer samples were exposed to UV irradiation (365 nm, 18 h) and
the Raman spectra were re-measured. It was found that the spectra
were comparable and this indicates that neither the UV-irradiation,
nor the presence of the photo-active nanoparticle, photodegrade the
silicone polymer.
7.3.2.5 X-Ray Photoelectron Spectroscopy
XPS of both the TiO2 and Au/TiO2 nanoparticle samples (Figures
52 and 53) showed a doublet in the Ti (2p) region corresponding to
titanium in TiO2. An oxygen peak in the O (1s) region corresponding
to oxygen in TiO2 was also observed. XPS of the Au/TiO2 sample
Table 8: Nanoparticle composition data from XPS measurements for tita-
nium (Ti), oxygen (O) and gold (Au) content
Sample Sample Description Ti Content O Content Au Content
(atom %) (atom %) (atom %)
TiO2 Unmodified TiO2 22.4 62.05 -
Au/TiO2 Gold-doped TiO2 20.54 53.24 0.51
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Figure 52: Fitted XPS spectra of Au/TiO2 nanoparticle powder sample. (a)
Labelled survey scan, (b) Au 4f scan, (c) Ti 2p scan and (d) O 1s scan
confirmed the presence of low quantities of gold (ca. 0.5 %), with
determined values in close approximation to composition values
obtained by Energy-dispersive X-ray spectroscopy (EDX). Comparing
Figure 52(c) - (d) with Figure 53(a) - (b), it is noteworthy that there is
no shift in the binding energies and chemical environments of the Ti
2p and O 1s in the two nanoparticle powder samples.
XPS of both TiO2 and Au/TiO2 nanoparticle-encapsulated silicone
samples showed evidence of nanoparticle encapsulation, with a
doublet in the Ti (2p) region corresponding to titanium in TiO2,
with a slight right shift in binding energy compared to the nanopar-
ticle powder samples. However, due to the low concentration of
gold present in the nanoparticle encapsulated polymer, it was not
possible to confirm the presence of gold in the Au/TiO2 nanoparticle-
encapsulated sample.
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Figure 53: XPS spectra of TiO2 nanoparticle powder sample. (a) Ti 2p scan
and (b) O 1s scan
7.3.3 Functional Properties
7.3.3.1 Wetting Properties
The wetting properties of a range of untreated and nanoparticle-
modified silicone samples were measured under laboratory tempera-
ture and lighting conditions. The water contact angle measurements
indicate that the polymer itself presents a highly hydrophobic
surface (120 o) and the water contact angle is reduced through the
encapsulation of TiO2 or Au/TiO2 nanoparticles (90 o). However, it
should be noted that no photo-activated polymer hydrophilicity was
observed on the nanoparticle-encapsulated samples upon irradiation
with a 365 nm UV lamp. It can be suggested that this is because the
nanoparticles do not form a thin film at the polymer surface, rather
they are dispersed throughout the polymer matrix and therefore
impact on the hydrophilicity of the polymer, rather than the UV-
activated hydrophilicity.
7.3.3.2 Photocatalytic Activity
TiO2 and Au/TiO2 nanoparticle films were prepared by drop-casting
a concentrated solution of nanoparticles onto a glass substrate and
the comparative photoactivity of these films was evaluated through
their efficacy to photodegrade stearic acid, a model organic pollutant,
under 365 nm UV irradiation conditions. The use of stearic acid as a
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Figure 54: (a) IR spectra of stearic acid upon UVA illumination (1.2 mW
cm−2) on a TiO2 drop-cast film. (b) Integrated areas obtained during illumi-
nation of TiO2 (full circles), Au/TiO2 (full diamonds) and plain glass control
(open circles) films. (c) Photo-activity rates (given as rate over irradiance) of
TiO2 and Au/TiO2 films obtained during UVA irradiation (BLB 365 nm)
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preferred method to assess the activity of photocatalytic materials is
based on a number of reasons including: (i) its high stability under
UV irradiation in the absence of a photocatalytic surface, (ii) the
ease of deposition of stearic acid films from methanol or chloroform
solutions, (iii) simple photodestruction kinetics (zero-order) such that
film thickness is not a critical factor when evaluating photo-activity
of surfaces and (iv) the photodestruction of stearic acid can easily be
monitored spectroscopically [44].
The overall oxidation reaction can be summarised as follows:
CH3(CH2)16CO2H + 26 O2
TiO2(h) > Ebg−→ 18 CO2 + 18 H2O (5)
and here, the photodestruction of stearic acid as a function of time,
on TiO2 and Au/TiO2 nanoparticle films, was monitored using IR
absorption spectroscopy, following the disappearance of typical C-H
bands at 2958, 2923 and 2853 cm−1 (Figure 54(a)). These peaks are
attributed to the asymmetric in-plane C-H stretches in the stearic acid
CH3 group and both the asymmetric and symmetric C-H stretches in
the stearic acid CH2 groups, respectively [44]
Using a conversion factor from the literature based on the integrated
area of the IR spectrum, where:
1 cm−1 ≡ 9.7 x 1015 molecules cm−2
the number of stearic acid molecules that have been degraded can
be estimated [44]. The photoactivity rates are estimated from linear
regression of the initial 20 - 30 % degradation steps (zero-order
kinetics regime) of the curves of the integrated areas (Figure 54(b)).
Preliminary photocatalytic tests of drop-cast films of the TiO2 and
Au/TiO2 powders indicate that the Au/TiO2 nanoparticle thin films
showed an enhanced photo-activity under 365 nm UV irradiation
regimes (Figure 54(c)).
The increased activity of TiO2-based systems containing noble metal
nanoparticles is typically explained in terms of an efficient charge
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Figure 55: Proposed mechanism of photocatalytic antimicrobial activity of (a)
TiO2 encapsulated silicone sample and (b) Au/TiO2 encapsulated silicone
sample
separation as shown in Figure 55 [35, 45], although conflicting ac-
counts regarding the mechanism of improved charge separation have
been commented on in the literature [31]. It has been proposed that
the photocatalysed charge separation enhancement mechanisms may
differ depending on the excitation wavelength used, for example UV-
light irradiation compared to visible-light irradiation [27, 46]. For UV-
activation, literature accounts suggest that the presence of the gold
deposited on the TiO2 nanoparticles can promote interfacial charge
transfer and due to the difference in the work functions of the titania
and gold, the conduction band electrons in the former, may be at-
tracted by the latter, hindering electron-hole pair recombination (See
Figure 55) [35, 47]. It has also been reported that the gold-titania con-
tact is a Schottky junction and this junction ‘forces’ electrons and holes
generated within this region, to move in opposite directions [35, 45].
After photo-excitation, electrons migrate to the metal, which traps the
electrons at the metal surface and provides a host for additional ac-
tive sites for photocatalysed reactions with targeted reactants [45, 48]
The hole diffuses to the surface of the TiO2 nanoparticle, where it can
react to oxidise organic species [48]. Through facilitating the transfer
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of photo-generated electrons and holes to the surfaces of the metal
and semiconductor respectively, the metal suppresses electron-hole
recombination and increases the photocatalytic efficiency of the TiO2
[35, 45].
7.3.4 Photobactericidal Activity
The light-activated antimicrobial activity of TiO2 nanoparticle- and
Au/TiO2 nanoparticle encapsulated medical grade silicone samples
was tested against representative Gram-positive and Gram-negative
bacteria commonly found in healthcare environments, S. aureus and
E. coli, respectively. Prior to microbiological testing, the samples were
pre-irradiated with a 365 nm UV lamp for 18 hours to photodegrade
any residual organic precursor material on the sample surfaces, after
which they were stored under dark conditions for 24 hours. In the
microbiology assays, the samples were irradiated using a 365 nm
UV lamp emitting an average of 1.8 mW cm−2, at a distance of
10 cm from the samples. A further sample set was maintained in
the dark for the duration of the experiment to determine whether
antimicrobial activity is due to a photocatalysed effect, or can be
attributed to intrinsic bactericidal properties of the modified titania
surfaces.
The antibacterial properties of silicone samples encapsulated with
either TiO2 nanoparticles or Au/TiO2 nanoparticles was compared
to that of a control, solvent treated silicone sample. Interestingly,
both the TiO2 nanoparticle- and Au/TiO2 nanoparticle-encapsulated
silicone demonstrated strong antimicrobial activity under dark con-
ditions when tested against S. aureus, reducing bacterial numbers to
below the detection limit (P < 0.001, Figure 56(a)). Consequently, no
additional photocatalysed antimicrobial effects could be established.
TiO2 is a photo-activated antimicrobial agent and therefore, the
potent bactericidal activity observed under dark conditions was
surprising. Since it has been noted that oleic acid can inhibit the
growth of Gram-positive bacteria including S. aureus [49], it can
be speculated that the intrinsic antibacterial activity of both the
TiO2- and Au/TiO2-silicone samples, may be attributed to the oleic
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Figure 56: Viable counts of bacteria (colony forming units (cfu) /mL) after
incubation on modified silicone polymers exposed to UV irradiation (365
nm): (a) S. aureus (15 min illumination) and (b) E. coli (95 min illumination).
The UV source emitted an average light intensity of 1.8 ± 0.1 mW cm−2 at a
distance of 10 cm from the samples. The  symbols indicate that the bacterial
numbers were reduced to below the detection limit of 500 cfu /mL
acid nanoparticle capping agent. Further experiments to test the
antimicrobial activity of a range of oleic acid-capped nanoparticles
and non-oleic acid-capped TiO2 and Au/TiO2 nanoparticles, would
be of benefit in elucidating the mechanism of dark kill observed in
this investigation.
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When tested against E. coli under dark conditions, as shown in
Figure 56(b), both the TiO2-encapsulated silicone and the Au/TiO2-
encapsulated silicone samples exhibited limited antimicrobial activity
and these effects were not highly significant (P < 0.01). These results
suggest that the bactericidal properties of the capping agent are not
as effective against this bacterium, as indicated in the literature [49].
However, when both the TiO2- and Au/TiO2-encapsulated silicone
samples were exposed to 365 nm UV irradiation, they induced the
lethal photosensitisation of E. coli, reducing viable bacterial numbers
to below the detection limit within 95 minutes (3.7 log kill, P < 0.001).
TiO2 is a UV-activated photocatalyst and generates mobile electron-
hole pairs upon absorption of photons with energy greater than that
of its band gap energy. The electron-hole pair can migrate to the
nanoparticle surface where the electrons reduce molecular oxygen
in the environs, generating superoxide anions and the positive
holes interact with adsorbed water, generating hydroxyl radicals.
The photo-generated radical species can subsequently react further,
resulting in the production of a wide range of radicals. These
radicals, including ROS, can initiate a non-site specific attack against
bacteria near the surface, oxidising organic matter and ultimately,
photo-destroying bacterial cellular membranes and components.
Moreover, due to the multi-site attack mechanism, the emergence of
bacterial resistance to this antimicrobial strategy is unlikely. This is
a highly desirable property in antibacterial surfaces developed for
applications in healthcare settings.
In this study, it was not possible to determine whether the deposition
of gold onto the titania nanoparticle enhanced its photocatalytic
activity. Rapid kills of both Gram-positive and Gram-negative
bacteria, S. aureus and E. coli, were achieved on both the TiO2
nanoparticle- and Au/TiO2 nanoparticle-encapsulated sample, with
viable bacterial numbers reduced by at least 3 log. Further microbial
investigations involving white light activation or shorter illumination
times, may shed light onto whether the presence of gold shifts the
TiO2 nanoparticle towards visible light photocatalysis, or improves
the antimicrobial efficacy over that of TiO2 alone. Moreover, microbial
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testing on surfaces incorporated with a range of oleic acid-capped
nanoparticles may be of interest, to further investigate whether the
antimicrobial activity under dark conditions can be attributed to the
nanoparticle capping group. It would also be advantageous in further
investigations to study organisms with known antibiotic resistance or
recent clinical isolates.
7.4 conclusion
This chapter details the development of a new class of potent
UV-activated antimicrobial polymers, developed by incorporating
TiO2 nanoparticles or Au/TiO2 nanoparticles into medical grade
silicone. The nanoparticles were incorporated using a simple “swell-
encapsulation-shrink” strategy. Dissimilar to other antimicrobial
polymers detailed in this thesis involving the incorporation of both
dyes and nanoparticles into medical grade silicone, the encapsula-
tion of TiO2 nanoparticles or Au/TiO2 nanoparticles did not affect
polymer colouration, a highly desirable property from a commercial
viewpoint.
These modified silicone polymers induced the lethal photosensitisa-
tion of E. coli within 95 minutes, with bacterial numbers reduced to
below the detection limit. Moreover, these surfaces achieved rapid
kills of S. aureus, resulting in > 3 log kills (below detection limit)
within 15 minutes, via a non-light-activated mechanism. It should
be noted that these samples demonstrate the most efficacious an-
timicrobial activity under dark conditions against the Gram-positive
bacterium, S. aureus, reported in this thesis. However, under the
lighting conditions used in this investigation, no enhancement in
the photo-activated antimicrobial activity was observed on the
Au/TiO2 nanoparticle-encapsulated polymer compared to the TiO2
nanoparticle-encapsulated silicone.
Overall, this thesis has detailed the development of a series of po-
tent photobactericidal polymers, activated by a range of lighting con-
ditions. These UVA-activated antimicrobial polymers are simple to
268
develop, achieve rapid kills over very short time scales and can be
utilised for both touch surface applications and medical device appli-
cations, provided suitable light delivery systems can be designed. It
may be possible to achieve UV-light delivery for medical device appli-
cations using a hollow core optical fibre. Moreover, their antimicrobial
effectiveness under dark conditions may help maintain low bacterial
numbers when the surfaces are not illuminated, increasing their at-
tractiveness as candidates for antimicrobial polymers. It is hopeful
that the use of these polymers in healthcare applications may help
decrease hospital surface contamination and reduce the incidence of
HAIs.
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C O N C L U S I O N S A N D F U T U R E W O R K
8.1 conclusions
The prevalence of HAIs, often caused by multi-drug resistant bac-
teria, highlights the necessity of the development of efficacious
infection-prevention strategies. One approach to reduce the spread of
infection is the use of self-sterilising surfaces to help both decrease
the risk of infection upon use of medical devices such as catheters
and also to disrupt the cycle of transmission of bacteria in healthcare
environments.
This thesis detailed the development of potent antimicrobial polymers
that demonstrate an enhanced efficacy induced by a light-activated
bactericidal mechanism. A novel approach was used, exploiting the
concept of PDT. The advantage of this strategy for use in healthcare
applications is two-fold. Firstly, the overuse of antibiotics and other
antiseptics has resulted in the emergence of bacterial resistance to a
host of antimicrobial strategies. These polymers however, induce the
lethal photosensitisation of bacteria through the generation of a range
of ROS that initiate a non-site specific attack against bacteria in the
vicinity, decreasing the likelihood of the emergence of bacterial resis-
tance to this approach. Secondly, whereas other bactericidal surfaces
lose effectiveness consequent to the build-up of dirt obscuring the
antimicrobial properties, these surfaces are self-cleaning in that the
photo-generated species oxidise organic matter contaminating the
polymer surface, thus maintaining the anti-infective efficacy. Further
work focused on the development of materials that harnessed a
dual-mechanism bacterial kill strategy, through the incorporation
of both photo-active antimicrobials and intrinsically antimicrobial
nanoparticles or other moieties, for the development of antimicrobial
surfaces that demonstrate bactericidal activity under dark conditions
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with enhanced kills upon light-activation.
Using a simple synthetic technique, a range of antimicrobial poly-
mers were developed for medical device applications such as urinary
catheters, in addition to hospital touch surface applications. For
medical device applications, the antimicrobial activity was activated
using either a 635 nm laser (crystal violet-coated, methylene blue
and 2 nm gold nanoparticle-encapsulated silicone), or a UVA source
(oleic acid functionalised titania- or gold-doped titania nanoparticle-
encapsulated silicone). These surfaces demonstrated rapid, potent
light-activated antimicrobial activity when tested against both
Gram-positive and Gram-negative bacteria. Moreover, the oleic
acid functionalised titania- and gold-doped titania nanoparticle-
encapsulated silicone polymers achieved significant kills in the dark,
when tested against S. aureus, reducing bacterial numbers by > 4 log.
Antimicrobial silicone surfaces, activated using a white hospital light
source, were also developed for hospital touch surface applications,
utilising the multi-dye-nanogold surface technology as well as a
novel antimicrobial combination of crystal violet and 3 nm zinc oxide
nanoparticles. Both materials induced the lethal photosensitisation
of key causative pathogens for HAIs. Moreover, for the first time,
significant dark kill was observed against both Gram-positive and
Gram-negative bacteria, highlighting the development of versatile,
‘dual-mechanism’ antimicrobial polymers for potential use in health-
care environments to decrease the risk of infection.
The development of a range of potent photobactericidal surfaces
has been examined and therefore, an in-depth investigation into
the photochemical properties of dye- and dye-nanoparticle encap-
sulated polymers, is of critical importance to gain insight into the
mechanism of photobactericidal activity demonstrated. This was
achieved using TR-EPR spectroscopy and TRNIR-1O2 phosphores-
cence measurements. These studies indicated that the presence
of small 2 nm gold nanoparticles enhance dye triplet state pro-
duction and subsequently lead to increased 1O2 generation upon
photo-activation. These findings facilitate an understanding of the
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underlying photophysics, providing key information on enhance-
ments observed in microbiological kills when antimicrobial surfaces
with incorporated dye-nanogold combinations were tested. The use
of a logical synthetic strategy that involves an extensive investigation
into the photochemical properties of dye-nanoparticle encapsulated
polymers, is crucial for future work in the design of more potent
photobactericidal materials that achieve rapid bacterial kills.
8.2 future work
Future work should focus on the use of TR-EPR spectroscopy as a
tool to optimise the light-activated activity of these surfaces. Singlet
oxygen production measurements in combination with CW-EPR
spectroscopy should also be utilised to investigate the mechanism
of photochemical activity, through examining the photo-generated
radical generation of these surfaces. In addition, further work
should include a strong emphasis on the synthesis of novel antimi-
crobial nanoparticles and the utilisation of an understanding of
the underpinning photophysics to advance materials development.
These materials should be tested against clinical strains of bacteria,
spore-forming bacteria such as C. difficile and viruses. The materials
developed will be of strong commercial interest for use in both
hospital touch surfaces and in invasive medical devices, to help
maintain low bacterial contamination levels on hospital surfaces,
reducing the risk of associated infection.
One aim of future investigations is to optimise the photobactericidal
activity of polymers that utilise multiple mechanisms of bacterial
attack, to reduce bacterial contamination levels in healthcare envi-
ronments. Dissimilar to prior research, the design approach should
be a strategic one, with a strong emphasis on the synthesis of new
antimicrobial nanoparticles and the use of an understanding of the
underlying photophysics to optimise the light-activated antimicrobial
properties of materials developed. In surfaces developed based
on dye-gold interactions, the gold nanoparticles used should be
functionalised with antimicrobial ligands, for example, oleic acid,
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to maximise antimicrobial activity exhibited under dark conditions.
In addition, TR-EPR should be used to optimise gold nanoparticle
polymer loading such that surfaces that generate optimal triplet state
production can be subsequently tested against bacteria.
Work achieved on the incorporation of antimicrobial zinc oxide
nanoparticles in combination with photosensitisers into medical
grade polymers, indicates that there exist dye-nanoparticle synergic
interactions, with indications of advantageous implications on the
exhibited photostability of the dye, although as yet, this has not
been investigated using TR-EPR. These polymers demonstrate one
of the most effective antimicrobial activities we have reported to
date, with substantial activity under dark conditions, in addition
to the reduction of bacterial numbers to below the detection limit
upon white light illumination. It is critical that the photochemical
mechanism is explored such that this technology can be refined to
achieve more potent antimicrobial polymers. Moreover, it is impor-
tant to explore the incorporation of this antimicrobial technology into
further polymers, for example, for use in paints, such that existing
surfaces can be modified to exhibit bactericidal functionality.
In addition to investigating the properties of the photo-excited
triplet states, CW-EPR in combination with a spin-trap should be
executed, to enable an examination of the photo-generated radical
distribution. These investigations will provide insight into whether
the presence of different nanoparticles impact on the photochemical
mechanism the triplet state dye undergoes, to be exact, whether
the presence of nanoparticles result in dye triplet state quenching
by molecular oxygen or substrate radicals. Polymers incorporated
with photosensitisers in combination with: gold nanoparticles, zinc
oxide nanoparticles, titania nanoparticles, copper nanoparticles and
so forth, should be investigated. This knowledge can be used to
promote the generation of a wide range of ROS to target bacteria
more effectively.
Further work should be focused on facilitating vital research
into the understanding of the photochemical mechanisms of the
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light-activated antimicrobial activity of dye-nanoparticle embedded
polymers. Using this knowledge, more effective bactericidal polymers
can be developed with antimicrobial functionality under both dark
and light conditions. The modification process can be manipulated
to incorporate antimicrobial agents that achieve bacterial kills via
multiple mechanisms, including both dark-kills and kills achieved by
the photo-generation of a wide range of ROS. These design tactics
will result in the development of polymers with enhanced rates of
bactericidal activity. The simple synthetic technique used to develop
these surfaces can be easily up-scaled for commercial production and
also enables this antimicrobial technology to be used in a wide range
of polymers for healthcare applications. Optimisation by the current
empirical approach is not effective as a long-term strategy and a
mechanistic understanding is critical to underpin future advances
in the development of bactericidal surfaces, for use in healthcare
technologies.
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